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 ABSTRACT  
The use of haemostatic materials that could be used to mitigate against the effects of 
the chemical warfare agent soman (GD) on contaminated personnel that may also 
present with wounds were investigated. To support the in vitro diffusion cell 
component of this work, the penetration rate of 14C-GD into different receptor fluids 
was evaluated to enable determination of the most appropriate receptor fluid to use 
as a sink for GD. Of the receptor media evaluated only 50% aqueous ethanol was 
able to maintain sink conditions. A number of haemostatic materials were shown to 
retain haemostatic efficacy in the presence of blood contaminated with GD, and were 
also shown to irreversibly sequester GD. The lead candidate, WoundStat™, was 
shown to be as effective a decontaminant as the current in service countermeasure 
fullers’ earth. Complementary in vivo studies using damaged ear skin in a terminally 
anaesthetised large white pig model showed that whilst use of WoundStat™ was not 
100% effective in the prevention of mortality after GD poisoning, it did increase the 
therapeutic window where further nerve agent-specific medical countermeasures 
could be employed. Perhaps most importantly, application of WoundstatTM onto GD 
contaminated damaged skin did not increase the toxicity of GD.  
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FOREWORD 
 
The improvised explosive device (IED) is a major threat that may be deployed by 
terrorists or insurgents on civilian or military populations. IED use has been cited as 
being the leading cause of explosively injured casualties during Operation Herrick in 
Afghanistan (Stalker, et al., 2011). The IED can be defined as being a “make shift” or 
homemade bomb which has often used by insurgents to attack military personnel 
and equipment. The loss of life and dehabilitating injury caused by these weapons is 
only too real, yet what if the explosive charge was not the primary hazard? What if an 
IED was merely a dissemination device for something more insidious, possibly a toxic 
chemical such as a chemical warfare (CW) agent? This threat has been previously 
alluded to (Weinbroum, et al., 2000). An IED is only one of a variety of ways that 
traumatically wounded casualties may be produced on the battlefield, ballistic injury 
from conventional weapons and even slips, trips and falls could cause wounds that 
may, in the event of a chemically contaminated battlefield, require decontamination. 
 
The work presented in thesis investigates the use of materials that could be used to 
mitigate the effects of CW agents on contaminated personnel who also present with 
superficial and / or haemorrhaging wounds. Contaminated wounds of this type, 
would, left untreated, potentially lead to loss of life.  
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CHAPTER 1: INTRODUCTION 
 
1.1. Dissemination of CW agents following explosion and incident resolution 
The detonation of an explosive chemical weapon dissemination device would initiate 
a chain of events that could produce casualties with injuries of varying severity and 
levels of contamination. The response to, and resolution of, such an incident 
depends on whether the incident is primarily civilian or military in nature, although as 
a top level overview, the incident response for both scenarios may be considered 
similar. If one considers the incident and the implications it generates in chronological 
order it can be broken down into:  
i. Detonation, the primary cause of traumatically injured casualties.  
ii. Dissemination of liquid or particulate material within the device, possibly 
radiological, biological or chemical in nature (although for the purpose of this thesis, 
discussion will remain exclusively in the domain of the chemical). The dissemination 
would produce chemically contaminated casualties, some of whom will also exhibit 
traumatic injuries.  
iii. Vapour dissemination in accordance with prevailing wind conditions at the incident 
site. The resultant vapour plume may cause additional, none traumatically injured 
casualties, downwind of the detonation site. 
iv. Personnel located in neither the primary liquid contamination radius or in the 
downwind vapour plume who are likely to be uncontaminated, although this may not 
initially be known. 
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The standard response would be to cordon off the incident site (to prevent 
bystanders inadvertently encroaching into the area becoming further casualties) and 
to set up a casualty decontamination area upwind of the contamination. An orderly 
evacuation of casualties would then proceed from the incident site to the cordon and 
into the decontamination area (Figure 1.1) where medical triage would be carried out. 
After first aid and decontamination procedures had been completed, transport to a 
suitable hospital facility would be feasible.  
 
The scenario outlined allows for medical aid to be given at the incident site itself, 
before, during or after decontamination, or at permanent medical facilities away from 
the incident site. In the case of haemorrhaging traumatic injury, treatment by 
necessity, must be immediate. Any chemical contamination will likely be seen as of 
secondary importance until haemostatic treatments have been successfully 
employed.  
 
One of the key questions is as to whether the use of haemostatic treatments 
complicates the process of decontamination. The answer is almost certainly, as the 
two processes have to occur consecutively, the cessation of haemorrhage followed 
by decontamination of the wound site. The advantage of having a method of 
simultaneously preventing haemorrhage and decontaminating a wound site cannot 
therefore be overstated. This is where the primary focus of this thesis resides, the 
development of haemostatic materials that could be used as a dual treatment for 
both haemostasis and decontamination. However, it is likely that the surrounding  
  
 
 
 
 
 
Figure 1.1: Schematic depicting the site of an agent release and where 
decontamination would take place. Wind direction will de
vapour release from the incident, with decontamination facilities setup 
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termine the direction of any 
 
 
upwind. 
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undamaged skin of a traumatically injured casualty will also be contaminated. Rather 
than necessitating an increase in logistical burden by having a standard 
decontaminant and a haemostatic decontaminant deployed side by side, confirming 
that a haemostatic decontaminant could be used as a general decontaminant would 
be advantageous. 
 
As outlined, further chemical agent deposition on personnel may occur from vapour 
dissemination. Chemical vapour poses not only a dermal hazard, but, also a 
respiratory hazard.  A number of chemicals (including the chemical warfare agents 
investigated for this work programme) possess sufficient volatility to be considered a 
vapour hazard, and, although outside the scope of this thesis, provision of adequate 
respiratory protection should be an important consideration. 
 
Upon reaching the decontamination area, immediately life threatening traumatic 
injuries would have been stabilised. The outstanding challenge remains one of 
chemical decontamination. Casualties can be split into two groups, contaminated and 
uncontaminated, although unless specific signs and symptoms have been exhibited, 
knowing the difference may be difficult to ascertain. The aim is now to progress 
though the decontamination area at a rate that will ensure any and all chemical 
deposits are removed, ideally with confirmation of zero remaining contamination 
upon egress from the decontamination unit.     
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The scope and complexity of managing an incident of this type cannot be 
understated. The project, of which the subject matter of this thesis forms a part, had 
the overall aim of refining and developing medical countermeasures and techniques 
which could be used in the management of incidents involving a chemically 
contaminated explosive device.   
 
1.2. Rationale for selection of chemical contaminant 
Although the scenario described would be valid for a wide range of toxic chemical 
disseminations, the most hazardous chemicals likely to be faced on the battlefield are 
the chemical warfare agents. Due to their acute toxicity the chemical warfare agents 
are of major concern and are the greatest challenge for a chemical decontaminant. 
Chemical warfare agents as a group possess a number of disparate mechanisms of 
action and physico-chemical properties, as such, an individual representative from 
three classes of chemical warfare agents was chosen as the starting point to 
commence this investigation, with this project primarily investigating first aid 
measures against a ‘G’ series nerve agent, soman (GD), although for completeness 
discussion of parallel projects involving the ‘V’ series nerve agent VX and the 
vesicant sulphur mustard, HD will be developed as necessary. 
 
1.3. Medical countermeasures for haemostasis and decontamination 
Logically, consideration first needs to be given to currently available medical 
countermeasures used in treating traumatic haemorrhaging injury and, separately, 
those used for skin decontamination of chemical warfare agents. A comparison of 
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any similarities between mechanisms of action for each type of countermeasure may 
offer opportunities for dual use countermeasure development. Haemostatic agents 
are defined as drugs or other agents that retard or stop bleeding. Mechanisms of 
action may be used to group similar haemostatic products, which briefly include 
electrostatic interactions with erythrocytes, activation of clotting factors or platelets, 
plasma absorption to concentrate clotting factors and use of tamponade effects.  
 
Chemical warfare agent skin decontaminants are typically either powders or liquids 
that passively decontaminate or actively decontaminate the skin. Passive 
decontaminants such as Fullers' earth and M291 powder physically absorb chemical 
agents from the skin surface, but, do not actively decontaminate what they have 
absorbed. Active decontaminants, such as Reactive Skin Decontaminant Lotion 
(RSDL), incorporate active moieties that break down any chemical warfare agent it 
comes into contact with. Unfortunately, due to incompatibilities between these skin 
decontaminants and living systems, they are not amenable for use as candidate dual 
use haemostatic decontaminants. However, their mechanisms of action share 
similarities with the mechanisms of action of a number of haemostats and these 
similarities offer a potential route for exploration.   
 
With the scope of the project outlined, the following sections detail the nature of 
traumatic injury, the action of chemical warfare agents on living systems and the 
experimental techniques that can be used and developed to determine the efficacy of 
candidate treatments.   
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1.4. Traumatic injury and medical management 
Traumatic injury, whether blunt or penetrating in nature, is not the only complication 
of a blast injury (Plurad, 2011). The physical trauma resulting from exposure to the 
detonation of an explosive device may be described in terms of primary through to 
quaternary blast injury (Sakorafas and Peros, 2008). Primary injuries are typically 
realised close to the detonation and consist of the deleterious effects caused by blast 
overpressure. Most affected are the ears, lungs and gastrointestinal tract, and, 
although outward signs may on the whole be negligible, the internal injuries caused 
can be severe. Secondary injuries are those caused by objects thrown out of the 
explosion, such as shrapnel, and are one cause of blunt or penetrating injury. 
Tertiary injury occurs from air displacement within the explosion zone, with the wind 
generated capable of propelling casualties against solid objects resulting in a 
secondary source of blunt or penetrating injury. Quaternary injuries include 
neurological disorders, whether physical or psychosomatic, and flash burns. It is the 
resulting secondary and tertiary blast injuries that are primarily of interest for this 
research project.    
 
After a traumatic injury event, uncontrolled bleeding is one of the leading causes of 
morbidity and death (Clifford, 2004;Alam, et al., 2005). The type of injury and how the 
injury is treated will vary between military combat casualties and civilian trauma 
patients (Carr, 2004) due to different demands on the medical services. One of the 
main differences is the transport time to a fixed hospital environment where 
emergency support and treatment can be given. For seriously injured civilians the 
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expectation will be for the casualty to reach hospital within an hour of injury in an 
urban area. In a combat zone, time to transport off the battlefield may be measured 
in hours. This problem may be exacerbated with the difficulties faced by emergency 
medical personnel in reaching a casualty quickly (Sakorafas and Peros, 2008). The 
type of traumatic injury between the civilian and military case may also be 
substantially different. Civilian traumatic injury is typified by blunt trauma, for which 
the “golden hour” therapeutic window for likely successful clinical outcome has been 
coined (Carr, 2004;Murdock, 2008). The time taken for a traumatically injured soldier 
to be evacuated to where medical support is available may increase the severity of 
the injury. The term the “platinum ten minutes” has been used to indicate the time by 
which successful intervention should be employed to the combat casualty (National 
Health Service, 2011).  
 
The trauma generated by penetrating ballistic injury with consequent uncontrolled 
haemorrhage is responsible for approximately fifty percent of combat deaths (Alam, 
et al., 2005) and these deaths will likely occur before definitive medical care can be 
provided. The options for treating a combat casualty within the “platinum ten minutes” 
will likely be limited to the equipment immediately available and will be administered 
on a buddy aid basis. A number of commercial off the shelf (COTS) haemostats are 
amenable to battlefield use (Neuffer, et al., 2004) and are deployable within this time 
frame and hence will be the primary focus as potential decontamination candidates. 
An initial survey of the literature for haemostats with potential battlefield application, 
are shown in Table 1.1. The haemostats include Celox® (Clay, et al., 2010), 
FastAct™ (Alam, et al., 2005), Hemcon® (Robinson, 2004), QuikClot ACS+® 
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(Robinson, 2004), SuperQR (Kheirabadi, et al., 2009), Vitagel™ (Marchan and 
Andrews, 2009) and WoundStat™ (Kheirabadi, et al., 2009;Clay, et al., 2010). 
Recombinant Factor VIIa, although extensively used in both forward surgical teams 
and combat support hospitals, it is not currently deployable on the battlefield 
(Kembro, et al., 2008) and hence was not included. 
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Name Physical Form Composition Mechanism of Action 
    
Celox® 
 
Solid Granular chitosan 
polymer 
Electrostatic interactions with 
erythrocytes to form a cross-linked 
clot 
    
FastAct™ 
 
Liquid Bovine proteins and 
antiseptic 
Activation of clotting factor IX 
    
Hemcon® 
 
Dressing Chitosan polymer 
based dressing 
Platelet activation 
    
QuikClot 
ACS+® 
 
Solid Synthetic zeolite. Plasma absorption to concentrate 
clotting factors, tamponade 
(blockage or closure) effect and 
activation of coagulation 
pathways. 
    
SuperQR 
 
Solid Potassium iron 
oxyacid salt mixed 
with a hydrophilic 
powder 
Plasma absorption to concentrate 
clotting factors, tamponade 
(blockage or closure) effect and 
activation of coagulation pathways 
    
Vitagel™ 
 
Liquid Bovine microfibrillar 
collagen, thrombin 
and CaCl2 
combined with 
autologous plasma. 
Mimics the final stage in the 
coagulation cascade. 
 
    
WoundStat™ 
 
Solid Mineral smectite. Plasma absorption to concentrate 
clotting factors, tamponade 
(blockage or closure) effect and 
activation of coagulation 
pathways. 
 
Table 1.1: Commercial off the shelf (COTS) haemostats which are amenable to 
battlefield first aid use.    
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1.5. Chemical warfare agents 
 
1.5.1. Historical aspects 
The use of Chemical Warfare agents as a means of waging war has evolved 
throughout human history (Chauhan, et al., 2008). During the 6th century BC, 
Helleborous roots were used to contaminate water supplies (Szinicz, 2005). The use 
of ignited pitch and sulphur during these early times has also been noted (Szinicz, 
2005). During the middle ages, the use of arsenical smokes by the China Sung 
Dynasty was reported (Szinicz, 2005). The development of chemistry as a science 
saw increasing military sophistication with the development arsenic and sulphur 
explosive devices by Leonardo da Vinci in the 15th Century. The rise of the discipline 
of organic chemistry in the late 19th century, gave the ability to synthesise a multitude 
of novel organic compounds. Among these compounds were chemical weapons, 
such as sulphur mustard (SM) (Malhotra, et al., 1999;Balali-Mood and Hefazi, 2005), 
which saw extensive use during the First World War (WWI) and may still be used by 
aggressors on the battlefield of today.  
 
The First World War saw use of chemical weapons on a previously unimaginable 
scale (Fries and West, 1921). Of the 150,000 tons of battle gases manufactured, 
125,000 tons were used causing an estimated 1,296,853 casualties (Prentiss, 1937) 
which caused 1.32 % of the battlefield deaths from all weapons systems used (Riley, 
2003). The classes of CW agent used can be divided into lacrimatory agents (e.g. 
ethylbromacetate), lung injurants (e.g. chlorine), systemic toxic agents (e.g. 
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hydrocyanic acid), vesicant agents (e.g. sulphur mustard) and respiratory irritants 
(e.g. diphenylchlorarsine) (Prentiss, 1937). Perhaps, the most notorious initial use of 
lethal chemicals was at Ypres, Belgium on the 22nd April 1915 (Vedder, 1925).  
German forces released a chlorine gas cloud that inflicted grave casualties on British, 
Canadian and French soldiers, estimated at 5,000 deaths and 15,000 wounded. The 
use of phosgene followed later that year, with sulphur mustard being introduced to 
the battlefield in July 1917. During the interwar years, and despite negative public 
opinion, chemical warfare agent use continued unabated, with large scale use of 
sulphur mustard by the Italians in Ethiopia in 1935 and 1936 (SIPRI, 1971). Perhaps, 
surprisingly, chemical weapons were not used on the European battlefield during the 
Second World War (WWII), although reported use was made by the Japanese 
military during incursions into China (Brown, 1968). Development of chemical warfare 
agents continued, with German development of the “G series” of nerve agents, 
initially tabun followed rapidly by sarin and soman between 1936 and 1944 (Szinicz, 
2005). The “V series” of nerve agents originated from research at Imperial Chemical 
Industries (ICI) in the mid 1950’s ((SIPRI, 1971)).  From the close of the WWII to 
modern times, infrequent use of chemical warfare agents by various militaries to 
further their aims have been made. Putting to one side the use of non lethal (to 
humans) agents such as herbicides (e.g. Agent Orange as used during the Vietnam 
War (Tuyet and Johansson, 2001)), the Iran Iraq conflict probably serves as the most 
recent reminder of military chemical use (Bijani and Moghadamnia, 2002;Ghanei and 
Vosoghi, 2002). The attack at Halabja, 16th March 1988, produced large numbers of 
casualties (up to 5,000 deaths and 10,000 injured) on a predominantly Kurdish 
civilian population by the Iraqi military. More recent times have seen the domain of 
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the chemical warfare agent no longer being confined solely to military use (Brennan, 
et al., 1999;Vale, et al., 2007). Extremist organisations and cults have manufactured 
chemical weapons of various types for use on civilian targets. March 20th, 1995, saw 
use of sarin in the Tokyo metro system by members of the Aum Shinrikyo cult against 
Japanese civilians (Tokuda, et al., 2006). Although, only thirteen fatalities resulted, 
the potential for which nerve agents could be used to cause disruption and mass 
hysteria reverberated around the world. 2001 saw disruption to mail delivery systems 
with anthrax spores being mailed a number of recipients including two US senators 
(Schwartz, 2009). Most recently in the UK was the discovery of ricin at a property in 
Durham during 2009, purportedly for use in a terror attack (Engelbrecht, 2010).  
 
1.5.2. Organisation for the Prohibition of Chemical Weapons 
In an attempt to halt nations using chemical warfare agents in their perceived 
national interests, the Chemical Weapons Convention (CWC) was opened for 
signatory on 13th January 1993. The CWC came into force on 29th April 1997, with 87 
state parties becoming bound by its terms and conditions under international law. 
The Organisation for the Prohibition of Chemical Weapons (OPCW) was formed and 
tasked with overseeing the implementation of the CWC with the 188 states that 
currently have membership. States being bound to the Convention have agreed to 
chemical disarmament. Essentially, this entails that currently held stockpiles of 
chemical weapons be destroyed along with any facilities capable of producing them. 
A verification regime was also put in place to limit transport and use of chemical 
warfare agents and a number of their precursors (full details are to be found on the 
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schedule 1, 2 and 3 lists within the annexes to the CWC). Although signatory states 
may no longer develop or use chemical warfare agents for aggressive purposes, it 
was seen as necessary for CW agents to continue to be used for the development of 
defensive research against future CW attack by non signatory states.   
 
1.5.3. Chemical warfare agent definition, toxicity and properties 
In today’s context, the term Chemical Warfare Agent refers to a broad spectrum of 
very toxic chemicals (Evison, et al., 2002;Ramirez and Bacon, 2003). The Chemical 
Weapons Convention (CWC) defines a chemical weapon as: “Toxic chemicals and 
their precursors, except where intended for purposes not prohibited under this 
Convention, as long as the types and quantities are consistent with such purposes”. 
Under this definition toxic chemical is given the meaning: “Any chemical which 
through its chemical action on life processes can cause death, temporary 
incapacitation or permanent harm to humans or animals. This includes all such 
chemicals, regardless of their origin or of their method of production, and regardless 
of whether they are produced in facilities, in munitions or elsewhere". It is important 
to note that subsets of chemical weapons (e.g. nerve and vesicating agents) vary 
widely in their acute toxicity and mechanisms of action. The potency spectrum 
(Figure 1.2) defines the approximate toxicity of chemical warfare agents within the 
boundaries of other toxic entities such as toxic industrial chemicals (TICs), toxins and 
biological agents. To generalise, a chemical warfare agent is not defined by any 
unique property. Dependent on environmental temperature, they can exist in a solid, 
liquid or gaseous state and dependant on the manufacturing process used may be 
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neat (of varying purity) or within a matrix, potentially solvated or in combination with 
another toxic entity. Confining the term chemical warfare agent to the “potency 
spectrum” definition we are considering a range of volatile liquids. Actual volatility is 
environment and specific agent dependent, and to a large degree accounts for how 
an individual agent is likely to be encountered and through which route(s) of entry it 
will be absorbed. Once absorption of a chemical warfare agent has occurred, lethal 
mammalian toxicity is typically of overriding concern. Traditionally, the LD50 value 
gives a good baseline comparison between the toxicities of different compounds. 
Estimated LD50, LCt50 and AEGL values, for human exposure, to either a liquid or 
vapour exposure for a range of volatile liquid chemical warfare agents is given in 
Table 1.2. This can, however, be misleading, especially from a military point of view, 
where any form of incapacitation that can cause casualties will increase the logistic 
burden. 
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Figure 1.2: “Potency spectrum” of chemical and biological agents. Of the chemicals, 
although chlorine and phosgene were extensively used during WWI, they are 
regarded primarily as toxic industrial chemicals (TICS) rather than chemical warfare 
(CW) agents due to their industrial uses. 
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Potency Spectrum Area: Chemical Warfare Agent 
   
Type: Nerve Agent Vesicant 
      
Agent Name 
Tabun 
(GA) 
Sarin 
(GB) 
Soman 
(GD) 
VX Sulphur Mustard 
(HD) 
LD50 21.4 24.3 5 0.07 20 
LCt50 70 35 35 15 900 
AEGL-1 
(Nondisabling) 
0.069  0.069 0.035 0.0057 4.0  
AEGL-2 (Disabling) 0.87 0.87 0.057 0.0065 6.0 
AEGL-3 (Lethal) 7.6 3.8 3.8 0.29 39.0 
 
Table 1.2: Estimated human LD50, LCt50 and Acute Exposure Guideline Levels 
(AEGL) values for agents within the potency spectrum area of chemical warfare 
agents. Values given are in mg.kg-1 (LD50) for a percutaneous liquid exposure or 
mg.min.m-3 (LCt50 and AEGL) for an inhaled vapour exposure. Given LCt50 values 
are for a 2 - 10 minute exposure, whereas, AEGL values are for a 10 minute 
exposure. The AEGL value considers the general population including susceptible 
individuals. NB. Due to assumed equipotent toxicity, values for GF (not shown) are 
the same as for GD. LD50 and LCt50 values are taken from an independent review of 
the U.S. Army's Chemical Defense Equipment Process Action Team (CDEPAT) 
review of the scientific basis for toxicity estimates in use by the Army (National 
Research Council (U.S.) and Committee on Toxicology, 1997). AEGL values are 
taken from work undertaken by the US National Research Council (Subcommittee on 
Acute Exposure Guideline Levels, et al., 2003). 
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1.5.4. Nerve agents 
Organophosphate nerve agents and organophosphate pesticides may be classified 
as organophosphate anticholinesterases due to their similar mechanisms of action 
(Vale, et al., 2003). Whereas organophosphate pesticides have a number of 
applications in both agricultural use and in human and veterinary medicines, nerve 
agents do not. This lack of useful application is due to their inherent acute 
mammalian toxicity. Although the mechanism of action between the two groups of 
compounds is similar, and indeed organophosphate pesticides are often used as less 
toxic simulants of nerve agents, structurally there are differences which account for 
their varying toxicities. Organophosphates that are classified as nerve agents fall 
under schedule 1 of the CWC (Section 1.5.2). 
 
Nerve agents are typically designated as either ‘G’ or ‘V’ agents, dependent on the 
country of discovery or magnitude of their toxicity (Cannard, 2006). Members of the 
‘G’ series of nerve agents include tabun (GA, ethyl dimethylamidocyanophosphate), 
sarin (GB, isopropyl metylfluorophosphonate), soman (GD, pinacolyl 
methylfluorophosphonate) and cyclosarin (GF, methyl cyclohexylfluorophosphonate). 
The ‘V’ series of nerve agents are typified by the phosphonothioate VX. In their pure 
state, nerve agents are colourless liquids of varying physico-chemical properties 
(Table 1.3). As a general rule, the ‘G’ series of nerve agents are more volatile than 
the ‘V’ series of nerve agents. Of the ‘G’ series, GA, GD and GF are expected to 
present relevant contact hazards. Nerve agents are esters of phosphoric or 
phosphonic acids, as such; they have the generalised structure shown in Figure 1.3. 
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Designator GA GB GD GF VX 
      
Formula C5H11N2O2P C4H10FO2P C7H16FO2P C7H14FO2P C11H25NO2PS 
      
CAS No. 77-81-6 107-44-8 96-64-0 329-99-7 50782-69-9 
      
Mol. Wt. 162.13 140.10 182.178 180.2 267.38 
      
Physical state Colourless to brown liquid 
Colourless 
liquid 
Colourless 
liquid Liquid 
Oily, amber 
coloured liquid 
      
Odour Faintly fruity N/A N/A Peaches Odourless 
      
Solubility in 
water (g.L-1 at 
20°C) 
72 Miscible 21 Almost insoluble 30 (at 25°C) 
      
Vapour 
Pressure (mm 
Hg at 20°C) 
0.037 2.10 0.40 0.044 0.0007 
      
Vapour 
density (air=1) 5.63 4.86 6.33 6.2 9.2 
      
Liquid density 
(g.ml-1 at 25°C 1.073 1.102 1.0222 1.1327 
1.006 (at 
20°C) 
      
Melting Point 
(°C) -50 -56 -42 -30 -39 
      
Boiling Point 
(°C) 78 158 198 239 298 
      
Log KOW 1.18 0.15 1.8 N/A N/A 
      
 
Table 1.3: Chemical and physical data for VX and the G series nerve agents. Data 
amalgamated from work carried out during the AEGL reviews (Subcommittee on 
Acute Exposure Guideline Levels, et al., 2003).  
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Figure 1.3: General nerve agent formula, where R = alkyl groups and X = an 
electronegative leaving group (e.g. Fluorine in the case of most of the ‘G’ series of 
agents). A nerve agent’s degree of toxicity depends upon the substituent groups 
attached to the phosphorus atom. 
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R1
R1 R2 X
CH3CH2O CN(CH3)2NTabun, GA
CH3CH2O SCH2CH2N(CH(CH3)2)2CH3VX
(CH3)2CHO FCH3Sarin, GB
(CH3)3C(CH3)HO FCH3Soman, GD
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1.5.4.1. Absorption and toxicity 
Nerve agents are generally encountered in either the liquid or vapour phase. In liquid 
form, skin penetration can be rapid and produces no overt damage to the skin itself, 
although local effects in the form of fasciculation and sweating may occur. As vapour, 
absorption across both the respiratory epithelium and cornea is rapid (Marrs, et al., 
1996). Further routes of absorption include the oral route should contaminated food 
or water be encountered (Vale, et al., 2007). Toxicity may be as a result of binding to 
acetylcholinesterase (with consequent toxic effects manifested from acetylcholine 
accumulation) or as a direct toxic effect from binding at non-acetylcholinesterase 
targets (including other enzymes and direct interaction with cholinergic receptors) 
(Pope, et al., 2005). Toxicity may be either delayed or prolonged due to storage 
within “reservoirs” such as the lung or skin before gradual release of the nerve agent 
(Clement, 1982;Kadar, et al., 1985). 
 
1.5.4.2. Mechanism of action 
The mechanism of action of all the organophosphorous nerve agents is similar; in 
that they have a high, broad spectrum affinity for serine based esterases. The acute 
deleterious effects produced by nerve agents revolve around the inhibition of the 
acetylcholinesterase (AChE) enzyme (Maxwell, et al., 2006). However, there are 
three known types of cholinesterase, namely, AChE, butrylcholinesterase (BuChE) 
and erythrocyte cholinesterase which are all inhibited by nerve agents (Naguib, 
2003). Acetylcholinesterase (EC 3.1.1.7) (Figure 1.4) is located primarily in the 
central nervous system (CNS) both at cholinergic synapses and neuromuscular 
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junctions (Arrowsmith, 2007). The role of AChE in the nervous system is to terminate 
cholinergic neuro-transmission of the neurotransmitter acetylcholine (ACh) (Pope, et 
al., 2005;RamaRao and Bhattacharya, 2012). Under normal physiological conditions, 
the substrate of acetylcholinesterase is acetylcholine. Reaction of acetylcholine at the 
active site of acetylcholinesterase gives rise to acetylation of the serine residue, with 
choline (Ch) being cleaved. Acetylcholinesterase is then regenerated by loss of the 
acetate group. The entire process occurs in a few milliseconds (Silman and 
Sussman, 2005) as shown in reaction scheme (RS) 1:  
 
    .  	
  	    
   	 …  1 
When a mammalian system is compromised by the ingress of nerve agent (NA) by 
any absorption route, the reaction scheme depicted in Figure 1.5 occurs. The first 
step gives rise to an acetylcholinesterase - nerve agent complex occurring at a rate 
dependent on the nerve agent and defined by the acetylcholinesterase inhibition rate 
constant (Ki). Acetylcholinesterase bound within the complex may spontaneously 
reactive at a rate dependent on the nerve agent and defined by the reactivation rate 
constant (Kr). These two steps are defined by the reaction scheme: 
 
    
   X       
  

! …  2 
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Figure 1.4: Left: Acetylcholinesterase (AChE) structure (ProteinBoxBot, 2007). Right: 
The active site of AChE contains residues of histidine, glutamic acid and serine, is 
located within a gorge where catalytic reactions may occur. Adapted from (Soreq and 
Seidman, 2001) 
 
  
Glu 334
His 447
Ser 203
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 Ki (M-1.min-1) Kr (h-1) Ka (h-1) 
    
GA 7.4 ± 0.2 x 106 0 0.036 ± 0.001 
GB 2.7 ± 0.1 x 107 0 0.228 
GD 9.2 ± 0.4 x 107 0 6.6 
GF 4.9 ± 0.006 x 108 0 0.099 ± 0.003 
VX 1.2 ± 0.0002 x108 0.021 ± 0.001 0.019 ± 0.001 
    
 
 
Figure 1.5: Reactions of nerve agents with cholinesterase, where, EST-OH is 
endogenous cholinesterase. The groups R1, R2 and X attached to the nerve agent 
phosphorous atom are defined in Figure 1.3. The rate constants Ki (inhibition rate 
constant), Kr (spontaneous reactivation rate constant) and Ka (aging rate constant) 
are defined for GA, GB, GD, GF and VX (Worek, et al., 2004).  
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The most important reaction rate, as far as nerve agent toxicology is concerned, is 
the reactivation rate of AChE after its reaction with nerve agent. The dephosphylation 
reaction responsible for this proceeds at different rates for different nerve agents, and 
may be complicated by a further reaction, commonly described as “aging” (Figure 
1.5). “Aging” involves the monodealkylation of the dialkyl-phosphonyl enzyme nerve 
agent complex which then becomes resistant to spontaneous reactivation and is an 
issue predominantly associated with Soman (GD). Soman has an "aging" half life of 
around 2 minutes after inhibition of human AChE (compared to Sarin (3 hours) and 
tabun (9 hours) (Worek, et al., 2005). The "aging" rate constants for individual nerve 
agents are defined in Figure 1.5. 
 
For mammals suffering from nerve agent intoxication, reaction schemes one and two 
occur simultaneously as competitive reactions. The spontaneous reactivation rate of 
AChE after reaction with nerve agent is slow (in the order of hours to days). This can 
be compared to the reactivation rate of AChE after reaction with ACh which is rapid 
(in the order of milliseconds) (Silman and Sussman, 2005). Due to this, after reaction 
with nerve agent, the AChE is said to be inhibited. Reaction scheme 2 may be 
rewritten as reaction scheme 3, with a simplification to allow for the negligible 
reactivation of AChE after nerve agent complexation: 
 
    
   X  …  3 
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Inevitably this leads to a depletion of active AChE, and over time, depending on the 
amount of nerve agent present, the reaction schemes 1 and 3 may be combined and 
rewritten to account for AChE depletion (reaction scheme 4): 
 
    
       
  …   4  
 
The toxicological consequence of the AChE inhibition is that at the synaptic cleft (or 
neuromuscular junction) there is a rapid and unchecked accumulation of ACh.  
 
If we consider the situation in the absence of nerve agent, reaction scheme 1 occurs 
without competition. Under these circumstances, the normal physiological role of 
acetylcholine hydrolysis by acetylcholinesterase occurs rapidly. In this situation, 
nerve impulses are transmitted from one synapse across the synaptic cleft by 
acetylcholine to the second synapse. After cholinergic transmission has been 
completed, the acetylcholine is released from the receptors to be hydrolysed by 
acetylcholinesterase. This break down terminates the effects of the nerve impulse. In 
the presence of nerve agent, reaction scheme 3 predominates. The phosphylated 
AChE is rendered unable to hydrolyse ACh (a situation termed as nerve conduction 
block). The accumulation of ACh in the synaptic cleft leads to a prolongation and 
intensification of the cholinergic effects, giving rise to the observed clinical 
manifestations of nerve agent poisoning, which include miosis, fasciculation, 
seizures, paralysis, apnoea and death (Marrs, et al., 1996;Friedewald, 2008).  
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1.5.4.3. Clinical manifestations 
The classical clinical manifestations of nerve agent poisoning are related to the 
effects of acetylcholine accumulation at the cholinergic receptors (Masson, 2011).  
The cholinergic receptors are subdivided into muscarinic and nicotinic receptors 
(based on their sensitivity to muscarine and nicotine respectively) (Rang, et al., 
1999). It is clear that nerve agent poisoning, via disruption of cholinergic transmission 
has consequences throughout the nervous system of a mammalian organism and not 
just at the central nervous system. These consequences may be grouped by receptor 
type and specific organ system effects. Muscarinic receptors are located in 
parasympathetic effector organs and may be divided into a number of subtypes 
which have different actions and are found in different locations. Briefly, M1 receptors 
are found in neuronal tissue, M2 receptors in the heart, M3 receptors in glandular 
tissue, M4 receptors in the striatum and M5 in the brainstem and hippocampus 
(Marrs, et al., 1996). Muscarinic effects mediated by nerve agents can be split 
between glandular specific effects e.g. salivation, lacrimation, sweating, rhinorrhea 
and smooth muscle specific effects e.g. miosis, diarrhoea and bradycardia. Nicotinic 
receptors are ligand gated ion channels located in autonomic ganglia and skeletal 
muscle. Nicotinic effects mediated by nerve agents can be split between autonomic 
ganglia effects e.g. pallor, tachycardia, hypertension and skeletal muscle effects e.g. 
fasciculation. Mention must also be made of nerve agent effects which are not 
mediated via AChE. As previously raised, nerve agents have broad spectrum affinity 
for esterases and may even have a direct effect on muscarinic and nicotinic 
receptors. Other signal transduction pathways that are also susceptible to nerve 
agent effects include calcium signalling, protein kinase C, MAP kinase, transcription 
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factors, cytoskeletal proteins, oxidative stress and the immune system (RamaRao 
and Bhattacharya, 2012) . 
 
1.5.4.4. Specific organ system effects 
Nerve agent exposure via the respiratory route affects both mucous glands and 
smooth muscle (Marrs, et al., 1996). Glandular response gives rise to increased 
secretion manifesting in the forms of salivation (secretion from the mouth) and 
rhinorrhea (secretion from the nose). Smooth muscle effects are exhibited in the form 
of bronchospasm (coughing) and bronchoconstriction (wheezing, tightness in chest, 
dyspnoea). Muscular effects such as fasciculation, sweating and tremor are typical 
signs of nerve agent toxicity that may be located at the site of absorption (in the case 
of percutaneous poisoning) or as a result of more generalised systemic poisoning. 
The response of the eye to nerve agent challenge is that of miosis (constriction of the 
pupil). Low vapour concentrations may elicit this response (Genovese, et al., 2008), 
for which onset is rapid (in the order of minutes) and can take days to resolve 
(dependent upon dose) (Vale, et al., 2003;Yanagisawa, et al., 2006). Miosis is 
traditionally seen as an indicator to nerve agent vapour exposure, although, 
interestingly, miosis may still occur even if the eye is not directly exposed and is 
exhibited via systemic toxicity (Chilcott, et al., 2003). Further eye effects may be 
exhibited through the lachrymal gland (lacrimation) and the ciliary muscle (spasm). 
Eye effects are mediated via the muscarinic receptor. Due to potential muscarinic 
and nicotinic effects overlapping, cardiovascular effects may include either 
tachycardia or bradycardia (Friedewald, 2008).  
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1.5.4.5. Progression of injury 
Progression of nerve agent intoxication will primarily depend on the route of 
absorption and the dose received, however, progression from mild to severe 
intoxication generally proceeds as: local effects such as ocular, respiratory and 
musculature effects which progresses onto cardiovascular and CNS effects including 
respiratory depression, apnoea and death.  
 
1.5.4.6. Diagnosis and treatment  
Survival of the acute cholinergic crisis caused by nerve agent ingress into the body 
will depend on a multitude of factors, including whether the correct diagnosis has 
been obtained and whether appropriate treatment has been given. Other than the 
signs and symptoms described, one of the routine methods available for diagnosis of 
nerve agent poisoning is whole blood cholinesterase determination (Zilker, 2005). 
Whole blood contains both erythrocyte cholinesterase (acetylcholinesterase within 
red blood cells) and butrylcholinesterase (within the plasma). As acetylcholinesterase 
is the enzyme affected by nerve agents at the neuromuscular junction and synapse, 
estimation of its depression using whole blood cholinesterase measurements is of 
great utility.  Links have previously been made between percentage ChE inhibition 
and signs and symptoms of nerve agent poisoning (Chilcott, et al., 2003;Maxwell, et 
al., 2006;Murnford and Troyer, 2011;Hamilton, et al., 2004;Joosen, et al., 2008).  
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Research into medical countermeasures to treat nerve agent poisoning has been 
ongoing for at least sixty years, during that time significant advances have been 
made which support the currently practiced treatment regimes (Hamilton and Lundy, 
2007). Treatment of nerve agent poisoning consists of two phases, immediate (first 
aid) treatment and decontamination which may be given close to the site of the 
exposure, followed by further pharmacological intervention and patient management 
in a hospital environment until the signs and symptoms of nerve agent toxicity have 
abated. Immediate decontamination may take place using an absorbent powder such 
as fullers' earth and / or using a decontaminant showering system depending on 
whether the incident takes place in a military or civilian scenario (Riley, 2003). 
Immediate pharmacological intervention (for military scenarios) is administered in the 
form of the combopen which contains a number of drugs which can alleviate nerve 
agent toxicity. The UK military issue combopen (Vale, et al., 2003) contains a 
muscarinic antagonist, an oxime and an anticonvulsant, namely, atropine, 
pralidoxime and avizafone (a diazepam pro drug). Atropine acts by blocking the 
action of acetylcholine at the muscarinic receptor and alleviates the muscarinic 
effects of nerve agent poisoning (Thiermann, et al., 2011). Oximes (Thiermann, et al., 
1999;Kassa, 2002;Worek, et al., 2007) comprise a group of pyridinium ring 
containing compounds which react with phosphorylated acetyl cholinesterase, 
removing the phosphyl moiety from the active site thereby enabling the acetyl 
cholinesterase to resume its normal physiological function according to the reaction 
scheme: 
 

   %&   …  5 
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As acetylcholinesterase is regenerated by the oxime, the reliance on atropine 
blockading the effects of excess acetylcholine diminishes. Unfortunately, the efficacy 
of acetylcholinesterase regeneration by the oxime is nerve agent specific (Worek, et 
al., 2004) and governed by the time post nerve agent exposure it can be 
administered. It should be noted that soman is particularly resistant to oxime therapy 
due to aging effects. The final drug housed within the combopen is avizafone, a pro 
drug of the anticonvulsant, diazepam. Seizures attributed to nerve agent poisoning 
can be severe, resulting in permanent damage or death to the casualty (Myhrer, 
2007). The use of an anticonvulsant can prevent or lessen the severity of seizures.  
After a casualty has received immediate treatment, been decontaminated and moved 
to suitable facilities, supportive care in the form of artificial ventilation with additional 
oxygen may be required along with further drug therapy (atropine, oxime, 
anticonvulsant) which can be tailored to the specific nerve agent if its identity is 
known (Zilker, 2005). 
 
Ideally, medical countermeasures against nerve agents should be evaluated against 
all the nerve agents they are envisaged to be needed to protect against. Realistically, 
for the timescales of the current programme this would not have been technically 
feasible. Instead, representative agents from each class were chosen on the basis of 
those representing the greatest percutaneous toxicity. From the G series, soman 
(GD), was selected for evaluation.  
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1.5.5. Soman 
Soman belongs to the “G” series of nerve agent and is commonly referred to as GD. 
This series of nerve agent were developed during the Second World War by German 
scientists, with soman first synthesised in spring 1944. A detailed history of the 
development of the “G” series of nerve agents has been compiled by Schmaltz, 
(Schmaltz, 2006). Although rare, a documented case of accidental poisoning in man 
by GD is cited in the literature (Sidell, 1974). The structure of GD is shown in Figure 
1.6. It is important to note that GD possesses two chiral centres in the molecule , one 
at the carbon in the pinacolyl moiety and one at the phosphorous atom, it is therefore 
found as a mixture of four stereoisomer’s (same molecular formula and sequence of 
bonded atoms, differing only in the three dimensional orientations of their atoms). 
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Figure 1.6: Structural Formula for Soman including identification of chiral centres. As 
indicated, soman exists as four stereo isomers. 
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The four stereoisomers are 
denoted as C(+)P(+), C(+)P(-), 
C(-)P(+) and C(-)P(-)
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Under the Cahn-Ingold-Prelog priority rules (CIP) the stereoisomer’s are designated 
RCRP, RCSP, ScRP and SCSP. The optical activity notation C(+)P(+), C(+)P(-), C(-)P(+) 
and C(-)P(-) may also be used, with C denoting chirality in the 1,2,2-trimethylpropyl 
moiety. The second notation system has been adopted for the purpose of this thesis.  
The isomers exhibit differing biological activities. The P(-) isomers have been found 
to exhibit a greater in vivo toxicity and more readily inhibit AChE than the P(+) 
isomers (Benschop, et al., 1981;Benschop, et al., 1984;Little, et al., 1989). The four 
stereoisomer’s comprise of two pairs of enantiomer’s (mirror image, but not super 
imposable) and two pair of diastereoisomer’s (not a mirror image, not super 
imposable) shown in Figure 1.7. 
 
1.5.5.1. Absorption of GD 
At room temperature GD exists as a volatile liquid which is colourless and odourless 
in its pure state. The physicochemical properties of GD are shown in Table 1.4.  As a 
chemical with a significant volatility, the most likely mode for exposure is scenario 
dependent, with absorption of GD likely to occur via the respiratory and percutaneous 
routes. This thesis particularly considers the dermal route of absorption. 
 
1.5.5.1.1. Percutaneous absorption of soman 
In the liquid phase, absorption of soman can occur across the skin to exert systemic 
toxicity without producing a local effect. The skin does, however, possess esterases 
which are able to metabolise GD whilst percutaneous absorption is in progress in a  
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Figure 1.7: The four stereoisomer’s of soman. The two pairs of enantiomer’s are 
separated by the vertical line. The two pairs of diastereoisomer’s are separated by 
the horizontal line. Both CIP and optical activity notation are used to describe each 
stereoisomer. 
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Soman (GD) 
 
Formula 
 
CAS No. 
 
Mol. Wt. 
 
State 
 
Colour 
 
C7H16FO2P 
 
96-64-0 182.18 Liquid Colourless 
 
Melting Point 
 
Boiling Point Density Vapour Pressure Volatility 
-  42 ºC 198 ºC 
 
1.022 
@ 25 ºC 
 
0.40 
@ 25 ºC 
3900 mg m-3 
@ 25 ºC 
 
Vapour Density 
 
Water Solubility Hydrolysis Rate Log KOW Log KOC 
 
6.3 (air =1) 
 
21 g L-1 
@ 20 ºC 
 
45 h T1/2 
@ pH 6.6 
1.78 a 
1.824 b 1.17 
 
 
Table 1.4: Identity and physicochemical properties of soman adapted from Munro 
(Munro, et al., 1999). Where, log KOW is the log of the octanol water partition 
coefficient, log KOC is the log of the organic carbon partition coefficient.  Log KOW 
value “a” obtained from (Benschop and Wesselman, 1989), Log KOW value “b” 
obtained from (Czerwinski, et al., 1998).  
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number of species including mouse skin (van Genderen, et al., 1985), guinea pig skin 
(Fredriksson, 1969b;van Hooidonk, et al., 1980) and human skin (van Hooidonk, et 
al., 1980). Species differences in the rate of soman skin absorption have been 
shown, with human skin being less permeable than mouse skin (van Genderen, et 
al., 1985). 
 
1.5.5.2. Mechanism of action 
A number of esterases that are present in the blood and nervous tissues of mammals 
and are subject to inhibition by soman. These include butrylcholinesterase, 
erythrocyte cholinesterase and acetylcholinesterase. Although the inhibition of 
acetylcholinesterase gives rise to the clinical manifestations of soman poisoning, all 
of the named esterases are inhibited. The effect of soman acting on multiple esterase 
species means that it may be classified as a broad spectrum esterase inhibitor. One 
positive consequence of this, is the systemic removal of soman by esterases other 
than acetylcholinesterase, giving a reduction in the amount of soman being available 
to reach and subsequently bind and inhibit AChE to give deleterious toxic effects. 
Sterri and co-workers conducted a comparison of blood versus brain cholinesterase 
inhibition in the guinea pig after intravenous, subcutaneous and percutaneous 
exposure to soman (Sterri, et al., 1982). The results showed that total inhibition of 
erythrocyte cholinesterase was almost completed within 1 minute for an intravenous 
challenge, by 60 minutes for a subcutaneous challenge or between 90 to 120 
minutes for percutaneous challenge. However, for all the exposure routes, brain 
acetylcholinesterase inhibition although high was not complete.  
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For soman that binds with acetylcholinesterase, soman rapidly loses a fluoride ion 
and phosphoylates the serine residue within the acetylcholinesterase active site. Of 
the nerve agents, soman is most subject to rapid aging (Section 1.5.4.2.). A 
phenomenon which results in permanent inactivation of acetylcholinesterase and for 
soman occurs within a few minutes of binding to AChE according to reaction scheme: 
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Once aging has occurred, soman is no longer amenable to oxime therapy (Section 
1.5.4.6.). 
 
1.5.5.3. Distribution  
Soman distribution to the blood supply from an intra muscular injection is rapid 
(Traub, 1985). From the vasculature, soman is primarily distributed to the highly 
vascularised organs including the liver, lung and kidney where it can remain for 
prolonged periods of time. Shih and co-workers were able to detect GD metabolites 
within the lung of rats for several days (Shih, et al., 1994). The binding of GD to 
tissue proteins in rats was determined to follow the order lung >> kidney > liver > 
brain > diaphragm (Fleisher and Harris, 1965). Due to its action as a broad spectrum 
esterase inhibitor, concentrations of soman in the brain are typically one hundred 
times lower than in the highly vascularised organs, however, even these amounts are 
sufficient to begin distributing to the cerebrospinal fluid (CSF) by two minutes. Traub 
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made the following observations whilst following the time course of soman interaction 
with the brain: By two minutes, brain nuclei were contaminated (indicating binding 
processing occurring from either GD or its metabolites). By thirty two minutes there 
was an observable shift from general neocortical and hippocampal labelling to a 
pattern that implicated cellular uptake rather than neutrophil uptake. At no point did 
the lipid rich sites (myelinated structures) accumulate GD or its metabolites. By 48 
hours, soman was associated predominantly to caudate and accumbens nuclei (in 
comparison with other brain areas) (Traub, 1985).  
 
1.5.5.4. Toxicity of soman 
The toxic effects caused by soman have been studied in a number of species 
including rats, cats and cynomolgus monkeys (Petras, 1994). Across all these 
species the following symptoms have been observed; generalised muscle 
fasiculations and tremor, uncoordinated movements, convulsions, respiratory distress 
and excessive salivation. Soman induced seizures have been linked with muscarinic 
receptor activation (section 1.5.4.3.) which gives rise to a cascade of biochemical 
events that culminate in a glutamate driven limbic static epilepticus (Pazdernik, et al., 
2001). As a result of this, brain damage has been found to be caused by soman in all 
species. It has been postulated that humans surviving GD exposure may experience 
long term nervous system damage with impairment of skilled movement, posture, 
locomotion, cognition, psychiatric disorders and autonomic regulation. It is likely that 
the mechanism for these neurotoxic effects are linked with ischemic hypoxia, cellular 
ischemia or direct soman neurotoxicity (Petras, 1981). Diurnal variation has 
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previously been observed with soman toxicity with lethality highest at 10am and 
lowest at 6pm. These timings correspond closely with periods of greatest and least 
physical activity. Perhaps unsurprisingly, brain cholinesterase levels were lowest at 
the time of greatest GD toxicity (Petras, 1994). The effect of environmental 
temperature can also modify soman toxicity, with conditions of thermal stress, both 
hot (31ºC) and cold (-1ºC) increasing soman toxicity (Wheeler, 1987;Wheeler, 1989). 
The likely reason for this is that the thermoregulatory system is effectively neutralised 
for multiple LD50 GD exposures, meaning that the body is unable to respond to 
temperature extremes whilst poisoned with GD. 
 
1.5.5.5. Metabolism and elimination 
The three major pathways for detoxification of soman include phosphylation of 
esterases and other proteins, enzymatic hydrolysis by phosphorylphosphatases and 
spontaneous hydrolysis (Reynolds, et al., 1985). The importance of each pathway for 
the four stereo isomers of GD have been studied by Benschop (Benschop, et al., 
1987). Essentially, enzymatic hydrolysis was the major pathway for P(+) isomers 
whilst the more toxic P(-) isomers proceed via an irreversible phosphylation pathway. 
Work by Shih supports this theory, with P(+) isomers being metabolised quickly 
(enzymatic hydrolysis)  (Shih, et al., 1994). Briefly, there was a slower hydrolysis 
phase for P(-) isomers with incomplete recovery (due to irreversible protein binding). 
Van Dongen studied soman metabolism using guinea pig, human and mouse skin 
homogenates. The data indicated that P(+) isomers were metabolised by skin 
enzymes, whereas, P(-) isomers were not (as they did not differ from spontaneous 
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hydrolysis rate constants) (van Dongen, et al., 1989). Soman administered 
subcutaneously in rats has been shown to be absorbed and distributed rapidly, with 
detoxification and elimination due to a combination of enzymatic and spontaneous 
hydrolysis combined with irreversible phosphorylation. Due to irreversible 
phosphylation, metabolite pharmacokinetics gave a slower, complex and incomplete 
elimination pattern when compared with sarin and GF (Shih, et al., 1994). 
 
1.5.5.6. Decontamination of soman 
Pathways for the decontamination of chemicals include hydrolysis, thermolysis and 
photolysis. Soman is moderately soluble in water with half lives of the order of 24 
hours. GD breaks down into a number of hydrolysis products (Munro, et al., 1999),  
at a rate which is dependent upon factors including pH and temperature (Broomfield, 
et al., 1986). Between pH 4 and 6 hydrolysis is minimal and constant, however, 
below pH 4 the hydrolysis rate increases exponentially with a more concentrated 
solution degrading more rapidly than a dilute solution. For example, a 2 mg ml-1 
solution in distilled water was 62% degraded by 24h (Shih and Ellin, 1984). Initially, 
hydrogen fluoride (molecular weight 20.01) is released to give pinacolyl 
methylphosphonic acid (molecular weight 180.18, Log KOW 1.63). Subsequent 
cleavage results in breakdown to 3,3-dimethyl-2-butanol (molecular weight 102.18, 
Log KOW 1.48) and methylphosphonic acid (molecular weight 96.02, Log KOW 0.70) 
(Figure 1.8). As for thermolysis and photolysis, soman and its hydrolysis products are 
thermally stable at temperatures less than 49ºC and soman and its hydrolysis 
products exhibit no significant phototransformations in sunlight. 
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Figure 1.8: Hydrolysis pathway for soman. Initially, hydrogen fluoride is released to 
give pinacolyl methylphosphonic acid (PMPA). Subsequent cleavage results in 
breakdown to 3,3-dimethyl-2-butanol (not shown) and methylphosphonic acid.  
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1.6. Skin research methodology 
The primary aim of the work conducted in this thesis was to evaluate the efficacy of 
existing commercial off the shelf (COTS) haemostatic products as skin 
decontaminants for chemical warfare agents. An effective product must have utility 
as a decontaminant not only on undamaged (normal) skin and physically damaged 
skin, but, also retain its haemostatic efficacy in haemorrhaging wounds. The toxic 
nature of chemical warfare agents ethically and morally precludes the use of human 
volunteers for such studies leading to the need to use other appropriate techniques. 
Such techniques can include in vivo animal models or in vitro models, ideally in 
combination so that the 3Rs (Reduction, Refinement and Replacement) of scientific 
animal experimentation can be strictly adhered to. This section will provide a review 
of  the function and morphology of skin along with the techniques available for 
measuring percutaneous absorption. 
 
1.6.1. The skin 
The skin is the largest organ in the body by weight, representing around 4% of the 
bodies mass (Cevc and Vierl, 2010), and, at the simplest level, can be viewed as one 
of the major interfaces between an organism and the environment within which the 
organism is situated. In other words, the structure and function of the skin depends 
on the environment of the species. As a major interface with the environment, the 
skin has an important role not only in protecting the organism from external 
deleterious insults, but also, in the life support mechanism of the organism. These 
functions enable the prevention of systemic and widespread localised damage, but, 
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can be overwhelmed if severe damage is inflicted with the resultant manifestation of 
acute or chronic injury. The functions of the skin are many and diverse, but may be 
classified broadly into defensive and supportive functions. Defensive functions can 
be assigned as antimicrobial, immune, prevention of percutaneous penetration, 
physical, thermal and ultraviolet. Life support functions may be classified into 
temperature regulation and prevention of catastrophic water loss (Lee, et al., 2006). 
 
Barrier function at the boundary with the environment is essential for the 
maintenance of both temperature (via sweat and arteriovenous anastomoses) and 
electrolyte and fluid balance (with water and nutrients being retained within the 
organism). Conversely, toxic environmental substances, viruses and bacteria are, to 
a certain extent, prevented entry. Where entry occurs, the skin is capable of 
xenobiotic metabolism.   
 
The skin is a sensory organ (touch and pain) capable of surveillance and action, 
responding to mechanical force and transmitting contact with the external world. The 
skin synthesises, processes and metabolises proteins, lipids and signalling 
molecules and is an integral component of the immune, nervous and endocrine 
systems. Further important functions include protection from physical damage, 
protection from ultra violet light (via melanocytes), automatic repair (wound healing) 
by continuous cell turnover, acting as a blood reservoir and being the site for Vitamin 
D synthesis. 
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1.6.2. Skin morphology 
Histologically, human skin can be subdivided into three main layers, namely the 
epidermis, dermis and hypodermis (Rushmer, et al., 1966), throughout which 
cutaneous appendages are spaced at irregular intervals (Figure 1.9). These in turn 
can be further subdivided into individual cell types and functions (Urmacher, 1990). 
The epidermis is the outermost layer of the skin, covering an area of 2 m2 (Hadgraft, 
2001) averaging between 0.06 and 0.1 mm thick across the human body except for 
the palm and sole where it exceeds 0.5 mm (Hsia, 1971). The epidermis comprises 
two distinct layers, the stratum corneum which comprises the upper 5 – 20 µm of the 
epidermis and the viable epidermis which comprises the lower 50 – 100 µm that is in 
direct contact with the dermis (Figure 1.10) (Holbrook and Odland, 1974). The dermis 
is a thicker layer of supportive, viable, connective tissue with nerve, lymphatic and 
vascular networks that on average is between one and two mm thick (although the 
boundary between this and the innermost layer of subcutaneous tissue is ill defined 
with no definite border, (Hsia, 1971)). The dermis is the source of cutaneous 
appendages such as hair follicles, sweat glands and sebaceous glands. The 
subcutaneous tissue (or hypodermis) is in direct contact with the dermis and 
averages a thickness of one to two mm and consists of lobules of fat cells. The 
morphology of the skin defines how the skin acts as an effective barrier to the 
percutaneous penetration of xenobiotics, with the outward facing stratum corneum 
representing a substantial barrier (Figure 1.11).  
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Figure 1.9: Schematic cross section through human skin. The subdivision into the 
three major layers: epidermis, dermis and hypodermis are indicated along with the 
major structural components. Photograph of Adam Rouilly skin section block model, 
Kent, UK.   
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Figure 1.10: H&E staining of human skin. The main layers of the skin are indicated. 
Keratin and erythrocytes stain red, the cytoplasm stains pink and cell nuclei stain 
blue. 
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Figure 1.11: Simplified diagram of the epidermis (defining individual cell layers), 
dermal epidermal junction and upper dermis. For a hazardous chemical present in 
the environment to reach the peripheral circulation and from there systemic toxicity, 
the stratum corneum must first be breached. Note: skin appendages are not shown 
on this diagram. 
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1.6.3. The epidermis 
The epidermis comprises keratinocytes, melanocytes, Langerhan’s cells and Merkel 
cells, each of these cell types have specific roles in the maintenance or protective 
function of the epidermal layer. The keratinocytes synthesise the stratum corneum, 
via a process of apical migration and comprise approximately 95 % of the epidermal 
layer (Menon, 2002). Melanocytes are involved with the skins pigmentation (Wickett 
and Visscher, 2006), Langerhan’s cells are involved with antigen presentation and 
immune responses (Callard and Harper, 2007) and Merkel cells are involved with 
sensory perception (Schaefer and Redelmeier, 1996).   
 
1.6.3.1. The stratum corneum 
The outermost extremity of the epidermis is the stratum corneum or horny layer. The 
stratum corneum is the non viable epidermis comprising a number of cell layers of 
flattened, stacked, hexagonal cornified cells (measuring 15-25 µm thick) that are in 
direct contact with the environment (Hadgraft, 2001). Anatomical location dictates the 
number of cell layers with genital skin having the least layers (4 to 8 layers) followed 
by the face, neck and scalp (7 to 14 layers) and extremities (12 to 19 layers). The 
palm and soles have (23 to 71 layers) and the heels have the greatest number of 
layers (50 to 122 layers) (Ya-Xian, et al., 1999). Individual corneocytes have a 
diameter of 20 to 40 µm and are 0.5µm thick (except for the palms and soles where 
the thickness increases by approximately 10 fold) and contain 70% insoluble bundled 
keratin by weight. The corneocytes origin can be traced back to an individual basal 
cell in the basal layer that is the interface between the epidermis and dermis (Cevc, 
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1996). Cell nuclei and other cellular organelles are absent in the stratum corneum. 
Skin hydration is low (10 – 30%) compared to that of the body (70%) (Menon, 2002).  
 
The extracellular region surrounding each corneocyte contains a variety of lipids and 
desmosomes which allow for effective cohesion between corneocytes. Desmosomes 
are intercellular junctions that provide strong adhesion between cells (Garrod and 
Chidgey, 2008). Corneodesmosomes, the desmosomes that join the corneocytes 
differ from those that join epidermal keratinocytes by the addition of the protein 
corneodesmosine (Wickett and Visscher, 2006). These intercellular tight junctions 
provide strong adhesion between the corneocytes and give the stratum corneum its 
rigid structure. Corneodesmosomes are gradually digested by proteases (including 
desmosglein I and stratum corneum chromotryptic enzyme (SCCE) leading to 
desquamation (Wickett and Visscher, 2006). Both the corneocytes and the 
intercorneocyte lipids are derived from keratinocytes through the terminal 
differentiation process. For normal skin the process of desquamation, the time for 
complete turnover of epidermal cells, takes from two to three weeks, however, 
disease states such as psoriasis can lower this to two to four days leading to 
substantially impaired barrier function (Lebwohl and Herrmann, 2005).  
 
The extracellular lipid matrix can be categorised into three main groups; cholesterol, 
ceramides and free fatty acids, accounting for approximately 90% of the lipid weight 
in the stratum corneum (Feingold, 2007). Cholesterol derivatives include cholesterol 
esters (2 - 5 % of SC lipids), free cholesterol (27 % of SC lipids) and cholesterol 
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sulphate (3% of SC lipids) (Wilkinson, 2008). Ceramides comprise over 40% of SC 
lipids and can be subdivided into a number of ceramide classes. The number of 
known ceramide classes have increased from  nine (Bouwstra and Ponec, 2006) to 
eleven (Masukawa, et al., 2008) to the current number of twelve (van Smeden, et al., 
2011), referred to as CER 1 to 12, they have small head groups that can form lateral 
hydrogen bonds with adjacent CERs. The tail groups of the CERs typically have a 
chain length of C24-C26 although a small fraction have a chain length of C16-C18 
(Bouwstra, et al., 2003). Fatty acids account for a further 9 % of SC lipids with the 
remaining 11% accounted for by triglycerides and others (Wilkinson, 2008). The 
spatial arrangement of these lipids is to form bilayers with aqueous and lipid domains 
consisting of hydrophilic head groups and lipid tail groups of 6 nm and 13 nm 
periodicity, stacked as lamellae as defined in the sandwich model (Bouwstra, et al., 
2003).  
 
1.6.3.2. The viable epidermis 
The stratum granulosum comprises increasingly flattened cells from one to three 
layers thick containing keratohyalin granules. The thickness of this layer can be seen 
as representative of the keratinisation rate, with the stratum granulosum largely 
absent in disease states such as psoriasis. Keratohyalin granules themselves are 
dense irregular amorphous deposits which lie along keratin filaments. They are found 
not only in the stratum granulosum but also the stratum spinosum, and comprise 
profilaggrin, loricin, cystatin A and keratins K1 and K10. Loricin and cystatin A are 
components used to construct the cornified cells. Profilaggrin, a highly 
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phosphorylated, histidine rich basic protein forms filaggrin within the granular layer 
(McGrath and Uitto, 2008). Filagrin aggregates along keratin filaments and 
undergoes proteolysis within the stratum corneum to release amino acids which act 
to retain epidermal moisture (Hsu, et al., 2008).   
 
The stratum spinosum comprises layers of polyhedral cells which begin to flatten as 
they approach the stratum granulosum. The stratum spinosum is rich in desmosomes 
which connect adjacent cells, giving rise to the layers alternative name, the prickle 
cell layer. The process of keratinisation begins in this layer with the synthesis of 
keratin filaments K1 and K10. Lamellar bodies of size 0.1 x 0.5µm (also known as 
Odland bodies or keratosomes) appear within keratinocytes in the stratum spinosum 
layer and are the main source of skin lipids, occupying 20% volume of the 
keratinocyte. These lipids are arranged as striated sheets containing acyl ceramide, 
acylglucoceramides, phospholipids, free sterol and cholesterol sulphate. A number of 
enzymes are also present in the lamellar bodies and include acid hydrolase, 
sphingomyelinase and phospholipase A2. 
 
The stratum basale comprises a single layer of cuboidal cells which adhere to the 
basement membrane via hemidesmosomes. In disease states this layer may be two 
or three layers thick. The stem cell keratinocyte population is contained in this layer 
along with melanoctyes which are primarily located in the stratum basale. 
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The basement membrane between the epidermis and dermis is an irregular layer due 
to upward indentations by dermal papillae and is typically 50 to 70 nm thick. It 
comprises two layers, the lamina densa and lamina lucida which contain type IV 
collagen (for mechanical stability) and laminin and bibronectin (for basal cell 
attachment).   Nutritive, immune and support systems are provided by the dermis to 
the epidermis via this junction, with restriction on the transfer of solutes based on 
charge and size allowing normal migrating cells, such as melanocytes and 
Langerhan’s cells, to pass. A major role of the dermal epidermal junction is to control 
keratinocyte production. 
 
1.6.3.3. Epidermal renewal and keratin development 
The epidermis undergoes continual turnover (known as apical migration) 
commencing at the stratum basale where a single layer of proliferative stem cells 
reside (Brouard and Barrandon, 2003) attached via hemi desmosomes to the dermal 
epidermal junction. These basal cells express several characteristic markers, 
including keratins and transcription factors (Fuchs, 2008). The basal epidermal stem 
cell periodically withdraws from the cell cycle, differentiates terminally to an epidermal 
keratinocyte, detaches from the basement membrane and begins the transit process 
through the epidermis leading to eventual sloughing from the skin surface as a 
corneocyte. The migration process is activated by protein kinase C and Ca++ which 
leads to the disintegration of the hemidesmosome and the formation of desmosomes. 
Within the basal layer there are low levels of the keratin filaments K5 and K14 which 
gives the keratinocyte some strength but still allows for cell division. As it migrates 
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upwards, the epidermal keratinocyte progresses through three differentiation phases 
which account for varying properties of each of the epidermal layers; spinosum, 
granulosum and corneum. The epidermal keratinocyte is forced towards the skins 
surface by the freshly produced epidermal keratinocytes beneath it. After leaving the 
stratum basale, the migration continues to the basale / spinosum layer transition. 
Here, changes in morphology and function occur with the synthesis of keratin by a 
shift in production from K5 and K14 keratin filaments to K1 and K10 keratin filaments. 
As the keratinocyte traverses the stratum spinosum, keratin accumulation reaches 
about 40% of the keratinocytes total protein (Rice and Cohen, 1996).  The plasma 
membrane thickens in upper spinous regions at the same time as lamellar bodies 
and keratohyalin granules appear. At the stratum spinosum / granulosum interface, 
profillagrin synthesis begins within keratohyalin granules and the keratinocytes 
undergo morphological transformation. The transformation involves a flattening of the 
cells structure along with an increase in cell volume. The cell’s plasma membrane, 
loses its phospholipid content to be replaced by sphingolipid, in the process 
becoming permeable, leading to a loss of the intracellular environment (Rice and 
Cohen, 1996). Without this environment, the keratin proteins extensively bond with 
each other through disulphide links. At the stratum granulosum / corneum interface, 
profillagrin begins to be converted into fillagrin leading to a zone of stable filaggrin. At 
this time the keratinocytes nucleus and other organelles undergo apoptosis and a 
cornified envelope is formed around the cell. The end product of these changes is the 
corneocyte which contains about 70% keratin and is surrounded by an intercellular 
lipid layer. After a time period of approximately a month from mitosis, the epidermal 
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keratinocyte reaches the surface of the stratum corneum where it is shed in the form 
of horny cell flakes (Fuchs, 2008). 
 
In terms of genetic programming apical migration follows the sequence proliferation, 
differentiation, apoptosis. Apoptosis as the final program in the sequence maintains 
epidermal homeostasis by balancing cell death in the stratum granulosum with 
proliferation in the stratum basale. The key enzymes involved in apical migration are 
transglutaminases (soluble involucrin and cystatin A are early substrates to form a 
scaffold to which insoluble precursors such as the main protein loricin are added in 
latter stages). Involucrin, cystatin A and loricin are only a few of the structural 
proteins in the cornified envelope, others include elafin, small proline rich proteins, 
keratin intermediate filaments, trichohyalin and filaggrin.  
 
1.6.4. The dermis 
The dermis is a vascularised, innervated tissue with appendages interspersed 
throughout. Both elastic and compressible it supports and protects the epidermis. 
The dermis comprises cells, fibrous molecules and a ground substance 
(macromolecules filling the space between fibres and dermal cells) (Kanitakis, 2002). 
As with the epidermal layer, anatomical location determines the thickness of the 
dermis with the palms and the soles having the greatest depth. Structurally the 
dermis can be subdivided into the upper papillary dermis, mid reticular dermis and 
deep dermal layers. Contact between the papillary dermis and the epidermis is 
provided by dermal papillae which project upwards and alternate with epidermal rete 
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ridges. The dermis comprises an interstitial collagen framework (approximating to 
seventy percent of dry skin by weight (Schaefer and Redelmeier, 1996)) which acts 
as a skeleton that the other tissues of the dermis build on and gives the skin its 
mechanical resistance. The collagen fibres are arranged within loose bundles in the 
papillary layer and become more tightly bound within the deeper dermal layers.  The 
skin’s elastic properties are provided by elastic fibres (elastin) which become thicker 
in the deeper dermal layers. The dermis contains a number of cell types. Cell types 
of note are the fibroblasts (that produce the fibres and ground substance) and the 
monocytes involved in cellular defence systems including phagocytosis, immune 
responses and antimicrobial agent release (Schaefer and Redelmeier, 1996). 
Melanocytes, involved with skin pigmentation, are also present within the dermal 
layer. The dermis, in comparison with the epidermis, is more permeable and 
vascularised, forming the bulk component of the skin. The vascular system runs 
throughout the dermal layer and is responsible for provision of the skin’s nutrients 
whilst at the same time allowing the body to thermally regulate itself. Functionally, the 
dermal layer contains the sense organs which detect pain and pressure perception 
along with cushioning and insulation. Appendageal support is also provided by the 
dermis. 
 
1.6.5. The hypodermis 
The deepest, innermost layer of the skin is the hypodermis which is mainly comprised 
of fat cells (adipocytes). Adipocytes are large (up to 100µm) rounded cells containing 
triglycerides and fatty acids within the cytoplasm (Kanitakis, 2002). Functionally, as 
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well as giving protection against mechanical injury the hypodermis is associated with 
insulation, thermoregulation and energy storage (Schaefer and Redelmeier, 1996). 
 
1.6.6. Other structures and cells within the skin 
Merkel cells (or touch cells) are present in the stratum basale layer of the epidermis 
and are involved with the sensory perception of pain, itch and temperature (Boulais 
and Misery, 2007). As such they are part of the peripheral nervous system, with 
Merkel cell-neurite complexes comprising sensory afferents and Merkel cells. The 
importance of Merkel cells to the somatosensory system has been recently confirmed 
(Maricich, et al., 2009). Langerhans cells are present in the stratum spinosum layer 
of the epidermis and are involved with the capture, uptake and processing of 
microbial antigens  (Valladeau, 2006).  
 
Hair follicles populate the entire cutaneous surface except for the soles of the feet 
and the palms of the hands. Functionally they provide insulation and sensory 
perception. Hair is morphologically and biologically different in different parts of the 
body, and varies in structure, rate of growth and response to stimuli (Giacomoni, et 
al., 2009). Hair types include lanugo (fetal hair), vellus and terminal (scalp, eyebrow 
and beard).  
 
Sebaceous glands secrete sebum via the differentiation and disintegration of 
sebocytes (termed holocrine secretion as the whole excretory cell is secreted) 
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(Schneider and Paus, 2010). In the human sebaceous gland, sebum comprises; 
squalene 15%, wax esters 25%, cholesterol 2.5%, cholesterol esters 2%, 
triglycerides 42% and fatty acids 15% (Walters and Roberts, 2002). The majority of 
sebaceous glands are associated with hair follicles (to form the pilosebaceous unit), 
however, hair follicle free sebaceous glands are found in the eyelids, nipples, genitals 
and ears (Schneider and Paus, 2010). Functionally, the purpose of the sebaceous 
gland is to secrete sebum.  Sebum itself aids in the maintenance of skin barrier 
function (Proksch, et al., 2008).  
 
Sweat glands are located in the dermis and produce sweat which is secreted through 
ducts onto the skin surface. Sweat glands may be either eccrine (secretion is 
released from the cell without distintegration) or apocrine (secretion occurs via pinch 
off of outer cell parts) (Wilke, et al., 2007). However, sweat glands showing 
characteristics of both gland types (known as apoeccrine glands) have also been 
observed (Sato, et al., 1987). The apoeccrine sweat duct is present in axillary skin 
and active only after puberty. Eccrine sweat glands populate the entire cutaneous 
surface area except for muco-cutaneous junctions. By anatomical location, the 
approximate number of eccrine glands per square centimetre are; back 64, forearm 
108, forehead 181, palms and soles 600 to 700 (Saga, 2002). A key function of the 
eccrine sweat gland is the thermoregulation of the body by sweating of an odourless, 
colourless hypotonic solution (pH 4.5 to 5.5) leading to evaporation and consequently 
cooling. Sweat is released from the eccrine sweat glands at a rate of 2 to 16 nl min-1 
gland-1 whilst sweating (Sato and Dobson, 1970). The secretory coil of the eccrine 
gland is 60 to 80µm in diameter and 2 – 5 mm in length (Saga, 2002). The apocrine 
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gland is a short duct gland sweat duct only active after puberty and restricted to hairy 
body areas (as it opens and secretes into the hair canal) (Wilke, et al., 2007). The 
secretion from the apocrine gland is oily and odourless containing lipids, protein and 
steroids. The milky appearance of apocrine sweat secretion may be due to mixing 
with sebum (due to the close proximity of the sebaceous gland) with any resulting 
odour due to bacterial action (Giacomoni, et al., 2009).  
 
1.6.7. Xenobiotic metabolism in skin 
The metabolising potential of the skin has been estimated to be approximately 2% 
that of the liver. One of the key differences between skin and liver metabolism is that 
of contact time, being long with skin enzymes and short with liver enzymes due to a 
blood flow of around 1 to 1.5 L min-1. Metabolism can be classed as endogenous 
(metabolism of hormones, steroids and inflammatory mediators) or exogenous 
(metabolism of xenobiotics, including chemicals from accidental or deliberate 
release). Many of the enzyme systems found in liver are also present in the skin and 
include esterases, reductases, hydrolases, peptidases and oxidative enzymes. 
Specific Cytochrome P450 dependent monooxygenase located with the skin include 
CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C9, 2C18, 2C19, 2D6, 2E1, 3A4 and 3A5 
(Svennsson, 2009).  
 
1.7. Xenobiotic percutaneous penetration 
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Section 1.6 has given a detailed description of the various skin layers and the 
structures and cells associated with them. Although the skin layers are capable of 
acting as a barrier to prevent the ingress of the vast majority of xenobiotics, 
environmental contaminants that possess the suitable physicochemical 
characteristics are able to penetrate through the skin. Of importance is work that has 
been carried out to determine the exact location within the skin of the main barrier to 
the ingress of xenobiotics and transport mechanisms through this barrier. 
 
As early as 1853 researchers had determined that the skins layers were not equally 
permeable (as reviewed by Scheuplein) (Scheuplein, 1976). Defence research 
carried out during the First World War into sulphur mustard skin interactions 
determined that repeated swabbing of a contaminated area of skin with kerosene 
could prevent vesication (for an exposure time of less than 15 minutes). Their initial 
conclusion was “It is quite evident that the dichloroethylsulfide is at first rapidly taken 
up by some element on - or adjacent to - the surface of the skin, and for 2 to 3 
minutes it may be completely removed, and for 10 to 15 minutes partially removed by 
prolonged washing with an organic solvent” (Smith, et al., 1919). The implication was 
that the skin barrier function must reside within the upper surface layers of the skin. 
Sulphur mustard extraction from the skin has since been evaluated in vitro with the 
conclusion that kerosene can remove sulphur mustard from the upper layers of the 
skin, supporting the conclusions of Smith (Hattersley, et al., 2008). Tape stripping 
studies were used to show that the barrier layer to the skin unequivocally resided 
within the stratum corneum (Blank, 1953). Since then more modern biophysical 
techniques such as transepidermal water loss (TEWL) have been in conjunction with 
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tape stripping to show that as the number of skin surface tape strips increase (and 
hence the removal of more surface skin layers) that TEWL also increased. TEWL is 
commonly used as a measure of skin barrier function although recent work has 
raised doubts to exactly how TEWL relates to the functionality of the skin barrier 
(Chilcott, et al., 2002). These studies confirm that the barrier to the ingress of 
xenobiotics resides within the stratum corneum. If the skin barrier is perturbed or 
removed by any form of damage, including blunt or penetrating trauma, the rate of 
absorption of xenobiotics from the surface of the skin will likely dramatically increase. 
Consequently, the employment of any dermal decontamination system would be 
more likely to prove less efficacious if applied to damaged skin rather than 
undamaged skin.  
 
The morphology of the stratum corneum, comprising corneocytes containing densely 
packed keratin protein and intercellular spaces composed of lipid bilayers with both 
hydrophilic and lipophilic domains provides the skin with its barrier function. However, 
it does not provide a perfect barrier as xenobiotics are able to penetrate the skin, 
although they are subject to using skin transport mechanisms. For a substance to 
penetrate through the skin, a number of factors will determine the extent and 
magnitude of the penetration.  
 
i. Solubility of the substance in the phase in which it is applied to the skin is 
of importance (unless the substance is applied in undiluted form). 
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ii. The ability of the penetrant to partition from the applied substance to the 
stratum corneum and, from there diffuse across the stratum corneum. 
iii. The ability of the penetrant to partition from the stratum corneum and into 
the viable epidermis.  
iv. Partitioning from the viable epidermis to the peripheral circulation within the 
papillary dermis. 
 
1.7.1. Diffusion 
Mathematically, diffusion processes through a single layer, simple membrane can be 
defined according to Fick’s first law, which relates diffusive flux to concentration 
through the postulation that flux goes from regions of high concentration to low 
concentration such that: 
+ ,  -. /001 
Where, J is the flux per unit area, D is the diffusion coefficient (negative due to 
molecular transfer occurring in the opposite direction to the concentration gradient), 
C is the concentration gradient and x is the linear distance travelled. 
 
Conventionally, Fick’s first law is rewritten as: 
+22 ,  34  5 
Where, JSS is the steady state flux per unit area, Kp is the permeability coefficient for 
the penetrant (from a given vehicle, unless applied neat) and C0 is the concentration 
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of the penetrant in the vehicle (assumed to be equal to the density of the penetrant if 
applied neat). 
The permeability coefficient comprises a number of parameters and can be rewritten 
as: 
36 ,  
37
8
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7  
Where, KM/V is the partition coefficient of the penetrant between the membrane and 
vehicle, DM is diffusion coefficient of the penetrant in the membrane and hM is the 
diffusional path length of the membrane. The reciprocal of the permeability coefficient 
is known as the total barrier resistance, R, and takes the form: 
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Each barrier phase has its own resistance which is additive when a series of barrier 
phases are encountered. As an approximation, for the skin, this may be confined to 
the stratum corneum and the viable epidermis: 
9:;<= >  2?   8@ 
Given that the skin cannot be regarded as a simple homogenous membrane, 
parameter value determinations for Kp and R are not simple tasks. However, 
permeability coefficients are experimentally determined parameters which inherently 
take into account the complexity of the membrane. The flux experiment allows 
experimental determination of the steady state flux (JSS) from which Kp and R can be 
derived according to Fick’s First Law, previously defined as: 
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The JSS is determined as the gradient of the steady state slope of the cumulative 
amount penetrated against time (Figure 1.12).  
 
1.7.2. Location of the barrier within the stratum corneum 
Transport of a penetrant through the skin can be broken down into a list of four likely 
possibilities (Figure 1.13), direct transport through the corneocytes (transcellular 
route), through the lipid bilayers surrounding the corneocytes (intercellular route), 
along hair follicles (transfollicular route) or through sweat glands (eccrine route). 
Barrier resistance is one of the evidence bases that have been used to confirm the 
most likely route for percutaneous penetration. The barrier resistance, R, has been 
experimentally derived for various compounds of increasing alkyl chain length 
including alkanols (Scheuplein and Blank, 1973). The alkanol studies showed that 
barrier resistance dropped exponentially with increasing alkyl chain length indicating 
that skin permeability increased as a function of alkanol hydrophobicity. It can be 
inferred therefore that the barrier resistance is lessened for environmental 
contaminants that can partition and diffuse across a lipid pathway. Further evidence 
for a primarily lipid pathway for skin diffusion is offered by the use of skin penetration 
enhancers that either dissolve lipids (organic solvents such as DMSO) or destabilise 
liquid crystalline phases (amphiphilics such as Azone (Engblom, et al., 1995)). 
 
  
  
 
Figure 1.12: Example of experimental determination of the Steady State Flux (J
taken as the gradient of the slope of cumulative amount penetrated against time 
(after the initial lag time has elapsed). Data shown is that of neat 
through dermatomed pig skin (mean ± standard deviation of n=6 animals)
al., 2006a). The JSS was 207 ± 62 g cm
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 h-1 (x 10-6) and the lag time was 6.3 ± 0.9 h.
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Figure 1.13: Potential routes of percutaneous penetration 
(penetration through the intercellular lipids), 
transcellular (direct transport through corneocytes)
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A popular analogy is to equate the properties of the stratum corneum to that of a 
brick wall, with the corneocytes taking on the role of the brick and the intracellular 
lipids taking on the role of the mortar. The bricks (that are ionic in nature) are 
comprised of dense protein and lack a lipid phase. The mortar, however, comprises 
lipid bilayers, and based upon the evidence, offers the likely route for the passage of 
the majority of penetrants when comparing the two.  
 
This leaves the follicular and eccrine routes as possible percutaneous absorption 
pathways, although, it is important to note that hair follicles and sweat ducts are not 
evenly distributed across the skins surface, so any role they may play would likely be 
as a co-pathway alongside the intercellular route. The surface area occupied by hair 
follicles is small (up to 1% of skin surface area). Apocrine glands and hair follicles are 
co-located meaning that apocrine secretions mix with sebum within the hair follicle 
before the skin surface is reached. On this basis, the follicular route is a lipophilic 
route and cannot be ruled out as a potential co-pathway alongside the intercellular 
route. The surface area occupied by eccrine glands is small (approx 1/10 of that 
occupied by hair follicles), functionally eccrine glands are empty when inactive and 
express large volumes of water when active meaning that the eccrine route is not a 
lipid pathway and can be ruled out as a penetration pathway.  
 
1.7.3. Factors affecting the penetration rate of a penetrant 
Given that the intercellular route through the lipid bilayers offers the most likely 
explanation for skin transport through the stratum corneum, thought also needs to be 
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given to the penetrant itself. The ability of a penetrant to partition between the various 
phases required for skin transport relies on the penetrant having a suitable molecular 
weight, typically less than 500 Daltons, known as the rule of 500 (Bos and Meinardi, 
2000) indicating that to some extent the stratum corneum acts as a molecular weight 
filter. Solubility parameters such as the octanol water partition coefficient should be 
within a suitable range, typically a negative log P value indicates that a substance will 
be too hydrophilic to penetrate the skin, whilst a log P value greater than three 
indicates that a substance will be too lipophilic and will be primarily retained within 
the stratum corneum. Charge on a penetrant will also impact the likelihood of 
percutaneous penetration. Generally, charged molecules will poorly penetrate the 
stratum corneum due to localised protein charges. It should be noted that this 
interaction can be overcome using iontophoretic techniques. The presence of 
hydrogen bonding groups on a penetrant will also limit percutaneous penetration due 
to interaction with hydrogen bonding groups present within the stratum corneum. The 
skin itself may also influence the penetration of the penetrant. Factors that may have 
a profound influence include anatomical location, age, gender, race, species, stress, 
disease states, follicular density, damage, regional blood flow and skin hydration 
status. The environment the skin is in will also have an influence on percutaneous 
penetration. Environmental temperature, diurnal variation, state of occlusion, vehicle 
(if any) that the penetrant is contained within are all factors that need consideration. 
 
1.7.4. Predicting skin permeability 
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To summarise, the process of percutaneous penetration is complex and a wide range 
of factors need to be taken into account before prediction of skin penetration can be 
made. However, this has not stopped research groups from developing a number of 
models for predicting skin permeability. A number of models have been developed 
for predicting skin permeability coefficients including, by amongst others, Potts and 
Guy (Potts and Guy, 1992), Kasting (Kasting, et al., 2008) and Lee (Lee, et al., 
2010). These models link the permeability coefficient (KP) to the octanol water 
partition coefficient (Koct) or the log of the partition coefficient (log Koct or log P) and 
the molecular weight (MW) of the compound according to the equation: 

A 34 ,  
A 3:B; -  C DE - 	 
Where, a, b and c are numerical values determined by the research group. The 
octanol-water partition coefficient is determined from the distribution of a chemical 
species between octanol and water and as such gives a measure of the chemicals 
lipophilicity.  
 
The use of linear regression models allows for the development of in silico modelling 
techniques which allow the prediction of KP values without the need to perform 
experimental studies. 
 
1.8. Measuring percutaneous penetration 
Models available for determining percutaneous penetration include; in silico 
mathematical models (used for both modelling existing data sets to extend to similar 
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compounds and for rank order correlations), in vivo animal models (used for 
evaluation of selected products), in vitro skin models (a variety of types including 
artificial, cultured, animal and human may be used depending on the study) and in 
vivo human models (the gold standard, however, ethical and moral constraints 
preclude use either entirely or until the pre clinical or clinical trials phase). Defence 
research, of the type this work aims to further, will not use an in vivo human 
approach, instead down selection of candidate products will be achieved using 
relevant in vitro techniques prior to validation of lead candidate(s) using a relevant 
animal model in vivo. 
 
1.8.1. In vitro percutaneous penetration determination 
The in vitro determination of percutaneous absorption offers a number of unique 
advantages not available when conducting in vivo studies. The precise control of 
experimental conditions (other than the skin membrane) is of immense value in 
obtaining reproducible data detailing both the permeation of a substance and its 
distribution within the skin. From the point of view of defence research seeking 
countermeasures against particularly toxic chemicals, in vitro human skin may be 
used to extrapolate how effective a countermeasure is likely to act in the in vivo 
human gold standard. Disadvantages with in vitro modelling are evident in the lack of 
a circulatory system and the inherent difficulties in preparing metabolically viable skin 
preparations. These disadvantages mean that pharmacokinetic effects (post skin 
penetration), pharmacodynamic effects (including vasodilation / vasoconstriction) and 
metabolic products resultant from transcutaneous metabolism are not elucidated. 
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Determination of percutaneous penetration is typically achieved using in vitro skin 
diffusion cell methodology (Figure 1.14). A variety of different diffusion cell designs 
have been developed using static and flow through techniques, however, the basic 
premise remains constant, that of a donor chamber in direct contact with the upper 
surface of a skin preparation and a receptor chamber in direct contact with the lower 
surface of the skin preparation. The penetrant of interest is placed onto the upper 
skin surface within the donor chamber and then time course samples are taken from 
a suitable receptor media within the receptor chamber. 
 
1.8.1.1. Guidelines concerning percutaneous penetration studies 
An understanding of what in vitro models can achieve is necessary before they can 
be used to determine experimental aims. To this end a number of protocols and 
guidelines have been assembled to enable skin researchers to execute studies that 
will be accepted by the wider scientific and non scientific communities. Perhaps the 
most useful of these is the Organisation for Economic Co-operation and 
Development (OECD) guideline 428 (OECD, 2004b), and its associated guidance 
documents (OECD, 2004a;OECD, 2010), which set the standard as to what is 
acceptable when conducting in vitro skin penetration studies using diffusion cells. 
These guidelines attempt to ensure that in vitro studies are carried out appropriately 
and aim to reduce variability from laboratories within different organisations.  
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Figure 1.14: In vitro static diffusion cells. Top left: From top - donor chamber, support 
or ‘frit’ for the skin sample. Magnetic stirrer bar which ensures even distribution of 
penetrant in the receptor fluid. Clamp which holds the ensemble together. Receptor 
fluid is subsequently collected via the sampling arm after removal of the ‘hat’. Top 
right: Jacketed variant – water is pumped through the outer jacket to maintain a 
constant receptor fluid temperature. Bottom: Bank of 9 jacketed diffusion cells in situ 
on a stirrer block. Visible to the rear are the tubing attachments for the heated 
jackets. 
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The OECD guidelines offer advice on all aspects of in vitro diffusion cell systems 
methodology, a detailed synopsis of which now follows due to the core of the 
research presented within this thesis, in either using or further validating, in vitro skin 
penetration techniques. The diffusion cell itself may be of the static or flow through 
type and should be constructed of inert materials and allow for good mixing of the 
receptor chamber. The membrane used within the diffusion cell should be maintained 
at 32 ± 1 ºC and ideally be human skin, but, animal skin may be used if necessary. 
The membrane preparation may be as epidermal membranes, full thickness skin or 
slice of skin prepared with a dermatome (to approx 500 µm). The receptor fluid 
bathing the underside of the skin preparation will ideally be a physiological buffer, 
however, the solubility of the penetrant within the receptor fluid should not be such 
that it is rate limiting. The penetrant exposure duration has a recommended 
maximum of 24 hours and should be applied as an application of up to 10 µl cm-2 
(liquids) or up to 5 mg cm-2 (solids). The exception to these application amounts is 
when infinite dosing studies are being performed. Study replicates for an individual 
condition should be no less than four.   
 
Even with a broad set of guidelines in place, inter laboratory (and even intra 
laboratory) skin diffusion cell experimental data are not always in agreement, even 
when similar protocols are followed, discrepancies between data sets are still 
encountered (Chilcott, et al., 2005a). An interesting point within the guidelines 
concerns the source of the skin, with human skin being the preferred option. 
However, animal skin may be the preferred option if in vivo work using the same 
animal model is required. It must be borne in mind, however, that to extrapolate any 
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results into man any variation in the penetration of a compound between the species 
must be accounted for, either with the addition of uncertainty factors or, ideally, with 
further studies using in vitro human skin. Examples of species difference in skin 
penetration are well documented (Barbero and Frasch, 2009). Also of interest is the 
choice of receptor medium, of utmost importance is that sink conditions for the 
penetrant are maintained for the duration of the study. Favoured, unless otherwise 
justified, is phosphate buffered saline at pH 7.4 to mimic physiological conditions. 
Lipophilic penetrants may require alternative receptor media for maintenance of sink 
conditions. Typically co solvents (ethanol) or binding proteins (bovine serum albumin, 
BSA) are used to increase solubility of the penetrant in this case. 
 
1.8.1.2. Animal models for percutaneous absorption 
Although, ideally human skin should be used for the determination of percutaneous 
penetration, work presented within this thesis uses skin from large white pigs. An 
animal model was chosen primarily due to the need to conduct a large number of 
diffusion cell studies for which insufficient human skin tissue was available. The use 
of animal models in toxicology studies will typically employ the most relevant model 
for subsequent data extrapolation to man (Simon and Maibach, 2000). In the case of 
skin penetration studies, the animal skin being used should exhibit properties close to 
that of human skin. However, availability and ease of handling and use also play a 
part which has led to a wide variety of laboratory animals including the mouse, rat, 
rabbit and guinea pig being used as animal models for percutaneous absorption. 
Perhaps the most relevant animal models for skin penetration research are the pig 
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and members of the primate family, as the skins from these animals most closely 
model human skin. However, the use of primates in skin research holds its own 
inherent difficulties and ethical constraints leaving the preferred animal model being 
the pig. There are similarities in the biochemistry, physiology and histology of human 
and pig skin, and, importantly, the permeability of pig skin is generally closest to that 
of human both in vivo (Bartek, et al., 1972) and in vitro (Bronaugh, et al., 
1982;Chilcott, et al., 2001;Dick and Scott, 1992;Galey, et al., 1976;Gore, et al., 
1998;Barbero and Frasch, 2009) . Another consideration is that an animal model 
should have similar responses to the chemical penetrant of interest, in the case of 
nerve agents, this includes signs of intoxication and measurable parameters such as 
cholinesterase inhibition. The majority of previous studies investigating the skin 
absorption of nerve agents have used rodent models such as the rat and guinea pig, 
as these animals have well characterised responses to anti-cholinesterase 
compounds. However, a number of studies have investigated the pig’s response to 
nerve agent challenge (Chilcott, et al., 2003;Duncan, et al., 2002;Dorandeu, et al., 
2007).  As it is generally accepted that the most appropriate animal model for human 
skin absorption is the domestic pig (Sus scrofa) (Wester and Noonan, 1980;Simon 
and Maibach, 2000), the in vitro studies described in this thesis were carried out 
using pig skin to enable subsequent comparison with down selected haemostatic 
decontaminants in an in vivo pig model. 
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CHAPTER 2: INTERACTIONS OF GD WITH THE SKIN 
 
2.1. Research goals 
A detailed search of the literature indicated that only limited research had been 
conducted on the interactions of Soman (GD) with the skin. One of the major 
research goals of this thesis was to add to this knowledge base in a number of 
specific areas. These areas can be defined as: 
 
2.1.1. Skin absorption kinetics of GD through porcine skin 
The quantification of percutaneous penetration for any chemical measured using in 
vitro diffusion cell techniques requires use of the guidance offered by OECD 
guidelines (Section 1.8.1.1.). Of particular interest, is the choice of receptor fluid, due 
to the broad array of choices available. Phosphate Buffered Saline (PBS), PBS with 
added Bovine Serum Albumin (BSA) and an Ethanol Water solution were evaluated. 
Choice of skin preparation is also of interest; although the use of fresh skin is 
preferred, experimental constraints often make the freezing of tissue necessary. 
Work conducted as part of this thesis makes a comparison of fresh and frozen tissue 
in skin research. 
 
 
2.1.2. Quantification of the GD skin reservoir 
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Previous work has alluded to the existence of a GD reservoir in a number of organs 
including the skin (Kadar, et al., 1985). Empirical knowledge of such a reservoir may 
be of importance to future work programmes seeking to develop medical 
countermeasures to dermal GD exposure. For example, exploitation of a removable 
GD reservoir could limit any subsequent systemic toxicity by removing not only 
surface contamination, but, also agent depots contained within the skin. The work 
presented here uses solvent extraction techniques, at a range of time points post GD 
exposure, as a proof of principle method to determine extractable fractions. 
 
2.1.3. Quantification of GD skin surface spreading 
One of the fundamental assumptions when measuring the penetration rate of a 
chemical through the skin is the knowledge of the surface area that the chemical has 
penetrated though. Without this information, amount per unit area penetration 
determinations cannot be made (although it is often assumed that a chemical will 
spread across the entire available surface area of a diffusion cell). Wrongful use of 
this assumption could potentially lead to gross underestimations in the true 
penetration rate. 
 
2.1.4. Comparison of diffusion cell systems 
Chronologically, work carried out initially used a commercially available water 
jacketed static diffusion cell system (Permegear™) (Figure 1.14 top right), whilst later 
work used an unjacketed Franz cell (Figure 1.14 top left). To ensure that both 
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systems gave comparable data for GD percutaneous penetration, they were 
evaluated simultaneously. The availability of two bespoke systems and the 
comparisons made allows for later discussion on implications for users of different 
systems in different laboratories both nationally and internationally. 
 
2.1.5. Research purpose  
The research presented within this section provides an assessment of the interaction 
of 14C-GD with the skin in vitro and allows for the postulation of a 14C-GD skin 
interaction scheme, from time of skin contact through to penetration into the receptor 
media. All of the work described makes use of Franz Static Diffusion Cells using 
either fresh or frozen skin samples. 
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2.2. Materials and methods 
The synthesis, use and destruction of GD was conducted in accordance with the 
Chemical Weapons Convention (1996) to which the UK is a signatory state.  
Radiolabelled pinacolyl methylfluorophosphonate (GD) was synthesised by TNO 
(Rijswijk, Netherlands) and had a radiochemical purity >97% (as determined by 
radiometric HPLC analysis). The 14C label was at the P-CH3 moiety (see Figure 1.6).  
The chemical purity of labelled and unlabelled GD was >97% by NMR.  Both 
radiolabelled and cold agent were mixed in appropriate proportions to give a nominal 
activity of approximately 0.5 µCi µl-1. Tritium (3H) labelled water was combined with 
non radiolabelled water to create a final dosing solution with a specific activity of 
approximately 5 µCi ml-1. Liquid scintillation counting (LSC) materials (Soluene-
350TM, Ultima Gold and opaque plastic vials) were purchased from Perkin-Elmer 
(Chandler’s Ford, Hampshire).  All other chemicals were analytical grade and were 
purchased from the Sigma Chemical Company (Poole, Dorset) or VWR International 
(Lutterworth, Leicestershire).  
 
The use of animals in this study was conducted in accordance with the Animals 
(Scientific Procedures) Act 1986. Weanling pigs (large white strain, weight range 20 - 
30 kg) were purchased from a local supplier.  Animals were pair-housed and given 
24 h access to food and water.  After one week acclimatisation, each animal was 
sedated with Hypnovel® (Midazolam, 6ml i.m., 5 mg ml-1) and culled with an overdose 
of Euthatal™ (sodium pentobarbitol, 6ml i.v., 200 mg ml-1).  The whole abdominal 
skin flank (approximately 40 x 30 cm) was excised from each animal. The skin was 
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either prepared for use immediately or stored flat between sheets of aluminium foil at 
-20ºC for up to three months prior to use. Prior to study commencement, skin 
samples were removed from cold storage and thawed in a refrigerator at 5ºC for 
approximately 24 hours. The skin was close clipped and the subcutaneous fat 
removed before being dermatomed (Humeca Model D42, Eurosurgical Ltd, Guildford, 
UK) to a nominal thickness of 500 µm prior to insertion into diffusion cells.  
 
Percutaneous absorption experiments were performed with Franz-type glass 
diffusion cells (Franz, 1975) of either unjacketed (Dstl engineering department, 
Wiltshire, UK) or jacketed (Permegear™, Hellertown, PA, USA) design. A 3 x 3 cm 
section of dermatomed pig skin was placed, epidermal side up, between the donor 
(upper) and receptor (lower) chamber. Each receptor chamber was filled with 5 ± 1 
ml (unjacketed) or 14 ± 1 ml (Permegear™ jacketed type) receptor fluid to a level that 
ensured the meniscus of the receptor fluid in the sampling arm was level with the 
skin surface. Depending on the study type the receptor fluid was phosphate buffered 
saline (PBS), PBS with added 5% bovine serum albumin (BSA) or 50% aqueous 
ethanol. The unjacketed cells, once assembled, were placed into a metal holder 
incorporating a circulating water supply upon a magnetic stirrer block. The 
Permegear™ diffusion cells, once assembled, were placed into bespoke holders, 
incorporating a magnetic stirrer and water heater attachments. In both cases, stirring 
of the receptor fluid was achieved via a Teflon coated magnetic follower in the 
receptor chamber. The skin surface within each diffusion cell was maintained at a 
temperature of approximately 32ºC (as confirmed by infrared thermography; FLIR 
Model P640 camera, Cambridge, UK) using water pumped at approximately 37ºC 
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through either the metal holder (unjacketed) or through the diffusion cell jackets 
(Permegear™) via a circulating water heater (Model GD120, Grant Instruments, 
Cambridge, UK). All diffusion cells were set up in a Category C fume cupboard and 
once assembled, were allowed to equilibrate for approximately 24 hours. Baseline 
samples (100µl unjacketed type or 250µl Permegear™ type) were taken, with 
replacement by fresh receptor media, from each receptor chamber prior to 
commencement of the experimental protocol. Topical dosing was performed by the 
direct application of undiluted, 14C-radiolabelled GD (100 µl (infinite dose studies) or 
10 µl (finite dose studies)) onto the centre of the skin surface within the donor 
chamber. Depending on the protocol the following procedures were followed: 
 
a) GD penetration through porcine skin under infinite dose conditions 
The infinite dose study used abdominal flank skin from 8 individual pigs and was 
conducted using unjacketed diffusion cells with an area available for diffusion of 0.19 
cm2. Three pieces of skin were used from each animal. One piece of skin from an 
individual animal was mounted over 50% aqueous ethanol, PBS and PBS containing 
5% BSA. A total of 24 diffusion cells were run, with 8 skin individual animal replicates 
for each receptor fluid type. Immediately after dosing with 100 µl neat 14C-GD, the 
cells were occluded with a piece of tin foil which was affixed to the glass rim of the 
donor chamber using a layer of inert chemically resistant perfluorinated cream (Dstl, 
Wiltshire, UK). 
 
b) GD penetration through porcine skin under finite dose conditions 
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The finite dose studies used abdominal flank skin from 11 individual pigs and were 
conducted using both unjacketed and jacketed (Permegear™) type diffusion cells. 
The area available for diffusion was 2.54 cm2 and 1.76 cm2 respectively. The 
receptor fluid used for this protocol was exclusively 50% aqueous ethanol.  The 
donor chambers for all cells within the study group were left unoccluded for the 
duration of the experiment. 
 
c) Studies using fresh versus frozen skin  
The fresh versus frozen skin comparison study used abdominal flank skin from 6 
individual pigs and was conducted using unjacketed diffusion cells with an area 
available for diffusion of 2.54 cm2. Twelve pieces of skin were used from each 
animal, six of which had been frozen for a two week period at -20ºC and six of which 
were used fresh. All cells were mounted over 50% aqueous ethanol receptor fluid.  A 
total of 72 diffusion cells were run, comprising six fresh and frozen skin individual 
animal replicates. Immediately after dosing with 1 ml 3H2O, the cells were occluded 
with a piece of tin foil which was affixed to the glass rim of the donor chamber using a 
layer of inert chemically resistant perfluorinated cream (Dstl, Wiltshire, UK). 
 
For the infinite, finite and fresh versus frozen dose studies, following application of 
the agent, samples (100µl unjacketed or 250µl Permegear™) of receptor chamber 
fluid were removed into 5 ml of scintillation fluid (Ultima Gold, Perkin Elmer LAS (UK) 
Ltd, Buckinghamshire, UK) at regular intervals up to 24 h post exposure.  Each 
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sample was replaced with an equivalent volume of fresh receptor fluid. Twenty four 
hours post-exposure a full dose distribution was performed as follows: 
1. The receptor chamber fluid was removed from each diffusion cell.  
2. For the occluded cells, the tinfoil was removed.  
3. The skin surface was swabbed with cotton wool.  
4. The skin from each diffusion cell was removed.  
At each stage, the component removed was placed into a glass vial (with the skin 
containing vials being weighed). Cotton wool swabs and tin foil had 20 ml ethanol 
added to them and skins had 10 ml of Soluene-350™ added to them. Dose 
distribution vials were then stored at room temperature (with occasional shaking) until 
the skin had solubilised, after which aliquots (250 µl) were removed into 5 ml of 
scintillation fluid.   
 
d) GD reservoir studies 
The reservoirs study used abdominal flank skin from 8 individual pigs and was 
conducted using unjacketed diffusion cells with an area available for diffusion of 2.54 
cm2. Six pieces of skin were used from each animal for a total of 48 diffusion cells. 
The receptor fluid used for this protocol was exclusively 50% aqueous ethanol.  The 
donor chambers for all cells within the study group were left unoccluded for the 
duration of the experiment. Eight cells (one from each animal) were dismantled at the 
following time points post GD exposure; 15, 30, 60, 180, 360 min and 24 hours. As 
for the infinite and finite dose studies, receptor fluids were collected and the skin 
surfaces were swabbed. To ensure all the surface GD had been removed, two swabs 
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were taken under this protocol. Swabs were placed into glass vials containing 20 ml 
ethanol. Skins were placed into glass vials and weighed prior to the addition of 20 ml 
acetonitrile. The skins were retained within the initial aliquot of acetonitrile for a 
period of 72 hours before being transferred to a second 20 ml of fresh acetonitrile for 
a further 72 hours and finally transferred to a third 20 ml of fresh acetonitrile for 
another 72 hours. At the end of this time, the skins were transferred into a fresh vial, 
weighed and had 10 ml of Soluene-350 added. 
 
e) GD skin surface spreading studies 
The skin surface spreading study used abdominal flank skin from 8 individual pigs 
and was conducted using unjacketed diffusion cells with an area available for 
diffusion of 2.54 cm2. Six pieces of skin were used from each animal for a total of 48 
diffusion cells. The receptor fluid used for this protocol was exclusively 50% aqueous 
ethanol.  The donor chambers for all cells within the study group were left 
unoccluded for the duration of the experiment. Eight cells (one from each animal) 
were dismantled at the following time points post GD exposure; 15, 30, 60, 180, 360 
min and 24 hours. Skins were gently dabbed with cotton wool to wick away any gross 
remaining surface contamination before being removed and placed into Kodak 
autoradiography cassettes (Sigma Chemical Company, Poole, Dorset) and frozen at 
-20ºC. Using dark room protocols, cassettes were opened and had autoradiography 
paper (Kodak Biomax) and intensifying screens inserted. After a period of 48 hours 
autoradiographs were developed by placing the paper into developing solution until 
spots could be visualised (less than one minute) and fixing for a period of 5 minutes. 
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Autoradiographs were then rinsed with distilled water and allowed to dry. All 
developing procedures took place in a category C fume cupboard. 
 
For each study type described, the amount of radioactivity in each sample was 
measured using a Perkin Elmer Tri-Carb liquid scintillation counter (Model 2810 TR), 
using the manufacturer’s 14C-quench curve library set to exclude single-photon (non-
radioactive) events. The amount of radioactivity in each sample was converted to 
amount of GD by comparison to standards (containing known quantities of 14C-GD) 
prepared and measured simultaneously. For the infinite and finite dose studies, 
cumulative 14C-GD penetration profiles for the 24 h study period were generated for 
each diffusion cell. Steady state (JSS) or maximum penetration rates (JMAX) were 
calculated by plotting the amount of 14C-GD penetrated against time and calculating 
the gradient of the slope. Skins that had a 14C-GD skin absorption rate with a 
correlation coefficient of < 0.98 or skins that had exhibited a large penetration of 14C-
GD during the diffusional lag-time were removed from the analysis as it was likely 
that the integrity of the skin had been compromised over the course of the study. 
Where applicable, statistical analysis was performed using a non-parametric ANOVA 
(Kruskal-Wallis test) with Dunn’s multiple comparisons post-test. A predetermined 
alpha level of 0.05 was used for each statistical calculation. 
 
 
  
87 
 
2.3. Results 
 
2.3.1. GD penetration through porcine skin under infinite dose conditions 
The absorption profile of 14C-GD (100µl, neat) through pig skin is shown in Figure 
2.1. All values are mean ± standard deviation of n=8 diffusion cells with skin acquired 
from 8 individual pigs with samples being taken at the time points shown. Penetration 
of 14C-GD into 50% aqueous ethanol receptor media increased steadily over the 24 
hour study duration, whereas, for the other two receptor media types (PBS and PBS 
with BSA), there was an apparent reduction in penetration from 9 hours.  
 
Due to the apparent biphasic nature of the cumulative penetration curves for the PBS 
receptor fluids, JSS values and lag times were calculated between 12 and 24 hours 
(Table 2.1) and 3 and 9 hours (Table 2.2). The value of the JSS for 14C-GD skin 
penetration into the 50% aqueous ethanol receptor media was similar (439 ± 158 and 
415 ± 250 µg.cm-2.h-1) for the two evaluated time ranges. Conversely, for the PBS 
receptor fluid, a statistical difference in JSS (219 ± 195 and 119 ± 116 µg.cm-2.h-1) 
was shown between the evaluated time ranges. Although a similar trend in 
penetration rate reduction for the measured JSS values for 14C-GD penetration into 
the PBS-BSA receptor media was apparent (166 ± 176 and 84 ± 78 µg.cm-2.h-1), it 
was not statistically significant. The experimentally determined values of JSS were 
used to determine the value of the permeability coefficient (KP) and the skins total 
barrier resistance (R) (Section 1.7.1).  
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Comparison of 14C-GD penetration into the three evaluated receptor fluids showed a 
significantly higher JSS into 50% aqueous ethanol than for either of the PBS 
containing receptor fluids when measured between 12 and 24 hours. However, when 
the JSS was evaluated between 3 and 9 hours, significance was only shown between 
50% aqueous ethanol and PBS-BSA. The lag time measured for 14C-GD penetration 
into each of the receptor fluids was similar when evaluated between 3 and 9 hours. 
Evaluation of lag times between 12 and 24 hours generated substantial negative lag 
times for the PBS containing receptor fluids, which whilst not realistic, are a 
consequence of the reduced penetration rates measured for these receptor fluids 
later in the experimental time course.  
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Figure 2.1: Cumulative amount of 14C GD penetrated through undamaged
abdominal flank pig skin using 3 different receptor media.Where,      = 50%
Aqueous ethanol,      = Phosphate buffered saline (PBS) and       = 5% Bovine
Serum Albumin (BSA) in PBS. All values are mean ± standard deviation of n=8
diffusion cells. Study was carried out under infinite dosing conditions using an
initialy applied dose of 100µl 14C GD.
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 Receptor Fluid Composition 
  
 
   
 
50% Aqueous Ethanol PBS PBS with 5% BSA 
 
   
 
   
 
   
JSS (g.cm-2.h-1 x10-6) 415 ± 250A,B 119 ± 116A 84 ± 78B 
    
Lag time (h) -0.4 ± 4.5 -6.5 ± 4.2 -4.6 ± 6.5 
    
KP (cm.h-1 x10-6) 406 ± 245 117 ± 113 82 ± 77 
    
R (h.cm-1 x10-6) 3456 ± 2078 16756 ± 13941 29306 ± 26426 
    
 
Table 2.1: Penetration rate (JSS), lag time, permeability coefficient (KP) and total 
barrier resistance (R) values for penetration of GD through 500 µm undamaged pig 
skin into 3 different types of receptor media (50% aqueous ethanol, phosphate 
buffered saline and phosphate buffered saline with 5% bovine serum albumin). Data 
obtained from measurements between 12 and 24 hours. For JSS values, statistical 
significance (P<0.05) is indicated between same labelled parameters. Negative lag 
times are a consequence of the reduced calculated JSS values later in the 
experimental time course. Study was carried out under infinite dosing conditions 
using an initially applied dose of 100 µl 14C GD. 
 
  
91 
 
     
 
 
 
  
 Receptor Fluid Composition 
  
 
   
 
50% Aqueous Ethanol PBS PBS with 5% BSA 
 
   
    
JSS (g.cm-2.h-1 x10-6) 439 ± 158A 219 ± 195 166 ± 176A 
    
Lag time (h) 1.7 ± 0.5 1.6 ± 0.3 1.7 ± 0.9 
    
KP (cm.h-1 x10-6) 429 ± 154 215 ± 191 163 ± 172 
    
R (h.cm-1) 2821 ± 1749 8829 ± 6780 16125 ± 13526 
    
 
Table 2.2: Penetration rate (JSS), lag time, permeability coefficient (KP) and total 
barrier resistance (R) values for penetration of GD through 500 µm undamaged pig 
skin into 3 different types of receptor media (50% aqueous ethanol, phosphate 
buffered saline and phosphate buffered saline with 5% bovine serum albumin). Data 
obtained from measurements between 3 and 9 hours. For JSS values, statistical 
significance (P<0.05) is indicated between same labelled parameters. Study was 
carried out under infinite dosing conditions using an initially applied dose of 100 µl 
14C GD. 
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The distribution of radiolabel within each diffusion cell was measured (Figure 2.2). 
Total recoveries of 14C-GD after undamaged skin penetration were 96.0 ± 11.0 % 
(50% aqueous ethanol receptor fluid), 89.2 ± 10.5 % (PBS receptor fluid) and 95.7 ± 
7.6 % (PBS with 5% BSA receptor fluid). In all cases, the majority (86.1 ± 15.9 %) of 
14C-GD was recovered from the surface of the skin indicating that infinite dosing 
conditions had been maintained throughout the study duration. Smaller amounts of 
14C-GD were recovered from within the skin and from the tin foil.  
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Figure 2.2: Dose distribution expressed as % recovery for 14C GD
recovered from;      skin surface swab,      within the skin,      occlusive tin
foil and      receptor fluid at 24 hours for each receptor media. All values
are mean ± standard deviation of n=8 diffusion cells (each cell containing
skin from a different animal). Study was carried out under infinite dosing
conditions using an initialy applied dose of 100µl 14C GD.
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2.3.2. GD penetration through porcine skin under finite dose conditions  
 
The absorption profile of 14C-GD (10µl, neat) through pig skin for the two different 
types of diffusion cell used is shown in Figure 2.3. All values are mean ± standard 
deviation of n=16 (Dstl Franz type) or n=12 (PermegearTM) diffusion cells with 
samples being taken at the time points shown. Values for the maximum penetration 
rates (JMAX) and lag times of 14C-GD through dermatomed abdominal flank skin for 
the two diffusion cell types are shown in Table 2.3. JMAX values were determined 
between 2 and 6 hours, where correlation coefficients were >0.98.  
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Figure 2.3: Cumulative amount of 14C-GD penetrated through undamaged
abdominal flank pig skin using two different types of static diffusion cell (Dstl
Franz type (   ) and Permegear (   )). All values are mean ± standard deviation
of n=16 (Dstl Franz type) or n=12 (Permegear ) diffusion cells.Study was
carried out under finite dosing conditions using an initially applied dose of 10 µl
14C GD.
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 Franz Diffusion Cell Type 
 
 
 
  
 
Unjacketed (Dstl) Jacketed (Permegear) 
   
   
JMAX (g.cm-2.h-1 x10-6) 10.80 ± 4.78 8.49 ± 2.53 
   
   
   
   
 
 
Table 2.3: Penetration rate (JMAX) of 14C-GD through 500 µm undamaged pig skin 
using two different types of Franz static diffusion cell. All values are mean ± standard 
deviation of n=16 (Dstl Franz type) or n=12 (PermegearTM) diffusion cells. Data 
obtained from measurements between 2 and 6 hours. Study was carried out under 
finite dosing conditions using an initially applied dose of 10 µl 14C GD. 
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2.3.3. GD reservoir studies 
Two skin surface swabs were used to remove any remaining 14C-GD surface 
contamination. The first swab consistently removed more than twice the 
contamination of the second swab for each of the reservoir assessment time points. 
Each skin was then subject to three acetonitrile extractions, in each case the majority 
of acetonitrile extractable 14C-GD was recovered during the initial extraction, with 
only residual amounts being recovered during extractions two and three. The 
unextractable portion of 14C-GD remaining within the skin after the three consecutive 
acetonitrile extractions was similar irrespective of the time at which the sample was 
taken. The amount of 14C-GD that penetrated through the skin into the receptor 
media increased the longer the experimental duration to a maximum of 
approximately 5% by 24 hours (Figure 2.4).  
 
Combination of the surface swab data to give total 14C-GD present on the skin 
surface and amalgamation of the acetonitrile extraction data to give total 14C-GD 
extractable from the skin are shown in Figure 2.5. Within the first 15 minutes of 
dosing the amount of 14C-GD present on the skin surface approximated to 10% of the 
initially applied dose. This value dropped at later sampling time points. The amount of 
acetonitrile extractable 14C-GD was similar to the amount of 14C-GD fixed in the skin 
until one hour post GD challenge. By three hours and up to 24 hours post GD 
challenge the amount of extractable GD was statistically less than the amount of GD 
that remained unextractable within the skin. 
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Up to the one hour sampling time point total 14C-GD recoveries were less than 50% 
of the originally applied dose, a value that had decreased to approximately 25% by 
24 hours. Figure 2.6 takes the unrecovered fraction into account and simplifies the 
location of 14C-GD into either on the skin surface, penetrated (whether extractable 
from the skin or not) and unrecovered. It is apparent that from 60 minutes post 
exposure the amount of 14C-GD unrecovered remains constant.  
 
The weight lost by skin samples upon extraction by acetonitrile was constant across 
the whole of this study, being in the region of 10-15% of the initial weight of the skin 
in most cases. Although this range was as large as 5-20% in some cases.    
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Figure 2.4: Percentage dose recovery of 14C-GD from diffusion cells dismantled at
the specified time points. Recovery was from the skin surface (swab 1      and
swab 2      ), extractable from the skin (acetonitrile extraction (AcN) 1      , AcN
extraction 2      , AcN extraction 3      ), fixed within the skin      or penetrated
through the skin into the receptor fluid      . All values are mean ± standard
deviation of n=8 diffusion cells.
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Figure 2.5: Percentage dose recovery of 14C-GD from diffusion cells dismantled at
the specified time points. Recovery was from the skin surface      (2 surface
swabs), extractable from the skin      (triple acetonitrile extraction), fixed within the
skin      or penetrated through the skin into the receptor fluid      . All values are
mean ± standard deviation of n=8 diffusion cells.
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Figure 2.6: Percentage dose recovery of 14C-GD from diffusion cells dismantled at
the specified time points. Recovery was from the skin surface      (2 surface
swabs), within or pentrated through the skin      (summation of extractable, fixed
and penetrated portions). The unrecovered fraction      was taken as the difference
between the initially applied dose and the total recovery. All values are mean ±
standard deviation of n=8 diffusion cells.
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2.3.4. GD skin surface spreading studies 
Within 15 minutes of the application of a single 10 µl liquid GD droplet to the surface 
of undamaged pig skin, the 14C-GD had spread to cover the entire diffusional surface 
area of the diffusion cell and beyond. The entire diffusional surface area was covered 
with 14C-GD for the entire 24 hour study (Figure 2.7). A full dose distribution was 
carried out for all skins after autoradiographic procedures had been completed 
(Figure 2.8). Total recoveries were in the region of 25 and 30%, with the majority of 
14C-GD being recovered from within the skin. Any losses of radioactivity from the skin 
whilst being prepared for and undergoing autoradiography were not accounted for 
and were part of the unrecovered fraction. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 2.7: Representative skin autoradiographs showing skin surface spreading of 
14C-GD at each of the specified time points across 
with 50% aqueous ethanol receptor media. The central dark area (more easily visible 
at later time points) shows the area of skin bathed by the receptor fluid. The dark 
patches further out indicate that the GD 
clamped between the donor and receptor chamber. A total of n=8 diffusion cells were 
dismantled and skin surface spreading evaluated at each time point.
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unoccluded, undamaged pig skin 
was able to seep into the skin tissue 
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Figure 2.8: Percentage dose recovery of 14C-GD from diffusion cells
dismantled at the specified time points. Recovery was from the skin
surface      , within the skin      or receptor fluid      . All values are mean ±
standard deviation of n=8 diffusion cells.
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2.3.5. Fresh versus previously frozen skin studies 
 
Cumulative penetration profiles of tritiated water through undamaged pig skin are 
shown in Figure 2.9. All values are mean ± standard deviation of n=36 diffusion cells 
(previously frozen skin) or n=33 diffusion cells (fresh skin), with skin acquired from 6 
individual pigs with samples being taken at the time points shown. The penetration 
profiles were similar in both shape and magnitude. Values for the steady state 
penetration rates (JSS) and lag times of tritiated water through dermatomed 
abdominal flank skin for both fresh and previously frozen skin are shown in Table 2.4. 
JSS values were determined between 2 and 24 hours, where correlation coefficients 
were >0.98. The experimentally determined values of JSS were used to determine the 
value of the permeability coefficient (KP) and the skins total barrier resistance (R). 
Statistical analysis of the data revealed statistical significance (p < 0.05) between the 
JSS values but not the lag times between fresh and frozen skin.  
 
Individual animal JSS values for each of the six animals used are shown in Figure 
2.10. All values are mean ± standard deviation of n=6 diffusion cells (except for fresh 
skin for animals 1, 3 and 4, where n=5) with skin acquired from an individual pig. The 
contribution by each animal to the amalgamated skin permeability data (Table 2.4) is 
shown in Table 2.5. In general, the range of JSS values were larger across animals 
for frozen skin than for fresh skin. Statistical analysis of this data showed significant 
differences (p < 0.05) between the JSS values for fresh and frozen skin when skins 
from two of the individual animals (indicated in Table 2.5) were compared. Skins from 
animal 5 exhibited higher JSS values whether fresh or frozen when compared to 
values from the other animals.   
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Figure 2.9: Cumulative amount of 3H2O penetrated through fresh      and
previously frozen       abdominal flank pig skin. All values are mean ± standard
deviation of n=36 (previously frozen) or n=33 (fresh) diffusion cells.
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 Abdominal Flank Skin 
 
 
 
  
 
Fresh Frozen 
 
  
   
JSS (g.cm-2.h-1 x10-6) 1644 ± 717* 2034 ± 698* 
   
Lag time (h) 1.52 ± 0.93 1.11 ± 0.78 
   
KP (cm.h-1 x10-6) 1644 ± 717 2034 ± 698 
   
R (h.cm-1) 694 ± 220 556 ± 203 
   
 
 
Table 2.4: Penetration rate (JSS), lag time, permeability coefficient (KP) and total 
barrier resistance (R) values for penetration of tritiated water through 500 µm 
undamaged fresh and previously frozen pig skin into 50% aqueous ethanol. All 
values are mean ± standard deviation of either n=36 (frozen) or n=33 (fresh) diffusion 
cells with skin taken from 6 individual animals. Data obtained from measurements 
between 2 and 24 hours. Statistical significance in the penetration of 3H2O through 
fresh and previously frozen skin is indicated (*). 
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Figure 2.10: Average JSS values for 3H2O penetration through fresh      or
previously frozen      abdominal flank skin from individual pigs. All values are
mean ± standard deviation of n=6 diffusion cells (except for fresh skins from
animals 1,3 and 4 where n=5).Statistical significance in the penetration of
3H2O through fresh and previously frozen skin from the same animal is
indicated (*).
*
*
*
*
Animal Number
J S
S 
(g.
cm
-
2 .
h-
1  
(x1
0-
6 ))
109 
 
 
 
Abdominal Flank Skin – Frozen Skin 
 1 2 3 4 5 6 
       
JSS  
(g.cm-2.h-1 x10-6) 
1870 ± 832 1511 ± 390 2245 ± 459* 2138 ± 456* 2894 ± 605 1547 ± 430 
Lag time (h) 1.35 ± 0.92 1.03 ± 0.63 2.00 ± 0.60 0.60 ± 0.43 0.87 ± 0.81 0.79 ± 0.51 
KP (cm.h-1 x10-6) 1870 ± 832 1511 ± 390 2245 ± 459 2138 ± 456 2894 ± 605 1547 ± 430 
R (h.cm-1) 629 ± 264 703 ± 197 465 ± 118 490 ± 128 363 ± 102 684 ± 169 
 
Abdominal Flank Skin – Fresh Skin 
 1 2 3 4 5 6 
       
JSS  
(g.cm-2.h-1 x10-6) 
1287± 246 1254 ± 176 1490 ± 239* 1389 ± 310* 2975 ± 583 1343 ± 338 
Lag time (h) 2.64 ± 1.81 1.47± 0.51 1.71 ± 0.52 0.95 ± 0.14 1.42 ± 0.59 1.07 ± 0.37 
KP (cm.h-1 x10-6) 1287± 246 1254 ± 176 1490 ± 239 1389 ± 310 2975 ± 583 1343 ± 338 
R (h.cm-1) 799 ± 144 812 ± 126 685 ± 111 754 ± 194 350 ± 84 787 ± 212 
       
 
Table 2.5: Penetration rate (JSS), lag time, permeability coefficient (KP) and total 
barrier resistance (R) values for penetration of tritiated water through 500 µm 
undamaged fresh and previously frozen pig skin into 50% aqueous ethanol. These 
values are means of n=6 replicates for each animal (except for fresh skin studies for 
animals 1, 3 and 4 where n=5). Data obtained from measurements between 2 and 24 
hours. Statistical significance in the penetration of 3H2O through fresh and previously 
frozen skin from the same animal is indicated (*). There was no significant difference 
in the lag times of 3H2O through fresh and previously frozen skin.  
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2.4. Discussion 
2.4.1. Influence of receptor fluid choice in diffusion cell studies 
One of the major considerations in the experimental design of an in vitro 
percutaneous penetration study is the choice of receptor fluid. The primary aim of the 
receptor fluid is to collect material that has penetrated the skin in a manner 
analogous as if a penetrant had absorbed through skin and into the peripheral 
vasculature in vivo. Absorption into the peripheral vasculature and from there into the 
rest of the body represents an “infinite sink” so the solubility of the penetrated 
material in the blood becomes largely irrelevant. However, in an in vitro diffusion cell 
to measure a biologically relevant penetration rate, “infinite sink” conditions are 
maintained by ensuring that the solubility of the penetrated material does not become 
rate limiting. For studies where the maintenance of viable skin is necessary, such as 
metabolism studies, the overriding factor is for a receptor fluid to be able to maintain 
skin viability within the diffusion cell system. Of equal importance, is a requirement 
that the penetrant must be adequately soluble within the chosen receptor media. 
Should this requirement not be met, it is likely that the receptor fluid could limit 
diffusion from the underside of the skin into the receptor fluid and lead to a gross 
underestimation in penetration rates. The current study used previously frozen, non 
viable tissue and, therefore, did not need to utilise receptor fluids that would maintain 
tissue viability. Of concern was whether GD, being a relatively hydrophobic 
compound, would exhibit suitable solubility characteristics within a traditional 
aqueous receptor fluid. The current study used both ethanol and bovine serum 
albumin (BSA) within the receptor fluid to increase penetrant solubility by offering a 
more lipophilic environment. 
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Previous work carried out into the percutaneous absorption of chemical warfare 
agents has used 50% aqueous ethanol as a receptor fluid to ensure that the receptor 
fluid did not become a rate limiting step in the diffusion process (Chilcott, et al., 
2007;Dalton, et al., 2006a;Dalton, et al., 2006b). However, the skin penetration of GD 
has not previously been determined using in vitro diffusion cell methodology. The 
solubility of GD in water (21 g.L-1) suggested that 5 ml of a standard phosphate 
buffered saline (PBS) receptor fluid may have offered sufficient sink conditions to be 
an appropriate receptor fluid for the 102 mg of applied GD (given that 86.1 ± 15.9 % 
of the applied GD was located on the skin surface upon study completion).  
 
The absorption profiles indicated that of the three evaluated receptor fluids, only 50% 
aqueous ethanol offered suitable sink conditions for GD. Steady state (JSS) flux was 
observed for GD penetrating into 50% aqueous ethanol after the initial lag phase, 
but, not for either of the PBS containing receptor fluids. For GD penetration into the 
PBS containing receptor fluids, the effect was similar, an initial flux of higher 
magnitude between 3 and 9 hours which then reduced over the twenty four hour time 
course, indicating that neither of the PBS based receptor fluids were able to solvate 
GD sufficiently. It should be noted that sufficient GD remained on the surface of each 
skin at the end of the each study so that diffusion should not have started to 
approach equilibrium (as it seemed to do with the PBS receptor media). 
 
112 
 
Of interest is why PBS with 5% BSA did not offer more suitable sink conditions for 
GD than PBS on its own. Studies by other researchers have shown the addition of 
BSA to the receptor media increases the solubility of lipophilic penetrants such as 
methyl paraben (Wilkinson, et al., 2007). Wilkinson and co-workers also evaluated an 
ethanolic receptor fluid alongside PBS and a BSA containing receptor fluid, with 
maximum absorption rates falling in the order of aqueous ethanol > BSA > PBS. The 
trend for the current study was aqueous ethanol > BSA = PBS. Explanation for the 
difference can only be due to the interaction of GD with ethanol and BSA. Ethanol is 
able to interact with and solvate lipophilic molecules due to its two carbon chain and 
is also able to hydrogen bond with hydrophilic molecules due to the presence of the 
hydroxyl group. This broad solvation ability allows ethanol to act as a general organic 
solvent for lipophilic compounds including GD. Conversely, the current study has 
shown that BSA is not a suitable solubility enhancing excipient for all organic 
molecules. BSA is typically chosen as a solubility enhancer for receptor fluids where 
it is necessary to maintain skin viability (Collier, et al., 1989). For studies where 
maintenance of skin viability is not of concern, this work has shown that ethanol 
water offers superior sink conditions, although, mention must also be made of other 
receptor fluids containing excipients such as polyethylene glycol (PEG) 20 oleyl ether 
that have recently been recommended to facilitate sink conditions for hydrophobic 
chemicals (Fasano and McDougal, 2008).      
 
The current study has shown that use of an ethanol water receptor fluid gave an 
increased measured GD penetration rate compared to the GD penetration rates 
using PBS receptor fluids. Without knowledge of actual in vivo GD skin penetration 
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rates it is not possible to determine which penetration rate is correct. Should the 
penetration rate of GD into an ethanol water receptor fluid be correct, then the PBS 
receptor fluids underestimate dermal absorption. However, should the penetration 
rate of GD into PBS based receptor fluids be correct, then use of an ethanolic 
receptor fluid overestimates dermal absorption. Interestingly, previous work 
evaluating the skin penetration of the lipophilic chemical fluazifop-butyl into a range 
of receptor fluids showed that only an aqueous ethanol receptor fluid predicted in 
vivo skin absorption (Ramsey, et al., 1994). Guideline documentation (OECD, 2010) 
recognizes that although saline may be an adequate receptor fluid for hydrophilic 
compounds, it is likely to underestimate the percutaneous absorption of lipophilic 
compounds.    
 
Questions have been raised as to whether an ethanolic receptor fluid disrupts the 
skins barrier layer and whether it is this disruption that leads to the observed 
increased penetration rates compared to PBS based receptor fluids. Previous work 
(Pershing, et al., 1993) indicates that ethanol concentrations have to exceed 75 % for 
penetration enhancement to be observed. Penetration rate enhancement by ethanol 
has been ascribed to lipid extraction (Van der Merwe and Riviere, 2005), however, 
this conclusion is not supported by the current study, as it would be expected that a 
disruption of this type would cause a reduction in the measured lag time when 
comparing aqueous ethanol to the PBS containing receptors fluids. In this study, all 
the lag times measured between 3 and 9 hours were similar suggesting that use of 
an ethanolic receptor fluid caused minimal barrier disruption. Given that use of a 50% 
aqueous ethanol receptor fluid in the current study was the only receptor fluid able to 
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maintain steady state flux for GD skin penetration suggests that the PBS receptor 
fluids were underestimating GD skin absorption.   
 
Ultimately, as long as a receptor fluid is able to maintain skin viability (if appropriate) 
and suitable sink conditions, experimental choice as to the most appropriate receptor 
fluid comes down to achieving experimental aims. However, the potential effect of 
any excipient in the receptor solution on the partitioning of the penetrant into the 
stratum corneum should not be discounted. It should be noted that neither PBS nor 
ethanol is in contact with the barrier layer in vivo and so could alter the partitioning of 
the penetrant and its solubility in the skin layers. It may be concluded that any in vitro 
diffusion cell determined penetration rates will be different from those achieved under 
in vivo conditions; however, this does not make the results meaningless. 
Interpretation of in vitro penetration measurements need to be interpreted in the light 
of the differences between the in vitro and in vivo conditions.  Using a receptor fluid 
such as 50% aqueous ethanol gives assurance that any determined penetration rate 
would not likely be an underestimate of in vivo penetration rates. This is particularly 
pertinent to the hazard assessment of toxic skin penetrants such as chemical warfare 
agents. In conclusion, the data from the current study has shown that the most 
suitable receptor fluid (from those evaluated) to use as a sink for GD was 50% 
aqueous ethanol. 
 
2.4.2. Infinite dose studies with porcine skin 
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The infinite dose study uses occluded conditions to ensure that the penetrant within 
the donor chamber remains in excess for the duration of the study by eliminating any 
potential evaporation of the penetrant. When the penetrant is volatile, such as GD, 
this will lead to overestimation of the penetration rate compared to an application 
under unoccluded conditions. Furthermore, under realistic exposure conditions, it is 
unlikely that a contaminated area of skin would be bathed in a chemical warfare 
agent. As such the infinite dose studies carried out can be viewed as the worst case 
scenario, and while unrealistic, offers valuable insight into how effective a medical 
countermeasure ideally needs to be to cover the worst eventualities. An advantage of 
the infinite dose study is that it allows derivations of parameters such as Kp and R 
which finite dose studies do not. 
 
The Jss value for GD through dermatomed pig skin was determined to be 439 ± 158 
g.cm-2.h-1 (x 10-6). Work by van Hooidonk (1980) has previously determined that 
penetration rate of GD through human skin and guinea pig skin to be 210 g.cm-2.h-1 
(x 10-6) and 414 g.cm-2.h-1 (x 10-6) respectively (van Hooidonk, et al., 1980). There 
are a number of important differences between these studies. The van Hooidonk 
study used full thickness tissue rather than split thickness. The use of full thickness 
skin may inhibit the penetration rate of lipophilic compounds due to the presence of 
extra dermis below the level of the peripheral vasculature which would not need to be 
crossed in vivo. It has been recommended that full thickness skin should be avoided 
in human skin in vitro diffusion experiments due to the generation of prohibitively long 
lag times (Henning, et al., 2009). A second difference was the choice of receptor 
fluid. The van Hooidonk study used a physiological salt solution (as metabolic 
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degradation was also being evaluated). As has been previously discussed, the use of 
a salt solution may have led to an underestimation of the true penetration rate. It is 
likely that the measured penetration rates in the van Hooidonk study would have 
been greater had split thickness skin and an ethanolic receptor fluid been used.  
 
The van Hooidonk study also evaluated the penetration rate of VX through human 
skin and guinea pig skin to be 168 g.cm-2.h-1 (x 10-6) and 516 g.cm-2.h-1 (x 10-6) 
respectively. Previous work conducted by Dalton and co-workers has evaluated the 
steady state penetration rate of 14C-VX through not only undamaged dermatomed pig 
skin, but, also human and guinea pig skin into a 50% aqueous ethanol receptor fluid 
(Table 2.6) (Dalton, et al., 2006a). A comparison of the VX penetration studies 
indicates that for both species, human and guinea pig, the methodology employed by 
van Hooidonk gave a lower penetration rate than the methodology employed by 
Dalton et al. The likely reasons, as discussed, between the values are due to 
differences in skin preparation and choice of receptor fluid. 
 
Table 2.6 compares previous VX penetration studies to the current GD pig skin 
penetration studies. Using identical methodology, the penetration rate of GD through 
split thickness pig skin was approximately twice that of VX, furthermore, the lag time 
value was significantly less for GD than for VX. That GD is a more rapid skin 
penetrant than VX has implications in the design of countermeasures to treat 
percutaneous nerve agent intoxication. It would appear that the requirements of a 
medical countermeasure to treat percutaneous GD poisoning will likely require a 
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more rapid onset of action to ensure adequate removal of agent before penetration 
can occur.  
 
OECD guidelines (Section 1.8.1.1) require that the success criteria for an in vitro 
diffusion cell study include a mass balance with a mean radioactivity recovery of 100 
± 10 % of the initially applied dose. The total recoveries at 24 h for all the infinite dose 
studies carried out achieved this criteria (94 ± 10 %), with the majority recoveries (86 
± 16%) being from the surface of the skin. Less than 5 % of the applied dose had 
penetrated through the skin and into the receptor fluid by 24h (Figure 2.2).  
 
Using the infinite dosing technique as a method for determination of the likely worst 
case scenario for GD penetration through porcine skin has provided upper limit 
values that both current and future countermeasures ideally need to be able to 
protect against. 
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Nerve Agent GD VX 
     
Species Pig Pig Human Guinea Pig 
JSS 
(g cm-2 h-1 x 10-6) 
439 ± 158 207 ± 62A 333 ± 226B 2406 ± 988A,B 
Kp 
(cm h-1 x 10-6) 
429 ± 154 205 ± 62C 330 ± 244D 2387 ± 980C,D 
TL 
(h) 
1.7 ± 0.5 6.3 ± 0.9E 4.6 ± 1.2F 0.9 ± 0.2E,F 
 
Table 2.6: Summary of the percutaneous absorption kinetics of 14C-GD, topically 
applied as undiluted liquid through undamaged dermatomed pig skin and 14C-VX, 
topically applied as undiluted liquid through undamaged dermatomed guinea pig, pig 
and human skin. In all cases the receptor fluid used was 50% aqueous ethanol. All 
values are average ± standard deviation. Steady-state fluxes for VX were measured 
between 2–24 h (guinea pig), 10–22 h (pig) and 9–24 h (human). Steady-state fluxes 
for GD were measured between 3–9 h (pig). Kinetic parameters were steady-state 
flux (JSS), permeability coefficient (Kp) and lag time (TL). Superscript capital letters 
indicate a significant difference (p > 0.05) between the same-labelled parameters. Kp 
assumes a liquid density of 1.008 g cm-3 at 25 °C for VX and 1.022 g cm -3 at 25 °C 
for GD. 
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2.4.3. Finite dose studies with porcine skin 
The finite dose study offers a more realistic contamination scenario than that 
employed by infinite dosing methodology. Not only is the system unoccluded, 
allowing volatile chemicals to evaporate, rather than placing an unrealistic 
contamination density of the skin surface, only a small droplet is applied. The finite 
dose study may be viewed as a likely contamination scenario rather than the 
definitive worst case scenario and is typically the methodology employed when 
determining the efficacy of potential chemical warfare agent decontaminants. 
 
The finite dosing methodology diffusion cell work presented in this thesis used two 
different types of static diffusion cells, while both of the Franz type, one was a 
commercially available system (PermeGear™) and the other an in house system. 
Static diffusion cells are used in laboratories both nationally and internationally and it 
is important that results generated in one laboratory are reproducible in another to 
enable confidence in the data generated. The guidelines and protocols that have 
been ratified go some way to affording data reproducibility. That laboratories have 
their own bespoke diffusion cell systems is accepted and reproducibility between 
laboratories has been evaluated using standardised protocols (Chilcott, et al., 
2005a). This, however, is the first time that two systems have been compared within 
the same laboratory to look at differences whilst using the same operator. From the 
data generated, both the PermeGearTM and Dstl in house system performed similarly, 
with no statistical difference in JMAX values between the two. This gives confidence 
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that different systems do perform similarly and differences between laboratories are 
most likely due to the human operator, rather than the system itself. 
 
The JMAX value for GD through dermatomed pig skin was determined to be 10.8 ± 4.8 
g.cm-2.h-1 (x 10-6) for the Dstl in house diffusion cell system and 8.5 ± 2.5 g.cm-2.h-1 (x 
10-6) for the PermeGearTM diffusion cell system. Comparison of GD skin penetration 
by infinite and finite dosing methodology showed an approximate 40 fold reduction in 
penetration rate. Other than the smaller volume of GD applied to the skin surface, 
another reason for the reduction in penetration rate was likely to be due to free 
evaporation of GD from the skin surface under finite dosing conditions (a situation 
deliberated prevented under infinite dose conditions and confirmed by a total 
recovery of (94 ± 10 %), (Section 2.4.2). Under unoccluded (finite) dosing conditions 
GD would be expected to volatilize with a half life of approximately 7.7 hours (Munro, 
et al., 1999) for GD not absorbed into the skin.  Interestingly, however, there was no 
difference in lag time between infinite and finite dosing conditions indicating that even 
if evaporation of GD occurs, skin penetration is still rapid. 
 
Dose distribution at 24 h showed a total recovery of approximately 25% of the 
applied dose. Given that the infinite dose study (section 2.4.2.) gave a total recovery 
of approximately 94% and the only difference (as far as the dose distribution was 
concerned) between the two studies was prevention of free evaporation, it is likely 
that the majority of the remaining 75% of the applied dose of GD evaporated from the 
skin surface over the 24 h study duration. As only negligible amounts of radioactivity 
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were recovered from the surface of the skin at 24 h (supporting the likelihood of 
evaporation under finite dosing conditions), the majority of the remaining 25% had 
penetrated into or through the skin. In terms of the actual amount penetrated, this 
equates to approximately 2.5 mg of GD or in terms of contamination density 
penetration, 1 mg.cm-2. The majority of the GD contamination did not penetrate 
through to the receptor fluid and can be assumed to be bound to skin components 
and not available to induce systemic toxicity. Should the maximum GD skin 
penetration rate of approximately 11 µg.cm-2.h-1 have occurred through a 
contaminated surface area comprising the head, neck, arms and hands (those areas 
potentially left unclothed, and approximating to 3420 cm2 of a total body surface area 
of 19000 cm2 (Hettiaratchy and Papini, 2004;Mosteller, 1987)) then the dose per hour 
would equate to 37.6 mg h-1. Given that the average person weighs 70 kg, this 
equates to 0.5 mg kg-1 h-1. The estimated human LD50 value for GD has been quoted 
as being 5 mg kg-1 (or 350 mg) (Chauhan, et al., 2008). Using this value it would be 
expected for the LD50 threshold to be reached as little as 10 hours after exposure to 
GD exclusively via the percutaneous route in the absence of decontamination. 
However, it must be emphasised that the current study did not take metabolism into 
account, which has been previously been shown to be substantial (up to 80%) in 
human skin (van Hooidonk, et al., 1980). 
 
2.4.4. GD reservoir studies 
This study has shown that there is a reservoir of 14C-GD in pig skin for up to 24 hours 
after contamination of the skin surface in vitro with liquid agent.  A proportion of this 
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reservoir was extractable with the organic solvent acetonitrile, and the amounts of 
extracted GD represent more than 10% of the initially applied dose up to one hour 
post challenge. The proportion of liquid GD that remained on the skin surface 
lessened as recovery time points progressed (from 8 ± 12 % at 15 minutes to 1 ± 1 % 
at 24 hours) , conversely, the proportion of unaccounted for GD increased (from 56 ± 
8 % at 15 minutes to 75 ± 2 % at 24 hours). The likelihood of the unrecovered 
fraction being due to evaporation from the skin surface is discussed in section 2.4.3. 
Interestingly, however, is the disparity in predicted half life time from the value of 7.7 
hours (Munro, et al., 1999). The current study shows that the unrecovered fraction of 
the applied dose reaches its first half life within 15 minutes of application. The value 
of 7.7 hours is stated to have been derived from a linear deposition model. Full 
details of the model are unfortunately not available. Should the model have 
considered a lower surface temperature than the skin surface temperature of 32°C 
used in the current study then that may explain the disparity. It should be noted that 
the current study does not directly measure evaporation, only the unrecovered 
fraction. At best this may be seen an indirect measure of evaporation, although, other 
losses such as lateral diffusion of GD in between the donor and receptor chambers of 
the diffusion cell and subsequent association into the ground glass joints cannot be 
discounted. The observation of lateral diffusion is discussed in section 2.4.5. Of the 
remaining 30 to 40% (depending on the reservoir quantification time point), a 
consistent 14 to 17% of the applied dose was fixed within the skin. The remaining 
extractable component represents the magnitude of the acetonitrile extractable GD 
skin reservoir. The extractable component was at a maximum at 15 minutes (19 ± 4 
%) and reduced to 2.5 ± 0.5 % by 24 hours. 
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The fixed GD fraction can be assumed to be either irreversibly bound to intra- or 
intercellular constituents (such as keratin (Verstappen, et al., 2012)) within the skin or 
not amenable to extraction by acetonitrile. Assuming the former supposition is true, 
the fixed proportion of the applied dose (14 to 17 %) would be unavailable for the 
manifestation of any systemic toxicity. This being the case, 20% or less of the initial 
applied dose of liquid GD (the combination of GD present in the receptor fluid and the 
extractable GD skin reservoir) would have been available to cause any subsequent 
systemic toxicity. At 15 minutes post exposure the amount of GD available to cause 
systemic toxicity was 19 ± 4 % of the applied dose which dropped to 7 ± 3 % by 3 
hours and to 6 ± 2 % by 24 hours. It would be expected for these values to remain 
similar throughout the study duration as any loss from the extractable reservoir 
should see a gain into the amount present in the receptor fluid. Explanation for this 
observation may be due to either the GD in the extractable skin reservoir diffusing 
back to the skin surface or that the GD was associated very closely with the upper 
skin layers and was not removable with dry swabbing (however, this would still be 
deemed as part of the reservoir). Either situation would then allow for evaporation 
from the skin surface (a process known as “off gassing”). It therefore seems likely 
that “off gassing” of GD from the skin reservoir occurs in tandem with skin penetration 
of GD from the skin reservoir. However, the magnitude of such an absorbed dose is 
more than sufficient to cause nerve agent toxicity. That back diffusion from within the 
skin occurs has important implications for the design and use of skin 
decontaminants. Early removal of a skin decontaminant may potentially result in 
secondary contamination of medical personnel from the GD skin reservoir.  
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It is questionable as to whether solvent extraction of the GD skin reservoir with 
acetonitrile was 100% efficient, as work with other chemical warfare agents, such as 
sulphur mustard, suggests that reservoirs cannot be completely removed using 
organic solvent extraction (Hattersley, et al., 2008). That the current study used 
sequential solvent extractions with minimal GD recovered in extractions 2 and 3 
suggests that the acetonitrile extracted as much GD as it was able to. The 
observation that the unextractable (fixed) fraction was a consistent 14 to 17 % 
irrespective of reservoir quantification time point offers further evidence that the 
solvent extraction was as efficient as it was able to be. Solvent extraction is a 
commonly used technique to quantify the amount of a chemical within the skin, 
particularly for studies were radiolabel is not used. A recent example determining the 
percentage of a UV filter extractable by solvent extraction showed recoveries in 
excess of 94 % (Scalia, et al., 2011). It is likely that the reason that acetonitrile 
extraction was not completely effective for GD was due to irreversible binding to skin 
constituents; however, use of further solvents could be evaluated to ensure that this 
is indeed the case. Should the solvent extraction method used for the current study 
not have been 100% effective then the extractable skin reservoir of GD would have 
been underestimated. This would lead to a maximum underestimation of the 
extractable reservoir by 14 to 17%.   
 
It is likely that a combination of back diffusion and skin penetration led to the 
extractable skin reservoir diminishing over time from 19 ± 4 % at 15 minutes to 2.5 ± 
0.5 % by 24 hours. The decrease in the extractable reservoir over the 24 hour study 
duration was consistent with the hypothesis that GD forms a transient depot within 
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the skin during percutaneous absorption. The maximum percentage of applied dose 
within the skin was achieved up to one hour after exposure (with 50% of this being 
extractable at 15 minutes post exposure), indicating that this is the optimum time for 
any countermeasure based on removing the depot. The existence of GD reservoirs 
has been previously reported in a variety of tissues including the lung and skin 
(Kadar, et al., 1985;Benschop, et al., 1981;Clement, 1982;Nordgren, et al., 
1985;Wolthuis, et al., 1981). In summary, the current work programme confirms the 
existence of GD reservoirs within the skin after a percutaneous exposure. 
 
2.4.5. Skin surface spreading of soman 
One of the key assumptions in the data interpretation of diffusion cell studies is that a 
penetrant diffuses across the entire surface area available for diffusion within the 
diffusion cell. Should this assumption be invalid and the penetrant diffuses across a 
smaller proportion of the available area then calculated penetration rates may 
substantially underestimate actual penetration rates.   
 
The data provided by the series of skin surface spreading studies have shown that 
the spread of 14C-GD either across the surface or within the upper skin layers 
(autoradiography being unable to distinguish between the two) is rapid, with complete 
coverage of the diffusional surface area within 15 minute of dosing. This allows for 
the appropriate conversion from amount of 14C-GD penetrated per unit time to the 
amount per unit area of 14C-GD penetrated per unit time. Complete coverage of the 
defined areas remained for the entire duration of each 24 hour study, although, it was 
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evident that for later time points the intensity of the radioactivity had diminished. The 
diminishing intensity correlated well with diminishing 14C-GD on the skin surface 
observed during both the skin surface spreading studies and the reservoir 
quantification studies.  
 
Interestingly, surface spread was not confined to the central area of the dosing 
chamber, with 14C-GD laterally penetrating through the skin that was clamped 
between the donor and receptor chamber to the periphery of the skin section. The 
implication of this is that less of the 14C-GD would have been available for skin 
penetration than previously thought, with evaporation not only taking place from the 
skin surface within the donor chamber, but, also from the skin periphery outside of 
the diffusion cell system. The contribution made to evaporation by GD from the 
peripheral tissue cannot be quantified from this series of studies, however, if the 
infinite (occluded) studies are taken into account, it can be seen that any periphery 
evaporation is negligible due to the approximate 100% dose recoveries made. It is 
likely therefore that although lateral diffusion takes place, it is limited and that the 
majority of laterally diffusing 14C-GD remains within the skin tissue.  
 
Comparison of these studies with the reservoir quantification studies (Section 2.4.4) 
showed that the amount of radioactivity fixed (not solvent extractable) for the 
reservoir studies correlated well with the amount of radioactivity found within the skin 
upon completion of autoradiography. The data suggests that the majority of the 
solvent extractable “free” GD evaporated from the skin surface during the 
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autoradiograph protocol. If this was the case, the hazard of secondary contamination 
to emergency responders cannot be under emphasised. 
 
2.4.6. Use of fresh or previously frozen pig skin in diffusion studies 
Freezing skin prior to use in diffusion cell studies is often a logistical necessity and is 
supported by OECD guidelines (although the preference would be to use fresh skin). 
This has led to the practice becoming commonplace (Barbero and Frasch, 
2009;Bronaugh, et al., 1986;Davies, et al., 2004). Concern regarding potential 
degradation in skin barrier function using previously frozen skin in skin penetration 
studies has led a number of researchers to conduct comparison studies. Studies by 
Harrison (1984), Bronaugh (1986) and Hawkins (1986) evaluated the effect of 
freezing on human skin permeability (Harrison, et al., 1984;Bronaugh, et al., 
1986;Hawkins and Reifenrath, 1986) with the conclusion that permeation did not 
increase through skin that had been stored frozen.  However, more recent work by 
Ahlstrom (2007) has shown increased permeability of water through previously 
frozen tissue (Ahlstrom, et al., 2007). The current study was designed to clarify 
specifically whether freezing had a detrimental effect on the skin barrier integrity of 
pig skin. The penetrant used for this study was tritiated water (not 14C-GD), the 
reason for this choice is that it is the standard penetrant for the evaluation of 
perturbation of skin barrier function (integrity testing), recommended by the OECD, 
prior to commencement of diffusion cell studies. 
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Storage of skin at -20ºC for 2 weeks produced a significant decrease in barrier 
function for 2 out of 6 animals when comparing individual animal data using tritiated 
water as a penetrant. For three of the other animals there seemed to be a trend for a 
reduced barrier function after freezing skin. There are a number of possible 
mechanisms which could explain reduced skin barrier function after freezing 
including perturbation of the lipid bilayers of the inter corneocyte lipids or potentially 
degradation of corneodesmosomes leading to reduced corneocyte adhesiveness 
(Sintov and Botner, 2006). Given that freezing has been shown to decrease pig skin 
barrier function means that this must be taken into account when evaluating 
penetration rate data from in vitro diffusion cell studies. The work reported supports 
the OECD guideline that the use of fresh skin is to be preferred, however, practically, 
use of fresh tissue is not often a realistic option (especially in the case of acquiring 
human in vitro skin). For studies of the type described in this thesis which use 
previously frozen skin, having a potential slight overestimation of penetration 
parameters may be viewed as beneficial as countermeasure research is generally 
interested in defining the worst case scenario to ensure that any countermeasure put 
into general service will be efficacious.   
   
2.4.7. Summary of interactions of GD with skin 
This work has investigated a number of aspects of GD skin penetration leading to the 
proposed interaction scheme in Figure 2.11. A droplet of GD coming into contact with 
the skin surface spreads rapidly either across the skin surface using the skin’s micro 
relief to facilitate spreading or within the upper layers of the stratum corneum by 
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lateral diffusion (or more likely a combination of both). By 15 minutes auto 
radiographic techniques have shown that the entire surface area available for 
diffusion within the diffusion cell system was covered.  
 
The amount of radioactivity removable from the skin surface with a dry swab at 15 
minutes post contamination was less than 10% of the originally applied dose, whilst 
the amount of radioactivity that was associated with the skin (either within the 
microrelief or actually within the skin) was approximately 35% of the applied dose. 
The remaining unaccounted for 55% was assumed to have volatilised from the skin 
surface. Of the 35% associated with the skin, approximately 18% was solvent 
extractable and 17% was not solvent extractable.  
 
The solvent extractable portion or “free” radioactivity was likely to have formed a 
depot or reservoir which would be available for percutaneous penetration whereas 
the “fixed”, non-extractable radioactivity would likely be bound to skin 
macromolecules and not available for skin penetration. It is likely, however, that the 
solvent extraction technique was not 100% efficient, so the approximate values for 
“free” and “fixed” should be interpreted with caution. The amount of “fixed” 
radioactivity remained constant for a 24 hour period whilst the amount of “free” 
radioactivity showed a steady decrease to around 2% of the applied dose at 24 
hours. It is important to note that the majority of “free” radioactivity did not penetrate 
through the skin, with less than 5% of the applied dose being present in the receptor 
fluid at 24 hours. The difference between “free” and penetrated can be accounted for 
by an off gassing mechanism, with the majority of the “free radioactivity” dissociating 
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from the skin and assumed to volatilise from the skin surface. For this scenario to be 
valid, the depot of “free” radioactivity would likely be within the upper surface skin 
layers or associated with radioactivity within the skins microrelief. That auto 
radiographic data shows the presence of radioactivity associated with the upper skin 
layers for the entirety of the 24 hour study period supports this observation.  
 
In the absence of volatilisation, using infinite dosing techniques, the steady state flux, 
JSS, through abdominal flank pig skin was 439 ± 158 µg.cm-2.h-1 whereas for a finite, 
single 10µl droplet with volatilisation, the maximum penetration rate was 10.8 ± 4.8 
µg.cm-2.h-1. These two values may be used to represent two different but specific 
scenarios, gross liquid contamination and small droplet contamination.  
 
  
  
 
 
 
 
Figure 2.11: Summary representation of the interaction of GD with skin.
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CHAPTER 3: EFFICACY TESTING OF HAEMOSTATIC PRODUCTS IN THE 
PRESENCE OF CHEMICAL WARFARE AGENTS: INTERACTIONS WITH GD  
 
3.1. Introduction 
The release of chemical warfare (CW) agent caused by an explosion may result in 
casualties presenting with contaminated, haemorrhaging wounds. There is an 
identified need to develop haemostatic products that can stop haemorrhage and 
decontaminate CW agents simultaneously (Section 1.1.).  A number of commercial 
off the shelf (COTS) haemostatic products have been identified as potential 
candidates to fulfil a dual role as both haemostat and chemical warfare agent 
decontaminant (Section 1.3.) However, it is of vital importance that a potential 
haemostatic decontaminant should not have its haemostatic ability compromised in 
the presence of CW agent, otherwise, it will only fulfil the role of decontaminant. 
Should the CW agent compromise haemostatic ability then the haemorrhaging 
casualty would not stop bleeding and would rapidly deteriorate. It was therefore 
essential to ensure that a candidate COTS haemostatic therapy retains its 
haemostatic properties in the presence of CW agent.  
 
The purpose of this in vitro study was to evaluate the effect of GD (Section 1.6) on 
the clotting efficacy of COTS haemostatic products. As the haemostatic 
decontaminant under development must display undiminished clotting ability in the 
presence of a range of CW agents, complementary studies have simultaneously 
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investigated the efficacy of the candidate haemostats in the presence of sulphur 
mustard and VX (Hall, et al., 2009).  
 
3.1.1. Determination of clotting efficacy 
A number of routine clinical methods are available to measure various clotting 
parameters including plasma thromboplastin (PT), partial thromboplastin time (PTT), 
platelet count, fibrinogen concentrations and thrombelastography (TEG). TEG offers 
the advantage of monitoring haemostasis as a whole dynamic process rather than as 
isolated endpoints (Mallett and Cox, 1992). Conventional clotting efficacy tests are 
generally performed at single time points in the blood coagulation process. As 
reviewed by Kashuk (Kashuk, et al., 2010), thrombelastography (TEG) was 
developed by Hartert in 1948 (Hartert, 1948) and allows haemostatic function to be 
assessed from a single blood sample. In comparison to other coagulation tests, the 
entire blood coagulation process from the initial platelet-fibrin interaction to eventual 
clot lysis may be observed. Standard coagulation tests tend to end with the formation 
of the first fibrin strands. TEG is being evaluated in both military and civilian settings 
to measure blood coagulation (Devlin and Gutierrez, 2010;Doran, et al., 2010;Dries, 
2010), and for the purpose of the current study allowed for rapid selection of 
candidate treatments without the need for in vivo testing. Another advantage of TEG, 
making it the preferred option for the current study, was the ability to rapidly analyse 
a number of blood clotting parameters from CW agent contaminated samples in 
tandem with  control samples. 
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3.1.2. Blood coagulation 
Blood coagulation is an important defence mechanism against bleeding. Rupture of 
the endothelium that allows exposure of blood to the extravascular tissue triggers the 
response of the coagulation system (Dahlback, 2000). The blood coagulation system 
in humans comprises three general processes: 
 
i. Immediate contraction of blood vessels at the site of vascular injury. 
ii. Platelet plug formation. 
iii. Platelet plug stabilisation via fibrin clot generation resulting from the 
interaction of tissue and plasma proteins primarily on the surface of 
activated platelets (Davie, 2003).   
 
The generation of fibrin results from a series of reactions involving blood proteins 
which are in precursor or inactive forms. Activated platelets provide the necessary 
phospholipid to initiate the blood coagulation cascade (Figure 3.1). The blood 
coagulation cascade comprises two complementary pathways, the intrinsic and 
extrinsic. The extrinsic cascade is critical to the initiation of fibrin formation whilst the 
intrinsic cascade plays a role in the growth and maintenance of fibrin formation 
(Davie, et al., 1991). The final steps of the coagulation cascade see the conversion of 
Prothrombin to Thrombin, the enzyme responsible for conversion of fibrinogen to the 
insoluble fibrin clot. From initiation to termination, the coagulation cascade involves a 
large number of plasma proteins and cofactors (Davie, 1986).       
135 
 
3.1.3. The TEG® system 
The TEG® system measures the properties of the forming clot through the use of a 
cylindrical cup which rotates through an angle of 45° over a 10 second period. Briefly, 
a pin is suspended in the blood held in the cup by a torsion wire. As the clot begins to 
form, the torque of the rotating cup is transmitted to the pin. In essence, the strength 
and rate of clot formation directly affects the extent of pin motion. The rotational 
movement of the pin is converted to an electrical signal that can be analysed by 
computer software to give a coagulation profile (Figure 3.2). Of importance for the 
current study were the “R time” which gives a measure of the time period from 
latency (time of sample placement) to initial fibrin strand formation. “K time” which 
gives a measure of the speed to reach a certain level (20 mm) of clot strength. “α” 
which gives a measure of the rapidity of fibrin build up and cross linking. “MA” or 
Maximum Amplitude which gives the ultimate strength of the fibrin clot. “TMA” or 
Time to maximum amplitude which gives the time to maximum clot strength and “CI” 
Coagulation Index, which describes the overall coagulation state as derived from the 
R, K, MA and α parameters. 
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Figure 3.1: Coagulation cascade and fibrin formation, modified from the original by 
Davie (Davie, 2003). The importance of the extrinsic pathway in the initiation of blood 
coagulation following vascular injury and platelet plug formation is indicated. Tissue 
factor is an integral glycoprotein acting as a receptor for Factor VII only after vascular 
injury and in the presence of Ca2+. PL refers to phospholipid provided by activated 
platelets. 
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Figure 3.2: Thrombelastography. Top left: components. Top right: coagulation profile 
indicating parameter derivation for R-time, K-time, angle parameter, MA (Maximum 
amplitude) and TMA (Time to maximum amplitude). Bottom: Coagulation profiles for 
normal and hypercoaguable (for example after haemostat use) samples.  
Cup rotates 45° per 10s period
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α, MA increased
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3.2. Materials and methods 
Soman, GD (O-Pinacolyl methylphosphonofluoridate) was supplied by the Defence 
Science and Technology Laboratory (Dstl, Porton Down, UK) and was reported to be 
>98% pure by GC-MS.  The storage and use of CW agents was in full compliance 
with the Chemical Weapons Convention (1986). Isofluorane-VET® (isofluorane; 
Merial Animal Health Ltd, Essex, UK), Hypnovel® (midazolam hydrochloride (5 
mg.ml-1); Roche Products Ltd., Hertfordshire, UK) and Dolethal® (sodium 
pentobarbitone (200 mg.ml-1); Vetoquinol, Buckingham, UK were purchased from a 
registered UK supplier.  Medical grade oxygen and nitrous oxide were obtained from 
BOC Ltd. (Surrey, UK).  The haemostatic products evaluated were QuikClot 
Advanced Clotting Sponge plus® (“ACS+”; Z-Medica, Wallingford, CT), WoundStat™ 
(TraumaCure, Inc., Bethesda, MD), Vitagel™ (Orthovita, Inc., Malvern, PA), 
HemCon® (HemCon Medical Technologies, Inc., Tigard, OR), Celox® (Medtrade 
Products Ltd., Crewe, UK), FastAct® (Wortham Laboratories Inc, Chattanooga, TN) 
and SuperQR (aka ProQR; Biolife, Sarasota, FL).   
 
The use of animals in this study was authorised under the UK Animal (Scientific 
Procedures) Act (1986). A total of six healthy female pigs (Sus scrofa, large white 
strain; initial weight range 20 - 25 kg) were purchased from a local supplier and were 
housed in a controlled environment (22 ± 2 °C, 53 ± 2 % relative humidity) and 
allowed access to food and water ad. lib. The animals were allowed limited 
interaction (via sight and sound) with neighbouring animals.  Pens were enriched with 
play items such as food cubes (International Market Supply, Cheshire, UK) and were 
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subject to a 12 h/12 h light/dark cycle. Authorisation for the use of animals was also 
obtained from the Animal Care and Use Review Office (ACURO) prior to the 
commencement of this work (protocol reference 07247002).   
 
One blood sample (7.5 ml) was taken per animal per animal day to give a total of 6 
blood samples daily. Samples were acquired from each animal following sedation 
with Hyponoval® (midazolam; 4 ml intramuscular administration) and induction and 
maintenance of anaesthesia (3 – 5 % isoflurane in 8 L min-1 O2) as per an existing 
Home Office animal licence (PL 30/2421). Blood samples were drawn from the 
cephalic vein or cranial vena cava into dried polystyrene tubes containing 3.2% 
sodium citrate (Teklab Ltd, County Durham, UK) and were equilibrated (on a tube 
roller) at room temperature (22°C) for 30 minutes prior to use. The actual anatomical 
location from which venous samples were obtained was altered on a daily basis to 
ensure minimum discomfort to the animals.  The animals were subject to frequent 
examination at least once a day by a veterinary surgeon. 
 
Blood-clotting parameters were measured using an eight-channel thrombelastograph 
haemostasis system (TEG 5000®) purchased from Medicell Ltd, London, UK.  The 
instrument was calibrated using quality control standards obtained from Haemoscope 
Corp. All other TEG consumables including cup/pins and 0.2 M calcium chloride 
(CaCl2) were purchased from MediCell Ltd. Samples for TEG analysis were prepared 
from aliquots of equilibrated, citrated whole blood placed into polyethylene vials.  
Where applicable, the vials were pre-treated with haemostatic agent (to give 0.45% 
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w/v granular test products or 0.45% v/v liquid products) and/or GD (0.5 µl ml-1).  After 
30 seconds of gentle mixing, aliquots (340 µl) of control (untreated) or treated blood 
samples were transferred to a TEG cup (containing 20 µl of CaCl2) in each of the 
TEG channels and the analysis was conducted until acquisition of maximum clot 
amplitude or for a total of 45 minutes (whichever occurred first).  
 
Statistical analysis was performed using the Kruskal-Wallis non-parametric, one-way 
ANOVA with Dunn’s multiple comparisons post test.  The level of significance was 
predetermined at 95% (α = 0.05). 
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3.3. Results 
 
3.3.1. Presence of candidate haemostats in pig blood 
Pig blood treated with FastAct®, SuperQR, Vitagel™ and WoundStat™ showed 
increased haemostasis kinetics as measured by R-time, K-time and Angle parameter, 
compared to that of untreated pig blood. Conversely, pig blood treated with Celox®, 
Hemcon® and QuikClot ACS+® showed similar kinetics of haemostasis to that of 
untreated pig blood (Figures 3.3, 3.4 and 3.5). The ultimate clot strength (Figure 3.5) 
was similar between pig bloods treated with any haemostat or left untreated. 
 
3.3.2. Presence of GD in pig blood 
The presence of GD contamination in pig blood significantly increased the measured 
parameters of haemostasis kinetics, R-time, K-time and Angle parameter, Figures 
3.3, 3.4 and 3.5 respectively. The reduction in R-time and K-time indicated that the 
onset of clotting was more rapid, whilst the increase in Angle parameter indicated 
that the overall rate of clot formation was increased. The ultimate clot strength was 
not affected by the presence of GD (Figure 3.6). 
 
3.3.3. Candidate haemostats evaluated in the presence of GD 
The presence of GD contamination in pig blood did not alter the haemostatic kinetics 
of any of the test products in terms of R-time (Figure 3.3), K-time (Figure 3.4) or 
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Angle parameter (Figure 3.5) compared to treatment in the absence of GD 
contamination. GD did, however, significantly affect the ultimate clot strength 
produced by Vitagel™ (Figure 3.6).  
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Figure 3.3: Effect of haemostatic agents on latency of clot formation in minutes (R-
time) in the presence or absence of GD. Haemostats evaluated were: Celox®, 
SuperQR, WoundStatTM, QuikClot ACS+® HemCon®, FastAct® and VitagelTM. All data 
are average ± standard error of n=6 (haemostats), n=42 (control) and n=42 (GD 
challenged control).  Asterisks indicate that the value was significantly different from 
the n=6 (paired) controls measured simultaneously (p<0.05).   
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Figure 3.4: Effect of haemostatic agents on the rapidity to reach 20mm clot strength 
in minutes (K-time) in the presence or absence of GD. Efficacy of haemostatic 
products in the presence or absence of GD in terms of the “K Time” parameter. 
Haemostats evaluated were: Celox®, SuperQR, WoundStatTM, QuikClot ACS+® 
HemCon®, FastAct® and VitagelTM. All data are average ± standard error of n=6 
(haemostats), n=42 (control) and n=42 (GD challenged control).  Asterisks indicate 
that the value was significantly different from the n=6 (paired) controls measured 
simultaneously (p<0.05).   
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Figure 3.5: Effect of haemostatic agents on the rapidity of fibrin build up and cross-
linking (clot strengthening kinetics) in terms of the “Angle” parameter in the presence 
or absence of GD. Haemostats evaluated were: Celox®, SuperQR, WoundStatTM, 
QuikClot ACS+® HemCon®, FastAct® and VitagelTM. All data are average ± standard 
error of n=6 (haemostats), n=42 (control) and n=42 (GD challenged control).  
Asterisks indicate that the value was significantly different from the n=6 (paired) 
controls measured simultaneously (p<0.05).   
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Figure 3.6: Effect of haemostatic agents on the ultimate strength of the fibrin clot in 
mm (Maximum Amplitude) in the presence or absence of GD. Haemostats evaluated 
were: Celox®, SuperQR, WoundStatTM, QuikClot ACS+® HemCon®, FastAct® and 
VitagelTM. All data are average ± standard error of n=6 (haemostats), n=42 (control) 
and n=42 (GD challenged control). The bar indicates a significant difference between 
the haemostat Vitagel and Vitagel contaminated with GD (p<0.05). 
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3.4 Discussion 
 
3.4.1. Overview 
Seven candidate haemostats were assessed for haemostatic efficacy in the presence 
and absence of GD by thrombelastography (TEG). Three products showed no 
haemostatic ability in the TEG test system. Three products were not adversely 
affected by the presence of GD and one product showed unacceptable 
characteristics in the presence of GD.  
 
3.4.2. Haemostats interaction with the TEG system 
The four candidate treatments which performed as haemostats in the TEG system 
were WoundStat™, SuperQR, FastAct® and Vitagel™. Three of the haemostatic 
products (Celox®, Hemcon® and QuikClot ACS+®) showed similar haemostasis 
kinetics to untreated pig blood, indicating that they were not amenable to in vitro TEG 
analysis. This result has been shown previously (Kheirabadi, et al., 2008), with both 
Celox®, and QuikClot ACS+®. It must be stated that this lack of efficacy using TEG 
analysis is not necessarily representative of their in vivo efficacy. There are a number 
of possible reasons why the three candidates did not increase the clotting rate of pig 
blood in the TEG system, the most likely of which is that they require pressure to be 
applied to the wound site (not reproducible in this in vitro system). This requirement, 
however, makes them less suitable for use in a buddy aid situation (where it is 
desirable for the haemostat to work effectively with the minimum of intervention from 
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other personnel). However, QuikClot ACS+®, WoundStat™ and SuperQR are thought 
to concentrate the clotting factors by absorbing water from the plasma. It is unlikely 
therefore that this is the mechanism of action by which haemostatic activity is being 
reduced, since it would affect all these agents, not just one. The data generated by 
this study indicate that TEG does not seem to be an appropriate test system for all 
haemostatic products. 
 
3.4.3. GD contaminated blood 
Perhaps most interestingly, GD itself had a haemostatic effect on pig blood. This 
finding has been reported by other researchers using an in vivo rabbit model (Lee 
and Clement, 1990) and so it is likely that the TEG analysis carried out is indicative of 
a real effect on haemostasis. It should be noted that Lee and Clement (1990) did not 
consider the pro-haemostatic effect to be of clinical relevance to nerve agent 
poisoning. The reason behind the observed pro haemostatic effect is currently 
unclear as the main mechanism of action of GD is inhibition of cholinesterase. 
However, recent studies have shown that organophosphates can increase cytokine 
release from the lymphocytes (Galloway and Handy, 2003;Kim, et al., 2007) 
therefore, it is feasible that the enhanced clotting rate observed is linked to this 
mechanism.  
 
3.4.3.1 Effects of organophosphates on blood coagulation 
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Work on the effects of organophosphates on in vivo blood coagulation has been 
undertaken by a number of researchers. The results from these studies indicate that 
organophosphates can both activate (Lee and Clement, 1990) and inhibit (Murray, et 
al., 1994) blood coagulation. An in vivo study using Paraoxon showed that changes 
in blood coagulation after exposure were biphasic, with hypercoagulability evidenced 
in the early phase followed by hypocoagulability in the late phase (Petroianu, et al., 
1999). Early phase effects were attributed to catecholamine release from the adrenal 
gland whilst late phase effects were attributed to inhibition of serine protease 
coagulation factors. Given that the current study was conducted in vitro, adrenal 
gland release does not offer a possible explanation for the observed 
hypercoagulability with GD. Interestingly, in vitro blood coagulation studies with 
paroxon have shown no coagulation activating effect (Petroianu, et al., 1997).   
 
3.4.4. Effect of GD on haemostat clotting ability 
GD had no statistically adverse affects on the blood clotting performance of 
WoundStat™, SuperQR and FastAct®, indicating that they were suitable candidates 
to potentially fill the role of haemostatic decontaminants from the point of view of 
interaction with GD (see also section 3.4.5. for interaction with VX and HD). However, 
one haemostatic product (Vitagel™), showed undesirable characteristics (decrease 
in ultimate clot strength) when contaminated with GD. Although, not determined to be 
statistically significant, there was an inconsistency between the K time and Angle 
parameter for Vitagel™ and Vitagel™ contaminated with GD when compared to the 
other evaluated haemostats. In general for the other haemostats, GD contaminated 
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pig blood caused a decrease in K time and increase in Angle parameter. For 
Vitagel™ however, the K time parameter increased and the Angle parameter 
decreased. It is likely that the decreased clotting rate attainable by Vitagel™ with GD 
contaminated pig blood when compared to normal pig blood offers explanation to the 
decrease in statistically observable ultimate clot strength.  
 
3.4.5. Parallel studies using HD and VX 
Two further chemical warfare agents, VX and HD (Section 1.5), where evaluated 
(Lydon, 2012;Hall, 2012) using the methodology described. Briefly, the addition of VX 
to pig blood gave similar results to that of GD with an observable decrease in R-time 
and K-time indicating that VX had a haemostatic effect on pig blood. In the presence 
of VX, a number of pro-haemostatic changes were observed for the candidate 
haemostats. These were; decreased R times for VitagelTM and SuperQR and 
increased overall rates of clotting for VitagelTM, SuperQR, HemCon® and 
WoundStatTM. In contrast, in the presence of HD, clotting parameters were not 
affected and HD did not affect the performance of the candidate haemostats. 
 
3.4.6. Candidate haemostat down selection for use as a decontaminant  
As three of the haemostats evaluated were not amenable to TEG methodology 
(Section 3.4.2.), it was not possible to make any definitive selections on the basis of 
the TEG studies alone. It was encouraging, however, that for those haemostats that 
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were amenable to TEG measurement, three out of the four showed no undesirable 
alteration in clotting characteristics in the presence of GD and two other CW agents. 
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CHAPTER 4: IN VITRO EFFICACY TESTING OF HAEMOSTATIC PRODUCTS AS 
CHEMICAL WARFARE AGENT DECONTAMINANTS 
 
4.1. Introduction 
Based on the initial review, a number of commercial off the shelf (COTS) haemostatic 
products are likely to be amenable to use as decontamination products, as, the 
mechanism of action of fluid absorption is similar to that of the mechanism of action 
of in service CW agent decontaminants such as the passive decontaminant fullers’ 
earth (Section 1.3). Appropriately formulated liquid haemostats with excipients (such 
as cholinesterase (Gordon, et al., 1999)) may also be able to sequester GD and 
arrest bleeding simultaneously. The purpose of this series of studies was to evaluate 
a number of candidate haemostats for efficacy as potential skin decontaminants 
against the nerve agent soman, prior to further in vitro studies using favourable 
candidates in a damaged skin tissue model. To qualify for selection a number of 
essential criteria were defined as follows. 
 
4.1.1. Skin decontamination efficacy 
 The candidate haemostatic decontaminant should approach the effectiveness of 
currently used military skin decontaminants (fullers’ earth, M291 powder) when used 
on undamaged skin. Inability in this area would potentially rule out the option of 
replacing current military decontaminants with a haemostat based skin 
decontaminant system. 
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4.1.2. Agent desorption characteristics of decontaminant 
The candidate haemostatic decontaminant should irreversibly sequester GD. 
Irreversible sequestration is of importance to first responders as off gassing from the 
haemostatic product could produce secondary casualties.  
 
4.1.3. Damaged skin decontamination efficacy  
The candidate haemostatic decontaminant should approach the effectiveness of 
current in service skin decontaminants when used on damaged skin. Inability in this 
area would lessen the likelihood of the candidate being efficacious in its main 
envisaged use of decontaminating haemorrhaging wounds. 
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4.2. Materials and methods 
The synthesis, use and destruction of GD in this study was conducted in accordance 
with the Chemical Weapons Convention (1996) to which the UK is a signatory state.  
Radiolabelled pinacoyl methylfluorophosphonate (GD) was synthesised by TNO 
(Rijswijk, Netherlands) and had a radiochemical purity >97% (as determined by 
radiometric HPLC analysis). The 14C label was at the P-CH3 moiety (see Figure 1.6). 
The chemical purity of unlabelled GD was reported to be >97% (by NMR).  Both 
radiolabelled and cold agent were mixed in appropriate proportions to give a nominal 
activity of approximately 0.5 µCi µl-1. Liquid scintillation counting (LSC) materials 
(Soluene-350TM, Ultima Gold and opaque plastic vials) were purchased from Perkin-
Elmer (Chandler’s Ford, Hampshire).  All other chemicals were analytical grade and 
were purchased from the Sigma Chemical Company (Poole, Dorset). The 
haemostatic products evaluated were QuikClot Advanced Clotting Sponge plus® 
(“ACS+”; Z-Medica, Wallingford, CT), WoundStat™ (TraumaCure, Inc., Bethesda, 
MD), Vitagel™ (Orthovita, Inc., Malvern, PA), HemCon® (HemCon Medical 
Technologies, Inc., Tigard, OR), Celox® (Medtrade Products Ltd., Crewe, UK), 
FastAct® (Wortham Laboratories Inc, Chattanooga, TN) and SuperQR (aka ProQR; 
Biolife, Sarasota, FL), “TOP”, a mixture of Tetraglyme, Oxime and Polyethyleneimine 
(Walter Reid Army Institute of Research, MD, USA), Lupasol P, a high molecular 
weight ethylenimine homopolymer  (BASF Aktiengesellschaft, Germany),  KBDO 
(potassium butadiene monoximate) liquid (E-Z-EM Inc., Canada), M291 
decontaminant (United States Army Medical Research institute of Chemical Defense, 
Maryland, USA) and  fullers’ earth (Sigma Chemical Co., Dorset, UK). 
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The use of animals in this study was conducted in accordance with the Animals 
(Scientific Procedures) Act 1986. Twelve weanling pigs (large white strain, weight 
range 20 - 30 kg) were purchased from a local supplier.  Animals were pair-housed 
and given 24 h access to food and water.  After one week acclimatisation, each 
animal was sedated with Hypnovel® (Midazolam, 6ml i.m., 5 mg.ml-1) and culled with 
an overdose of Euthatal™ (sodium pentobarbitol, 6ml i.v., 200 mg.ml-1).  The whole 
abdominal skin flank (approximately 40 x 30 cm) was excised from each animal. The 
skin was stored flat between sheets of aluminium foil at -20ºC for up to three months 
prior to use.  Prior to study commencement, a skin sample from one animal was 
removed from cold storage and thawed in a refrigerator at 5ºC for approximately 24 
hours. The skin was close clipped and the subcutaneous fat removed before being 
dermatomed (Humeca Model D42, Eurosurgical Ltd, Guildford, UK) to a nominal 
thickness of 500 µm prior to insertion into diffusion cells. For the damaged skin 
studies, a thickness of 100 µm was removed from the epidermal side by 
dermatoming (Humeca Model D42, Eurosurgical Ltd, Guildford, UK). The 100µm 
slice was then discarded. The remaining 400 µm of skin was mounted in the diffusion 
cells.  
 
Percutaneous absorption experiments were performed with Permegear™ Franz-type 
glass, water jacketed diffusion cells with an area available for diffusion of 1.76 cm2. A 
3 x 3 cm section of either tinfoil (agent desorption study) or undamaged (skin 
decontamination efficacy study) or damaged (damaged skin decontamination efficacy 
study) dermatomed pig skin was placed, epidermal side up, between the donor 
(upper) and receptor (lower) chamber. Each receptor chamber was filled with 14 ± 1 
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ml 50% aqueous ethanol receptor fluid to a level that ensured the meniscus of the 
receptor fluid in the sampling arm was level with the skin / tin foil surface. Once 
assembled, each diffusion cell was placed into a diffusion cell holder, incorporating a 
magnetic stirrer and water heater attachments. Stirring of the receptor fluid was 
achieved, via a Teflon coated iron bar situated within the receptor chamber. The skin 
surface within each diffusion cell was maintained at a temperature of approximately 
32ºC (as confirmed by infrared thermography; FLIR Model P640 camera, Cambridge, 
UK) using water pumped at 36ºC through the diffusion cell jackets via a circulating 
water heater (Model GD120, Grant Instruments, Cambridge, UK). Once assembled, 
the diffusion cells were allowed to equilibrate for approximately 24 hours. For the 
decontamination efficacy studies, baseline samples (250µl) were taken, with 
replacement by fresh receptor media, from each receptor chamber prior to 
commencement of the experimental protocol. Due to space considerations within the 
fume cupboard, a maximum of 36 diffusion cells were set up for each study, allowing 
for 6 treatment regimes of n=6 diffusion cells.   
 
Dependent on the study type the following protocols were followed: 
 
(a) Skin decontamination efficacy  
Topical dosing was performed by the direct application of undiluted, 14C-radiolabelled 
GD (10 µl) onto the centre of the skin surface within the donor chamber. 
Decontamination using one of the test products (200 mg or volume equivalent) was 
carried out 30 seconds post GD exposure. Following application of the agent, 
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samples (250 µl) of receptor chamber fluid were removed into 5 ml of scintillation 
fluid (Ultima Gold, Perkin Elmer LAS (UK) Ltd, Buckinghamshire, UK) at regular 
intervals up to 24 h post exposure.  Each sample was replaced with an equivalent 
volume of fresh receptor fluid. Twenty four hours post-exposure a full dose 
distribution was performed.  
 
(b) Agent desorption 
Topical dosing was performed by the direct application of undiluted, 14C-
radiolabelled GD (10 µl) onto the centre of the tin foil surface within the donor 
chamber. If required, decontamination using one of the test products (200 mg) was 
carried out 30 seconds post GD exposure. Following application of the agent, the 
diffusion cells were left either unoccluded or were occluded with a piece of tin foil. 
Three hours post-exposure a dose distribution was performed. The agent desorption 
protocol was repeated at an elevated temperature of 45ºC. 
 
A full dose distribution was carried out after each experimental protocol as follows: 
first, the receptor chamber fluid was removed from each diffusion cell. Second, the 
test product was gently removed from the skin or tin foil surface. Third, the skin / tin 
foil surface was swabbed with cotton wool. Finally, the skin / tin foil from each 
diffusion cell was removed. At each stage, the component removed was placed into a 
glass vial. Test products had 20 ml scintillation fluid added to them, cotton wool 
swabs had 20 ml ethanol added to them and skins had 10 ml of Soluene-350 added 
to them.  Dose distribution vials were then stored at room temperature (with 
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occasional shaking) until the skin had solubilised, after which aliquots (250 µl) were 
removed into 5 ml of scintillation fluid.  The amount of radioactivity in each sample 
was measured using a Perkin Elmer Tri-Carb liquid scintillation counter (Model 2810 
TR), using the manufacturer’s 14C-quench curve library set to exclude single-photon 
(non-radioactive) events. The amount of radioactivity in each sample was converted 
to amount of GD by comparison to standards (containing known quantities of 14C-
GD) prepared and measured simultaneously.  In this way, cumulative 14C-GD 
penetration profiles for the 24 h study period were generated for each diffusion cell.   
 
Maximum penetration rates (JMAX) were calculated by interpolating the peak value 
obtained by plotting the amount of GD per unit time (under finite dose conditions) 
against time. Where applicable, statistical analysis was performed using a non-
parametric ANOVA (Kruskal-Wallis test) with Dunn’s multiple comparisons post-test. 
Differences between mean values were judged statistically significant at an alpha 
level of 0.05.  Area under the curve analysis was carried out using GraphPad Prism 5 
for each 24 hour penetration profile. To allow cross study comparison, each 
treatment cumulative penetration profile was normalised relevant to the study control 
cumulative penetration profile and converted to a percentage to give the parameter 
%CDAUC. 
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4.3. Results 
 
4.3.1. Efficacy of decontamination from undamaged skin  
There was a significant reduction in both the rate (Jmax) and extent  (total penetration 
at 24h) of 14C-GD skin absorption though skins that had been treated with the 
standard powder CW agent decontaminants fullers’ earth (Jmax 0.5 ± 0.6 µg.cm-2.h-1, 
total penetration at 24h: 6.2 ± 7.8 µg.cm-2) and M291 powder (Jmax 0.7 ± 0.3 µg.cm-
2
.h-1, total penetration at 24h: 7.5 ± 3.3 µg.cm-2) compared to untreated skins (Jmax 
3.7 ± 0.6 µg.cm-2.h-1, total penetration at 24h: 42.0 ± 8.7 µg.cm-2). Similarly, there 
was a significant reduction in both the rate and extent of 14C-GD skin absorption 
though skins that had been treated with the haemostatic powders, Super-QR (Jmax 
0.9 ± 0.4 µg.cm-2.h-1, total penetration at 24h: 10.3 ± 4.6 µg.cm-2), WoundStat™ (Jmax 
0.6 ± 0.3 µg.cm-2.h-1, total penetration at 24h: 6.8 ± 3.2 µg.cm-2) and QuikClot ACS+® 
(Jmax 1.3 ± 0.7 µg.cm-2.h-1, total penetration at 24h: 16.0 ± 9.0 µg.cm-2). One 
haemostatic powder (Celox®) did not decrease the skin absorption of 14C-GD (Figure 
4.1). For Celox® treated skin there was a qualitative increase in the amount of 14C-
GD penetrating the skin (Jmax 5.8 ± 1.9 µg.cm-2.h-1, total penetration at 24h: 50.7 ± 
15.2 µg.cm-2), however, in comparison to the untreated control, this result was not 
significant.  
 
Dose recovery of 14C-GD (Figure 4.2) were in the region of 70 % for fullers’ earth, 
Super-QR and WoundStat™ treatment with the majority of radioactivity recovered 
from the powders themselves rather than other compartments. Dose recoveries for 
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Celox® and QuikClot ACS+® were less than 10 % of the applied dose. Dose recovery 
for the positive control was less than 5 % of the applied dose. The unrecovered 
fractions of the dose recoveries were assumed to have volatilised from the skin 
surface due to the unoccluded conditions that were utilised for the test. 
 
One product (HemCon®) fell into the wound dressing category, it caused a significant 
increase in the rate and extent of 14C-GD penetrating the skin (Jmax 22.8 ± 6.2 µg.cm-
2
.h-1, total penetration at 24h: 300 ± 97 µg.cm-2) compared to untreated skin (Jmax 9.3 
± 3.0 µg.cm-2.h-1, total penetration at 24h: 125 ± 40 µg.cm-2)  (Figure 4.3). Dose 
recovery of 14C-GD (Figure 4.4) was in the region of 30 % for Hemcon® treatment 
with the majority of the radioactivity recovered from the dressing itself.  
 
Compared to the untreated control, the standard liquid CW agent decontaminant, 
KBDO liquid significantly reduced both the rate (Jmax 3.4 ± 1.4 µg.cm-2.h-1 (KBDO 
liquid treated), Jmax 11.5 ± 4.0 µg.cm-2.h-1 (untreated control) and extent (penetration 
at 6h: 20.6 ± 8.4 µg.cm-2 (KBDO liquid treated), 71.4 ± 23.8 µg.cm-2 (untreated 
control) of 14C-GD skin absorption for 6 hours post exposure. However, by 24 hours 
significantly more radiolabel had penetrated skin treated with KBDO liquid (total 
penetration 381 ± 109 µg.cm-2 ) than had penetrated the untreated control skin (total 
penetration 125 ± 40 µg.cm-2) (Figure 4.3). 
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Figure 4.1: Cumulative 14C-GD penetration through untreated (     ) or treated
pig skin over 24 hours from an initial topical 10µl dose at t = 0. Treatment was
applied topically at 30 seconds post GD exposure using Celox (     ), SuperQR
(     ), Woundstat  (     ), QuikClot ACS+ (     ) or Fullers Earth (     ). All
values are mean ± standard deviation of n=6 diffusion cells. Fullers Earth,
SuperQR, Woundstat  and QuikClot ACS+ significantly reduced both the
rate and extent of GD skin absorption compared to untreated skin.
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Figure 4.2:  Dose recovery (%) at 24 hours of 14C-GD remaining on the skin
surface (swab), within the skin (membrane), sequestered into the test
material (either haemostat or standard decontaminant) or penetrated into the
receptor media. The skins were either untreated (     ) or test materials
(Celox (     ), SuperQR (     ), Woundstat   (     ), QuikClot ACS+ (     ) or
Fullers Earth (     )) were placed onto the skin surface 30s after the skin had
been contaminated with GD. Statistical significance between the extent of
GD penetration at 24 hours though untreated and treated skins is indicated
(*). There was no statistical significance between the amount of GD
sequestered by Fullers Earth, SuperQR and Woundstat  .
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Figure 4.3: Cumulative 14C-GD penetration through untreated (     ) or treated
pig skin over 24 hours from an initial topical 10µl dose at t = 0. Treatment was
applied topically at 30 seconds post GD exposure using Hemcon (     ),
FastAct (     ), KBDO liquid (     ), Vitagel  (     ) or Lupasol P (     ). All
values are mean ± standard deviation of n=6 diffusion cells. Hemcon,
FastAct and Vitagel  significantly increased the extent of GD skin absorption
from 6 hours compared to untreated skin. Lupasol P and KBDO liquid
significantly reduced the extent of GD skin absorption compared to untreated
skin, however, for KBDO liquid by 24 hours the extent of absorption was
increased compared to untreated skin.
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Figure 4.4: Dose recovery (%) at 24 hours of 14C-GD remaining on the skin
surface (swab), within the skin (membrane), sequestered into the test material
(either haemostat or standard decontaminant) or penetrated into the receptor
media. The skins were either untreated (     ) or test materials Hemcon (     ),
FastAct (     ), KBDO Liquid (     ), Vitagel  (     ) or Lupasol P (     ) were
placed onto the skin surface 30s after the skin had been contaminated with GD.
All values are mean ± standard deviation of n=6 diffusion cells. Statistical
significance between the extent of GD penetration at 24 hours though untreated
and treated skins is indicated (*).
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Two haemostatic liquids (Vitagel™ and FastAct®) were investigated. Both caused a 
significant increase in the amount of 14C-GD penetrating the skin from 6 hours 
(penetration at 6h: 249 ± 90 µg.cm-2 (Vitagel™), 197 ± 60 µg.cm-2 (FastAct®), 71.4 ± 
23.8 µg.cm-2 (untreated control) (Figure 4.3). When Vitagel™ and FastAct® were 
used in conjunction with TOP the enhancement of skin penetration from 6 hours was 
prevented (penetration at 6h: 84.4 ± 12.9 µg.cm-2 (TOP + Vitagel™), 67.0 ± 15.1 
µg.cm-2 (TOP + FastAct®), 53.2 ± 14.1 µg.cm-2 (untreated control). Treatment with 
TOP alone was initially similar to the untreated control, however, by 24h a significant 
reduction in 14C-GD skin penetration was evident (penetration at 24h: 28.7 ± 2.6 
µg.cm-2 (TOP), 105 ± 23 µg.cm-2 (untreated control) (Figure 4.5). Dose recovery of 
14C-GD for Vitagel™ and FastAct® treatment were in the region of 15 % (Figure 4.4) 
which increased to around 30 % when the haemostatic liquids were combined with 
TOP (Figure 4.6). Dose recoveries of 14C-GD from the excipient only treatments 
(TOP and Lupasol P) were approximately 30 % and 10 % respectively. 
 
Area under the curve analysis with normalisation relative to controls (Figure 4.7) 
allowed comparison between studies. Seven products significantly reduced 14C-GD 
skin penetration compared to untreated controls.  
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Figure 4.5: Cumulative 14C-GD penetration through untreated (     ) or treated
pig skin over 24 hours from an initial topical 10µl dose at t = 0. Treatment was
applied topically at 30 seconds post GD exposure using M291 Powder (     ),
TOP (     ), TOP + Vitagel  (     ) or TOP + FastAct (     ). All values are
mean ± standard deviation of n=6 diffusion cells. Treatment with TOP and
M291 powder significantly decreased the extent of GD skin absorption
compared to untreated skin.
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Figure 4.6: Dose recovery (%) at 24 hours of 14C-GD remaining on the skin
surface (swab), within the skin (membrane), sequestered into the test material
(either haemostat or standard decontaminant) or penetrated into the receptor
media. The skins were either untreated (     ) or test materials M291 Powder
(     ), TOP (     ), TOP + Vitagel   (     ) or TOP + FastAct (     ) were
placed onto the skin surface 30s after the skin had been contaminated with
GD. All values are mean ± standard deviation of n=6 diffusion cells. Statistical
significance between the extent of GD penetration at 24 hours though
untreated and treated skins is indicated (*).
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Figure 4.7: Skin penetration of 14C-GD as a percentage of the control dose 
expressed in terms of the area under the curve value for the duration of the study. 
Decontamination was at 30 seconds post GD exposure using Fullers Earth, M291, 
KBDO liquid, Celox®, SuperQR, WoundStatTM, QuikClot ACS+®, HemCon®, TOP, 
FastAct®, VitagelTM, TOP +VitagelTM, TOP + FastAct® or Lupasol P . All data are 
average ± standard error of n=6 diffusion cells. 
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4.3.2. Agent desorption characteristics from decontaminant  
The agent desorption studies sought to determine whether or not candidate 
treatments could irreversibly sequester CW agent. As skin was not required to make 
this assessment, CW agent was placed onto a non absorbent tin foil surface, prior to 
treatment application. Over the three hour time period, none of the haemostatic 
products evaluated (Super-QR, WoundStat™ or QuikClot ACS+®) exhibited 
significant loss of 14C-GD at ambient room temperature (comparing unoccluded to 
occluded conditions). Similarly, fullers’ earth did not exhibit significant loss of 14C-GD 
(Figure 4.8 and 4.9). This indicated that all the products tested irreversibly 
sequestered GD for the period of the test. In comparison, at ambient room 
temperature, the unoccluded control exhibited significant loss of 14C-GD compared to 
the occluded control. At an elevated temperature of 45°C neither WoundStat™ or 
fullers’ earth exhibited significant loss of 14C-GD. In contrast QuikClot ACS+® did 
exhibit significant loss of 14C-GD (Figure 4.10 and 4.11). This indicated that only 
WoundStat™ and fullers’ earth irreversibly sequestered GD for the period of the test 
at the elevated temperature. As for the ambient room temperature study, the 
unoccluded control exhibited significant loss of 14C-GD compared to the occluded 
control. 
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Figure 4.8: Dose recovery (%) at 3 hours of 14C-GD placed onto tin foil at
room temperature under both unnoccluded (     ) and occluded (     )
conditions. Treatments (Woundstat  or Fullers Earth were applied 30
seconds post GD exposure under both unnocluded and occluded
conditions. Where,     = unnocluded Fullers Earth,     = occluded Fullers
Earth,     = unoccluded Woundstat  and     = occluded Woundstat .
Compartments measured were; GD present on the donor chamber
(Chamber swab), GD sequestered into the test material / remaining on tin
foil surface (Treatment / Foil) or present on occlusive foil (occlusive
conditions only). Statistical significance between GD recoveries comparing
unoccluded and occluded conditions is indicated (*). All data are mean ±
standard deviation of n=6 cells.
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Figure 4.9: Dose recovery (%) at 3 hours of 14C-GD placed onto tin foil at
room temperature under both unnoccluded (     ) and occluded (     )
conditions. Treatments (SuperQR or QuikClot ACS+ were applied 30
seconds post GD exposure under both unnocluded and occluded
conditions. Where,     = unnocluded SuperQR,     = occluded SuperQR,
.     = unoccluded QuikClot ACS+ and     = occluded QuikClot ACS+.
Compartments measured were; GD present on the donor chamber
(Chamber swab), GD sequestered into the test material / remaining on tin
foil surface (Treatment / Foil) or present on occlusive foil (occlusive
conditions only). Statistical significance between GD recoveries comparing
unoccluded and occluded conditions is indicated (*). All data are mean ±
standard deviation of n=6 cells.
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Figure 4.10: Dose recovery (%) at 3 hours of 14C-GD placed onto tin foil
at elevated (45°C) temperature under both unnoccluded (     ) and
occluded (     ) conditions. Treatments (Woundstat  or Fullers Earth were
applied 30 seconds post GD exposure under both unnocluded and
occluded conditions. Where,     = unnocluded Fullers Earth,     = occluded
Fullers Earth,     = unoccluded Woundstat  and     = occluded
Woundstat . Compartments measured were; GD present on the donor
chamber (Chamber swab), GD sequestered into the test material /
remaining on tin foil surface (Treatment / Foil) or present on occlusive foil
(occlusive conditions only). Statistical significance between GD recoveries
comparing unoccluded and occluded conditions is indicated (*). All data
are mean ± standard deviation of n=6 cells.
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Figure 4.11: Dose recovery (%) at 3 hours of 14C-GD placed onto tin foil at
elevated (45°C) temperature under both unnoccluded (     ) and occluded
(     ) conditions. Treatment (QuikClot ACS+) was applied 30 seconds post
GD exposure under both unnocluded and occluded conditions. Where,     =
unnocluded QuikClot ACS+,     = occluded QuikClot ACS+. Compartments
measured were; GD present on the donor chamber (Chamber swab), GD
sequestered into the test material / remaining on tin foil surface (Treatment /
Foil) or present on occlusive foil (occlusive conditions only). Statistical
significance between GD recoveries comparing unoccluded and occluded
conditions is indicated (*). All data are mean ± standard deviation of n=6
cells.
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4.3.3. Efficacy of decontamination from damaged skin  
There was a significant reduction in both the rate (Jmax) and extent (total penetration 
at 24h) of 14C-GD skin absorption though damaged skins that had been treated with 
the standard powder CW agent decontaminant fullers’ earth (Jmax 3.9 ± 5.1 µg.cm-2.h-
1
, total penetration at 24h: 28.2 ± 31.4 µg.cm-2) compared to damaged untreated 
skins (Jmax 183 ± 44 µg.cm-2.h-1, total penetration at 24h: 1280 ± 303 µg.cm-2). 
Similarly, there was a significant reduction in both the rate and extent of 14C-GD skin 
absorption though skins that had been treated with the haemostatic powders, Super-
QR (Jmax 15.1 ± 3.4 µg.cm-2.h-1, total penetration at 24h: 195 ± 39 µg.cm-2) and 
WoundStat™ (Jmax 27.3 ± 21.8 µg.cm-2.h-1, total penetration at 24h: 199 ± 148 µg.cm-
2). There was no statistical difference between the penetration of 14C-GD though 
untreated and QuikClot ACS+® treated skin (Jmax 85.0 ± 63.2 µg.cm-2.h-1, total 
penetration at 24h: 599 ± 439 µg.cm-2) (Figure 4.12). 
 
Super-QR and WoundStat™ were statistically comparable in performance to fullers’ 
earth (Figure 4.12). Dose recovery (Figure 4.13) was in the region of 80% for fullers’ 
earth, 70% for WoundStat™, 60% for SuperQR and 40% for QuikClot ACS+®. In all 
cases the majority of radioactivity was recovered from the powders rather than other 
compartments. The unaccounted for portions of the dose recoveries were assumed 
to have volatilised from the skin surface due to the unoccluded conditions that were 
utilised for the test. 
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Figure 4.12: Cumulative 14C-GD penetration through untreated (     ) or treated
damaged pig skin over 24 hours from an initial topical 10µl dose at t = 0.
Treatment was applied topically at 30 seconds post GD exposure using Fullers
Earth (     ), SuperQR (     ), Woundstat  (     ) or QuikClot ACS+ (     ). An
untreated, undamaged skin control (     ) was used also evaluated. All values
are mean ± standard deviation of n=6 diffusion cells.
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Figure 4.13: Dose recovery (%) at 24 hours of 14C-GD remaining on the
skin surface (swab), within the skin (membrane), sequestered into the test
material (either haemostat or standard decontaminant) or penetrated into the
receptor media. The skins were either untreated (damaged (     ),
undamaged (     ) or test materials (SuperQR (     ), Woundstat  (     ),
QuikClot ACS+ (     ) or Fullers Earth (     )) were placed onto the skin
surface 30s after the skin had been contaminated with GD. All values are
mean ± standard deviation of n=6 diffusion cells. Statistical significance
between the extent of GD penetration at 24 hours though damaged
untreated and treated skins is indicated (*).
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4.4. Discussion 
 
4.4.1. Skin decontamination efficacy of haemostats 
This in vitro study has shown that a number of COTS haemostatic products are 
potentially amenable to fulfil the role of skin decontaminants against GD when 
applied before 30 seconds after exposure. Standard military doctrine, however, 
indicates that decontaminant application should be completed by 2 minutes post 
exposure. In a battlefield scenario, 30 seconds approximates to the minimum likely 
time that would elapse before a haemostatic product would be applied to a 
haemorrhaging wound. The purpose of this study was to identify candidate test 
compounds that could both decontaminate and arrest haemorrhage. That being the 
case, a time delay of 30 seconds was deemed to be appropriate.   
 
4.4.1.1. Haemostat category performance 
Three broad categories of haemostat were investigated, powders, wound dressings 
and liquids.  In general, the haemostatic powders were more effective than either 
haemostatic wound dressings or haemostatic liquids. The combination of 
haemostatic liquids with the potentially reactive excipient TOP (Tetraglyme, Oxime, 
Polyethyleneimine) did not significantly improve their performance as candidate 
decontaminants. The effectiveness of the haemostatic powders is most likely due to 
their absorptive mechanism of action: haemostasis achieved via fluid and low 
molecular weight compound removal from the blood. The haemostatic liquids (with or 
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without TOP) and wound dressing did not perform effectively as GD decontaminants. 
This ineffectiveness (and in some cases enhanced absorption of GD was evident) 
may have been due to their occlusive nature. It is well known that occlusion of 
volatile chemicals, such as GD, can enhance skin absorption via prevention of 
volatilisation of liquid away from the skin surface.   
 
4.4.1.2. Standard military decontaminant performance 
Three standard military decontaminants were included in the present study to provide 
a benchmark for the candidate test compounds to be compared against. As expected 
all three (Fullers Earth, M291 and KBDO liquid) were efficacious decontaminants, 
however, in the case of KBDO liquid, apparently only for six hours post exposure. A 
potential confounding factor is the underlying assumption that the radio labelled 
chemical is exclusively the parent compound (in this case GD) for the duration of the 
study and not a breakdown product. The mechanism of action of reactive 
decontaminants such as KBDO liquid is decontamination of CW agent to potentially 
less toxic breakdown products. Further investigation is required to determine which 
breakdown products subsequently penetrated through the skin.  
 
4.4.1.3. Experimental design observations 
When considering the study design involving medical countermeasures against CW 
agents, a typical stance, and the one employed here, is to test the worst case 
scenario. Worst case allows the identification and rejection of ineffective products at 
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an early stage in the study design. To this end a number of facets were incorporated 
including use of a receptor fluid consisting of 50% aqueous ethanol and leaving test 
products in contact with the skin surface for duration of the study (they would 
normally be removed after a suitable interval). The obvious benefit of leaving the test 
product in situ for the duration of the study is that it allows for any desorption 
characteristics to be elucidated. Just because a product is initially effective does not 
give the full picture. It is important to take into account any subsequent desorption 
which could potentially lead to an increase in dermal absorption. A robust approach 
eliminates the selection of potentially ineffective test compounds.   
 
4.4.1.4. Parallel studies with VX and HD 
The haemostatic products were also evaluated against HD and VX (Lydon, 
2012;Hall, 2012). On undamaged skin, two products (WoundstatTM and QuikClot 
ACS+®) were effective against HD and eight products (SuperQR, WoundstatTM, 
QuikClot ACS+®, Celox®, HemCon®, TOP, TOP +VitagelTM and TOP + FastAct®) 
were effective against VX. On the basis of decontamination efficacy across all three 
chemical warfare agents, WoundstatTM, QuikClot ACS+® and SuperQR were selected 
for further evaluation. 
 
4.4.2. Agent desorption characteristics from haemostats 
 
4.4.2.1. GD desorption from candidates at room temperature 
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At room temperature, all three of the selected haemostats irreversibly sequestered 
GD for the three hour study duration. A more rigorous test was to evaluate GD 
sequestration at elevated temperatures. It is not unreasonable to assume that the 
candidate product may be expected to perform well in temperatures approaching 
45°C. Super-QR was not evaluated at elevated temperatures due to its withdrawal 
from the programme prior to this experimental aspect (Super-QR was withdrawn due 
a lack of efficacy against HD).  
 
4.4.2.2. GD desorption from candidates at elevated temperature 
Of the two remaining candidates, this in vitro study has shown that WoundstatTM 
irreversibly sequesters GD at both room temperature and elevated temperatures 
when applied by 30 seconds post exposure. Irreversible sequestration at both room 
and elevated temperature was also exhibited by fullers’ earth. It has already been 
postulated that the effectiveness of the haemostatic powders is most likely due to 
their absorptive mechanism of action, a mechanism of action shared with fullers’ 
earth. On the basis of this and earlier studies, it would seem that WoundstatTM and 
fullers’ earth have similar absorptive properties. 
 
4.4.2.3. Importance of irreversible sequestration 
The ability of the selected haemostat to irreversibly sequester GD is of fundamental 
importance to the work programme. Secondary contamination from possible off 
gassing, either at the scene, or after evacuation, has the potential not to only further 
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injure the casualty, but also any attending medical personnel. Too reiterate, it would 
not be desirable for the selected candidate haemostat to only transiently absorb the 
chemical warfare agent. 
 
4.4.2.4. Parallel Studies with VX and HD 
The selected haemostatic products were also evaluated against HD and VX at both 
ambient and elevated temperatures (Lydon, 2012;Hall, 2012). There was no 
measurable loss of either VX or HD from WoundstatTM at ambient temperatures, 
however, at elevated temperature significant volatilisation (approximately 10%) was 
shown for both VX and HD. VX and HD were found to off gas from QuikClot ACS+® 
and SuperQR at both ambient and elevated temperatures. 
 
4.4.3. Damaged skin decontamination efficacy of haemostats  
This in vitro study has shown that all three selected COTS haemostatic products are 
potentially amenable to fulfil the role of skin decontaminants against GD in vivo when 
applied by 30 seconds post exposure onto damaged skin tissue.  
 
4.4.3.1. Haemostat powder decontaminant performance 
All three of the selected haemostats were powder based. It is likely that their 
absorptive mechanism of action was responsible for their effectiveness at 
sequestering the chemical warfare agents evaluated. On the basis of the current 24 
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hour study, it is reasonable to infer that GD is irreversibly sequestered within the 
haemostat (at a skin temperature of 32°C) as there is no evidence of increased 
absorption at any point during the study after the initial lag phase.   
 
4.4.3.2. Military decontaminant performance 
Fullers’ earth was used as a positive control for both the undamaged and damaged 
skin in vitro diffusion cell studies. Fullers’ earth was as effective against GD on 
damaged skin as it was on undamaged skin.  It would seem that fullers’ earth would 
be an ideal candidate to evaluate as a haemostat in its own right. However, the use 
of fullers’ earth in wounds is contraindicated due to difficulties associated with the 
removal of fine particles from the wound site and the likelihood of any retained 
particles causing fibrosis and granuloma formation (Cooper, et al., 1994).  
 
4.4.3.3. Parallel studies using HD and VX 
The haemostatic products were also evaluated against HD and VX (Lydon, 
2012;Hall, 2012). WoundstatTM and QuikClot ACS+® were effective decontaminants 
on damaged skin against both HD and VX, however, QuikClot ACS+® was 
qualitatively less effective than WoundstatTM. SuperQR was ineffective against HD on 
damaged skin (although it was effective against VX). 
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4.4.3.4. Undamaged vs damaged skin absorption 
Perhaps unsurprisingly, 14C-GD penetrated through damaged skin more rapidly and 
to a greater extent (approximately 10 fold) than through undamaged skin (Figure 
4.12).  A number of researchers have investigated the skin permeability of a range of 
chemicals with differing log p values after damage from a variety of sources including 
mechanical damage (Bronaugh and Stewart, 1985;Gattu and Maibach, 2010). Gattu 
concluded that damage resulted in enhancement of absorption of molecules and that 
this enhancement was more pronounced for hydrophilic molecules compared to 
lipophilic molecules. Of interest was a 6 fold enhancement in the penetration of 
methyl paraben through mechanically abraded skin (methyl paraben and GD have 
similar log p values, measured at 1.96 and 1.8 respectively). Assuming that a ten fold 
difference in penetration rate between in vitro undamaged and damaged skin 
correlates to in vivo undamaged and damaged skin for GD, then a countermeasure 
developed for human in vivo use on contaminated damaged skin would likely have a 
requirement to be substantially more efficacious than if the countermeasure was only 
required to decontaminate undamaged skin. 
 
4.4.4. Candidate haemostat selection for use as a decontaminant  
The series of tests described were carried out as an assessment of the required 
performance criteria (Section 4.1) of the haemostatic decontaminant. In all tests and 
across all three chemical warfare agents used, WoundstatTM consistently 
outperformed the other candidate haemostatic decontaminants. Furthermore, 
WoundstatTM consistently performed as well as the standard in service powder 
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decontaminant fullers’ earth. On this basis, WoundstatTM was selected as the sole 
candidate for in vivo evaluation.   
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CHAPTER 5: IN VIVO EFFICACY TESTING OF HAEMOSTATIC PRODUCTS AS 
CHEMICAL WARFARE AGENT DECONTAMINANTS 
 
5.1. Introduction 
The use of in vivo animal models remains the method of choice to study whole body 
systemic interactions with nerve agents. The toxicity of nerve agents is such that it 
would be unethical to conduct nerve agent studies in human volunteers, although this 
does not preclude the use of less toxic simulants such as methyl salicylate. Although, 
traditionally smaller animal models such as the guinea pig have been extensively 
used for in vivo nerve agent studies, the pig is arguably a more relevant model for 
nerve agent exposure via the percutaneous absorption route. 
 
5.1.1. The pig as an in vivo model 
Percutaneous absorption through pig skin has been shown to be more representative 
as a model for human skin than that of rodents and has the advantage of allowing 
neat, rather than diluted chemical to be topically applied. Furthermore, for studies 
which also involve the withdrawal of multiple blood samples, a large animal model 
offers the advantage of a large circulating blood volume. Less well characterised is 
the response of the pig to nerve agent exposure after absorption has taken place 
(although for the characterisation of medical countermeasure efficacy, which operate 
on a pass / fail criteria, this may not be a major concern). Work to further characterise 
the pig for nerve agent exposures continues unabated both nationally and 
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internationally (Bjarnason, et al., 2008;Dorandeu, et al., 2007;Mikler, et al., 
2011;Sawyer, et al., 2011;Sawyer, et al., 2012;Tenberken, et al., 2010;Chilcott, et al., 
2005b). 
 
5.1.2. Adherence to the 3R’s 
For the current study, adherence to the 3R’s (refinement, replacement and 
reduction), has prompted the analysis of a substantial in vitro body of data to allow 
selection to the favoured test product. To this end, initial in vitro evaluation studies 
had been undertaken to answer a series of questions to allow effective product 
selection prior to in vivo evaluation. An effective candidate would retain haemostatic 
ability in the presence of a range of CW agents (nominally GD, VX and HD). This was 
seen as an essential quality due to the fact that that the haemostat would need to 
have continued efficacy when in intimate contact with CW agents. 
Thrombelastographic evaluation of CW agent spiked blood sample showed that this 
was the case for a number of test products. Of primary importance, was that an 
effective candidate would also have demonstratable efficacy as a CW agent skin 
decontaminant. This was shown to be the case for both normal and damaged skin in 
vitro using a range of CW agents including GD, VX, and HD. A final criterion was the 
desire that an effective candidate would irreversibly sequester any CW agent that it 
had absorbed from the skin surface. It is important to note that any re-release of CW 
agent from the test product would not only have potential consequences for the 
casualties, but, also for any attending medical personnel. A number of test products 
were shown to have this ability. 
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5.1.3. Haemostatic decontaminant for in vivo evaluation 
From the initial in vitro studies (Chapter 4), the most efficacious product was 
determined to be Woundstat™. Although a number of test products were shown to 
be effective against GD challenge, only Woundstat™ consistently passed tests 
involving GD, VX and HD.  
 
5.1.4. Study purpose 
The purpose of the current study was to use a damaged skin in vivo pig model to 
evaluate Woundstat™, with the aim of determining whether a) it could both 
simultaneously act as a haemostat to prevent catastrophic blood loss after 
haemorrhaging injury, and b) whether it could effectively decontaminate a chemical 
warfare agent contaminated wound. As one of a suite of evaluation studies, this 
particular study was primarily concerned with the decontamination efficacy of the test 
product rather than its ability to induce haemostasis (a characteristic already proven 
for COTS haemostats). The definitive, final evaluation study will use a 
haemorrhaging wound model contaminated with CW agent to make the final efficacy 
evaluation. The current study also allowed for the clinical manifestations of GD 
poisoning to be defined and the absorption and distribution of 14C-GD to be 
quantified. 
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5.2. Materials and Methods 
The synthesis, use and destruction of GD in this study was conducted in accordance 
with the Chemical Weapons Convention (1996) to which the UK is a signatory state.  
Radiolabelled pinacolyl methylfluorophosphonate (GD) was synthesised by TNO 
(Rijswijk, Netherlands) and had a radiochemical purity >97% (as determined by 
radiometric HPLC analysis). The 14C label was at the P-CH3 moiety (see Figure 1.6).  
The chemical purity of unlabelled GD was reported to be >97% (by NMR).  Both 
radiolabelled and cold agent were mixed in appropriate proportions to give a nominal 
activity of approximately 0.4 MBq µl-1. WoundStat™ was purchased from 
TraumaCure, Inc. (Bethesda, MD). Batch WS-07-1200, expiry 03/12/10 was used for 
the procedure.  
 
The use of animals in this study was conducted in accordance with the Animals 
(Scientific Procedures) Act 1986. Animal studies reported here were compliant with 
both UK Home Office and USAMRMC Animal Care and Use Review Office (ACURO) 
guidelines. Female pigs (sus scrofa) of weight range 15 to 25 kg were purchased 
form a local supplier. Each animal was habituated for a minimum of seven days and 
given 24 h access to food and water by animal technicians. After acclimatisation, 
each animal was sedated with Hypnovel® (Midazolam, 6ml i.m., 5 mg ml-1) prior to 
induction of anaesthesia using up to 5% isofluorane delivered via a facemask. After a 
15 minute stabilisation period, the pig was intubated with an endotracheal tube (7mm 
cuffed, lubricated with KY jelly). Surgery was conducted under isofluorane (1.5 to 3 
%) respiratory anaesthesia. 
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Vital signs including pulse rate, ECG, arterial blood pressure, breathing rate, core 
temperature, CO2 and SPO2 monitored for the duration of the study using a Propaq 
Encore (Welch Allyn, USA) physiological monitoring system. 
 
5.2.1. Surgery 
Surgery was carried out under aseptic conditions to give arterial and venous access. 
The internal carotid artery and jugular vein were canulated using 2 mm catheters. All 
catheters were primed with sterile saline prior to introduction to the animal. Incisions 
were sutured using a vicryl straight needle suture. Anaesthesia was transitioned from 
respiratory isofluorane to intravenous Alfaxan (alphaxalone, Astra Zeneca) upon the 
completion of surgery. Alfaxan infusion rates were of between 12 to 24 ml.hr-1 
dependent upon clinical signs. Baseline samples and physiological measurements 
were taken during a 30 minute stabilisation period after transition onto intravenous 
anaesthesia. The pig was placed in a sling housed within a category C fume 
cupboard prior to preparation of the outer ear dosing site. The dorsal aspect of the 
left ear was secured to the sling with a flat piece of metal in a horizontal position. 
Skin damage (were required by experimental protocol) was achieved by 
dermatoming (Humeca Model D42, Serial No. 42116, Eurosurgical Ltd, Guildford, 
UK) a 3 cm2 area of outer ear skin to a depth of 100 µm. Any bleeding from the 
wound was transient and was removed using sterile, saline soaked gauze. A dosing 
chamber constructed from a sawn off 20 ml syringe was glued over the wound site 
using Vetbond surgical adhesive. The animal remained within the fume cupboard 
until study completion. 
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5.2.2. Blood Sample Processing 
Arterial blood samples were taken at various time points for determination of whole 
blood cholinesterase, clinical blood parameters, haematocrit levels, 
thrombelastography (TEG) and radioactivity quantification. Samples for clinical blood 
parameters were drawn into a blood gas syringe and run immediately on a GEM 
3000 blood gas analyser, parameters obtained were pH, pCO2, pO2, Ca2+, Na2+, K+, 
lactate, glucose and haematocrit. CO-Oximetry samples were run using a GEM OPL 
(Oxygen Portable Laboratory) to give the parameters THb (Total haemoglobin), 
O2Hb, COHb, MetHb, RHb, SO2m, FHb and SHb. Samples for whole blood 
cholinesterase and haematocrit were taken into sodium EDTA vials. Haematocrit 
sample were run immediately whilst whole blood cholinesterase samples were frozen 
at -20ºC prior to analysis to ensure lysis of the blood cells.  Samples for TEG and 
radiometric analysis were taken into sodium citrated vials. TEG samples were run 
according to methodology in Chapter 3 whilst radiometric samples were collected 
and frozen at -20ºC for later analysis. Sample acquisition for an individual study was 
dependent on each individual study protocol. 
 
5.2.3. Baseline parameter determination 
Six animals were surgically prepared as described above before being monitored and 
sampled for 6 hours. Animals were euthanized prior to being subject to post mortem 
as described in the terminal procedures and post mortem section.   
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5.2.4. Determination of GD dosing volume 
Eight animals were surgically prepared prior to receiving a GD dose of varying 
volume (0.3 µl kg-1 to 3 µl kg-1) as a single droplet onto dermatome damaged ear skin 
within the dosing chamber using a Gilson positive displacement pipette. The droplet 
was left in situ without interference for the duration of the study. Animals were 
monitored and had blood sampled either until the animal suffered from terminal nerve 
agent effects or the maximum study duration of six hours was reached. Whether or 
not the animal died during the study, the euthanisation procedure was followed prior 
to post mortem (as described in the terminal procedures and post mortem section).  
 
5.2.5. Determination of WoundstatTM efficacy 
Twelve animals were dosed with a fixed volume of GD (0.3 µl kg-1) as a single droplet 
onto dermatome damaged ear skin within the dosing chamber using a Gilson positive 
displacement pipette. Thirty seconds after GD challenge, six animals had an excess 
(2 g) of WoundstatTM placed onto the surface on the damaged skin site, completely 
covering the GD present on the skin surface. The applied WoundstatTM was left in 
situ for the study duration. Six control animals received no treatment after GD 
challenge with the droplet being left in situ with no interference. As with the dosing 
volume determination study, animals were sampled and monitored until the animal 
succumbed to the toxic affect of the nerve agent or the six hour maximum study 
duration was reached. The animal was then euthanized (irrespective of whether it 
had died due to nerve agent poisoning) prior to post mortem.  
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5.2.6. Terminal procedures and post mortem 
Animals were culled with an intravenous overdose of Euthatal™ (sodium 
pentobarbitol, 6ml i.v., 200 mg ml-1) prior to exsanguination using suction through the 
arterial line. The ear dosing site was excised and removed from the animal using a 
scalpel. For studies using WoundstatTM, this was emptied into a glass vial with any 
remaining WoundstatTM being dry swabbed from the skin surface and retained in a 
separate vial.  The dosing chamber was then removed and placed into a vial. The 
skin surface of the dosing site was swabbed with dry cotton wool with the swab being 
retained. After these operations had been completed, the ear dosing site was 
separated into 2 sections, the central dosing area and the periphery of surrounding 
skin tissue. The skins were placed into separate glass vials. A post mortem was 
performed, with organ weights being taken for brain, lungs, heart, spleen, pancreas 
and liver. Sections of these organs as well as diaphragm were retained for further 
analysis. 
 
5.2.7. Cholinesterase activity determination 
The Ellman method (Ellman, et al., 1961) was used to analyse samples of arterial 
whole blood that had been stored for a minimum of 30 minutes at -20°C. Aliquots of 
whole blood were incubated at 30°C using a hot plate, in cuvettes containing 5,5 – 
Dithiobis – (2 nitrobenzoic) acid (DTNB), sodium bicarbonate (NaHCO3), 
acetylthiocholine iodide and a pH8 phosphate buffer. The reaction of these 
compounds was measured using a spectrophotometer (Ultrospec 6300 pro, 
Biochrom Ltd, Cambridge, UK) with an 8 cell holder at a wavelength of 412nm over a 
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10 minute period. Substrate blanks and sample blanks were run alongside each test 
sample. Preparation details for these solutions and amounts added to each cuvette 
are given below. Phosphate buffers at pH7 and pH8 were made up from 0.1M 
sodium dihydrogen orthophosphate (NaH2PO4.2H2O), molecular weight 156.01 
(weight of 7.8g made up to 500 ml with distilled H2O) and 0.1M disodium hydrogen 
orthophosphate (Na2HPO4.2H2O), molecular weight 177.99 (weight of 35.6 g made 
up to 2000 ml with distilled H2O). For 1000 ml of the pH7 phosphate buffer, the 
required volumes were approximately 195 ml 0.1M sodium dihydrogen 
orthophosphate, 305 ml 0.1M disodium hydrogen orthophosphate and 500 ml 
distilled H2O. For 2000 ml of the pH8 phosphate buffer, the required volumes were 
approximately 52 ml 0.1M sodium dihydrogen orthophosphate, 948 ml 0.1M disodium 
hydrogen orthophosphate and 1000 ml distilled H2O. For both of the phosphate 
buffers, the pH was adjusted as necessary and checked using a calibrated pH meter. 
Buffers were stored at 4°C and checked daily until required. The DTNB solution 
comprised: 198 mg of 5,5 – dithiobis – (2 nitrobenzoic) acid (DTNB), molecular 
weight 396.35 added to 75 mg  sodium bicarbonate (NaHCO3), molecular weight 
84.01, and made up to 50 ml with 0.1M pH7 phosphate buffer. From this stock 
solution, a DTNB working solution of 2.5 ml DTNB stock made up to 100 ml with 
distilled H2O was made daily. Acetylthiocholine iodide, molecular weight 289.18, 44.1 
mg was made up to 50 ml with distilled H2O. Whole blood (25µl) that had previously 
been stored frozen at -20°C in EDTA tubes was diluted into 4.975 ml of pH8 
phosphate buffer. The diluted blood was shaken gently to ensure thorough mixing 
prior to use. 
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5.2.7.1 Ellman assay procedure 
Eight cuvettes were measured simultaneously; these were split into sample blanks, 
substrate blanks and whole blood test samples. Cuvettes for sample blanks 
contained 1 ml distilled H2O, 1 ml diluted whole blood and 1 ml DTNB working 
solution. Cuvettes for substrate blanks contained 1 ml acetylthiocholine iodide 
solution, 1 ml pH 8 phosphate buffer and 1 ml DTNB working solution. Cuvettes for 
test samples contained 1 ml diluted whole blood, 1 ml acetylthiocholine iodide 
solution and 1 ml DTNB working solution. Each cuvette contained a total volume of 3 
ml, with a total amount of blood within that volume (for test and sample blanks) of 5µl. 
The absorbance at 412 nm was measured for each solution every 30 seconds for 10 
minutes. The absorbance output was exported to Microsoft Excel where the rate of 
reaction for the sample blank, substrate blank and test sample were determined. The 
reaction rate for each test sample was corrected by subtracting the sample and 
tissue blanks which had been run simultaneously. The percentage cholinesterase 
activity in each test sample post GD dosing was determined by reference to an 
assigned pre GD dosing sample of 100% activity.  
 
5.2.8. Radiometric analysis 
Radiometric dose distribution was carried out to quantify the amount of GD present in 
the following compartments at the conclusion of the study: within the skin at the 
dosing site, within the skin around the periphery of the dosing site, on the surface of 
the skin and within the dosing assembly.  For WoundstatTM studies, the WoundstatTM 
was retained to quantify absorption efficiency. Each compartment was taken into a 
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vial as described earlier. Iso propyl alcohol was used to extract radioactivity from the 
skin cotton wool swabs and dosing chambers, skin samples were solubilised using 
soluene 350 and Ultima Gold liquid scintillation fluid was used to extract radiolabel 
from WoundstatTM treated samples. After solubilisation of the skin tissue, all 
compartments were sampled into Ultima Gold liquid scintillation fluid.  The amount of 
radioactivity in each sample was measured using a Perkin Elmer Tri-Carb liquid 
scintillation counter (Model 2810 TR), using the manufacturer’s 14C-quench curve 
library set to exclude single-photon (non-radioactive) events. The amount of 
radioactivity in each sample was converted to amount of GD by comparison to 
standards (containing known quantities of 14C-GD) prepared and measured 
simultaneously. 
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5.3. Results 
The results generated during the in vivo studies are grouped into a number of 
discrete sections beginning with baseline parameter determination (six animals), then 
GD dose ranging studies used to determine the clinical manifestations of GD 
poisoning (which comprised eight animals run sequentially) and finally twelve animals 
in the main study group which received a fixed (µl kg-1) GD volume with or without 
WoundstatTM treatment.  Animals in the main study group were challenged with 14C-
GD. The results are presented in three sections; clinical manifestations of GD 
poisoning (incorporating data from control animals), damaged skin absorption and 
distribution of 14C-GD and efficacy of a haemostatic decontaminant candidate in vivo. 
 
5.3.1. Clinical manifestations of GD poisoning 
Data collecting during the dose ranging studies included observed signs, monitored 
physiological signs, whole blood cholinesterase, arterial blood gas analysis and 
thrombelastography (TEG). Together these gave a broad assessment of the clinical 
manifestations of GD poisoning following percutaneous damaged skin exposure in 
the large white pig. Animal usage for the study comprised a total of 14 animals; 6 
negative controls and 8 animals that received various mg.kg-1 challenges of GD 
(Table 5.1) onto damaged ear skin. 
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Challenge (mg.kg-1) Assigned Physiological Signs TTD (min) 
3 High Early / Intermediate / 
Late onset 
12 
0.3 Low Early only Survived 
1 Medium Early / Intermediate / 
Late onset 
34 
1 Medium Early / Intermediate / 
Late onset 
114 
1 Medium Early / Intermediate Survived 
1 Medium Early / Intermediate / 
Late onset 
15 
0.75 Medium Early / Intermediate / 
Late onset 
11 
0.3 Low Early / Intermediate / 
Late onset 
138 
 
Table 5.1: GD challenges applied to damaged pig ear skin on individual animals. 
Doses were assigned at challenge levels of high (3 mg.kg-1), medium (0.75 to 1 
mg.kg-1) or low (0.3 mg.kg-1). The physiological signs (Section 5.3.1.1) and time to 
death (TTD) for each animal did not correlate with the assigned challenge level. 
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5.3.1.1. Physiological signs of GD poisoning 
Physiological signs were either physically observed or measured using a ProPaq 
monitoring system. Observations were recorded throughout the time course of each 
study until either apnoea or euthanasia. Observable clinical signs in GD poisoned 
animals included miosis, mastication, fasiculations (both head and body), tremors, 
nasal secretions, salivation and body spasm, apnoea and death. The appearance of 
these overt signs (if present) was consistent in relation to the onset of apnoea. 
Regardless of the GD challenge, early signs of GD poisoning included mastication, 
fasiculations and tremor. Intermediate signs included miosis, salivation and nasal 
secretions. Late onset effects (just prior to apnoea) included lacrimation and body 
spasm. None of the signs were dose specific, with the time to onset of apnoea 
seemingly unrelated to the GD challenge received.  The monitored physiological 
signs measured both pre-exposure and immediately preceding apnoea or 
euthanisation are shown in Table 5.2. Differences between pre exposure and end of 
study parameters for GD exposed animals were consistent with the onset of apnoea. 
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GD challenge 
(mg.kg-1) 
0  0.3  0.75  1  3 
Pre 
exposure End 
 Pre 
exposure End 
 Pre 
exposure End 
 Pre 
exposure End 
 Pre 
exposure End     
Pulse Rate 163 ± 19 156 ± 31  163 ± 4 145 ± 33  144 66  153 ± 25 113 ± 90  167 93 
Systolic 
Pressure 
(mmHg) 120 ± 9 106 ± 10 
 
119 ± 3 155 ± 52 
 
130 120 
 
104 ± 10 92 ± 28 
 
119 172 
Diastolic 
Pressure 
(mmHg) 93 ± 7 79 ± 9 
 
46 ± 73 58 ± 95 
 
98 88 
 
79 ± 9 62 ± 25 
 
97 130 
Mean 
Pressure 
(mmHg) 107 ± 6 93 ± 8 
 
84 ± 33 104 ± 65 
 
107 103 
 
91 ± 11 74 ± 29 
 
108 146 
C02 (kPa) 6.2 ± 0.1 5.9 ± 0.7  5.8 ± 0.4 7.3 ± 1.6  6.4 0.7  6.1 ± 0.2 2.8 ± 4  5.9 0.5 
Breathing 
Rate 36 ± 13 33 ± 9 
 
36 ± 11 13 ± 12 
 
52 0 
 
50 ± 11 5 ± 11 
 
52 0 
Sp02 (%) 93 ± 3 92 ± 7  93 ± 3 49 ± 67  89 0  93 ± 4 54 ± 4  89 74 
Body Temp 
(°C) 38.2 ± 0.6 38.1 ± 0.5 
 
38.3 ± 0.9 34.6 ± 4.9 
 
37.8 37.3 
 
38.2 ± 0.4 37.3 ± 0.8 
 
38.6 38.3 
 
 
Table 5.2: Monitored physiological signs in pigs during steady state anaesthesia both pre GD exposure and at the end of the 
experiment (immediately preceding apnoea of euthanisation) at a range of challenge doses. Data from a total of 14 animals as 
follows; n=6 for GD challenge of 0 mg.kg-1, n=1 for GD challenge of 0.75 and 3 mg.kg-1, n=2 for GD challenge of 0.3 mg.kg-1 
and n=4 for GD challenge of 1.0 mg.kg-1.  
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5.3.1.2. Whole blood cholinesterase 
Whole blood cholinesterase did not significantly vary from the original cholinesterase 
value of 100% for the six hour study duration for the control group (Figure 5.1). In 
contrast, there was a rapid blood cholinesterase inhibition for GD poisoned animals. 
For all GD challenge levels, whole blood cholinesterase had decreased to less than 
5% of the original value by 10 minutes post contamination. Whole blood 
cholinesterase levels generally remained below the 5% level until the onset of 
apnoea. For the challenge levels chosen, whole blood cholinesterase inhibition was 
independent of GD dose given, indicating that for the challenge levels used, extent of 
whole blood cholinesterase inhibition was not a reliable indicator of final clinical 
outcome. Similarly, the observed physiological signs (section 5.3.1.1.) did not 
indicate the rapidity and extent of the cholinesterase depression. 
 
5.3.1.3. Blood parameters 
Generally, exposure to GD caused an elevation in arterial blood gas parameters 
(except for pO2 which decreased) immediately prior to apnoea (Table 5.3). Of 
particular interest was the increase in blood glucose after GD exposure. Changes in 
Co-Oximetry parameters are shown in Tables 5.3 and 5.4.     
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Figure 5.1: Total whole blood cholinesterase (ChE), shown as percentage of
original (pre GD challenge) activity in anaeathetised pigs following damaged ear
exposure to liquid GD. All values are mean ± standard deviation of up to 6
animals. GD challenge levels were 0 mg.kg-1 (     , n=6), 0.3 mg.kg-1 (     , n=2),
0.75 mg.kg-1 (     , n=1), 1 mg.kg-1 (     , n=4) and 3 mg.kg-1 (     , n=1).
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GD challenge (mg.kg-1) 0  0.3  0.75  1  3 
Pre 
exposure End 
 Pre 
exposure End 
 Pre 
exposure End 
 Pre 
exposure End 
 Pre 
exposure End     
At 37oC pH 7.5 7.5  7.5 ± 0 7.4 ± 0.1  7.5 7.1  7.5 ± 0 7.3 ± 0.1  7.5 7.3 
pCO2 (kPa) 5.7 6.3  5.2 ± 0.1 8.4 ± 4  5.2 12.1  5.6 ± 0.3 7.9 ± 1.8  5.9 9.7 
pO2 (kPa) 8.5 9.6  10.9 ± 2 5.2 ± 5.6  10.0 0.3  10.7 ± 1.1 5.1 ± 2.9  8.9 0.7 
Na+ (mmol/L) 136.0 135.0  138.0 ± 1.4 139.0 ± 1.4  140.0 137.0  137.8 ± 2.2 138.3 ± 2.5  139.0 138.0 
K+ (mmol/L) 3.9 3.5  4.1 ± 0.1 4.2 ± 0.7  3.9 10.1  4.0 ± 0.2 5.8 ± 1.5  3.8 7.4 
Ca++ (mmol/L) 1.4 1.3  1.4 ± 0 1.4 ± 0  1.6 1.5  1.4 ± 0.1 1.4 ± 0  1.4 1.4 
Glu (mmol/L) 4.9 4.7  3.8 ± 0.6 8.6 ± 2.9  3.6 3.6  4.7 ± 0.3 11.5 ± 7.7  3.5 3.2 
Lac (mmol/L) 0.7 0.3  1.1 ± 0.6 5.6 ± 0.4  0.6 5.5  0.8 ± 0.5 4.8 ± 3.8  0.7 3.8 
Hct (%) 30.0 28.0  29.0 ± 0 33.0 ± 1.4  27.0 36.0  28.0 ± 1.4 37.0 ± 2.6  32.0 35.0 
Co-oximetry THb (g/dL) 10.0 9.6  10.4 ± 0.4 11.1 ± 0.4  10.5 11.9  10.0 ± 0.3 12.9 ± 0.8  10.9 11.9 
O2Hb (%) 92.4 93.8  95.3 ± 4 52.2 ± 56.1  92.4 8.8  95.2 ± 1.5 54.7 ± 33.6  92.5 10.8 
COHb (%) 0.0 0.1  0.2 ± 0.3 0.0 ± 0  0.0 0.1  0.0 ± 0 0.2 ± 0.2  0.0 0.0 
MetHb (%) 1.7 1.6  1.6 ± 0.4 1.1 ± 0.8  1.9 0.4  1.8 ± 0.8 1.7 ± 0.7  1.8 0.5 
HHb (%) 5.9 4.5  3.0 ± 4 46.7 ± 57  5.7 90.7  3.0 ± 1.6 43.5 ± 34  5.7 88.7 
SO2 (%) 94.0 95.5  97.1 ± 4 53.0 ± 57.3  94.2 8.8  97.0 ± 1.5 55.8 ± 34  94.2 10.8 
 
Table 5.3: Blood parameters measured in pigs during steady state anaesthesia both pre GD exposure and at the end of the 
experiment (immediately preceding apnoea of euthanisation) at a range of challenge doses. Data from a total of 9 animals as 
follows; n=1 for GD challenge of 0, 0.75 and 3 mg.kg-1, n=2 for GD challenge of 0.3 mg.kg-1 and n=4 for GD challenge of 1.0 
mg.kg-1. 
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GD challenge (mg.kg-1) 0  0.3  0.75  1  3 
Pre 
exposure End 
 Pre 
exposure End 
 Pre 
exposure End 
 Pre 
exposure End 
 Pre 
exposure End     
Derived HCO3- (mmol/L) 34.3 36.7  32.3 ± 0.6 34.0 ± 7.8  29.0 30.3  32.9 ± 0.7 31.5 ± 2  34.3 35.1 
Parameters 
HCO3std 
(mmol/L) 32.9 34.4 
 
31.8 ± 0.2 29.4 ± 1.9 
 
28.8 22.0 
 
31.7 ± 0.4 27.1 ± 3.3 
 
32.6 27.8 
TCO2 (mmol/L) 35.6 38.1  33.5 ± 0.6 36.0 ± 8.7  30.2 33.1  34.3 ± 0.8 33.3 ± 1.8  35.7 37.3 
BE(B) (mmol/L) 10.3 12.2  8.8 ± 0.4 7.0 ± 4.1  5.1 -1.0  8.8 ± 0.6 4.2 ± 3.9  10.0 6.3 
O2ct (ml/dL) 12.8 12.6  13.7 ± 0.1 7.9 ± 8.3  13.5 1.5  13.2 ± 0.6 9.5 ± 5.4  14.0 1.8 
O2cap (ml/dL) 13.6 13.2  14.2 ± 0.5 15.3 ± 0.7  14.3 16.5  13.6 ± 0.4 17.5 ± 1.2  14.8 16.4 
A-aDO2 (kPa) 2.4 2.0  1.2 ± 0.7 4.1 ± 1.4  2.8 5.1  1.0 ± 0.6 4.8 ± 3  2.3 6.7 
pAO2 (kPa) 12.1 12.0  13.1 ± 0.6 9.6 ± 4.6  13.3 5.3  12.5 ± 0.4 10.0 ± 2  12.1 7.3 
paO2/pA02 0.8 0.8  0.9 ± 0.1 0.5 ± 0.4  0.8 0.1  0.9 ± 0 0.5 ± 0.3  0.8 0.1 
CcO2 (ml/dL) 13.9 13.3  14.4 ± 0.4 15.4 ± 0.5  14.6 16.3  13.9 ± 0.5 17.7 ± 1.1  15.1 16.4 
 
Table 5.4: Derived blood parameters measured in pigs during steady state anaesthesia both pre GD exposure and at the end 
of the experiment (immediately preceding apnoea of euthanisation) at a range of challenge doses. Data from a total of 9 
animals as follows; n=1 for GD challenge of 0, 0.75 and 3 mg.kg-1, n=2 for GD challenge of 0.3 mg.kg-1 and n=4 for GD 
challenge of 1.0 mg.kg-1. 
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5.3.1.4. TEG measurements 
The coagulation profile for pig blood with GD contamination at a range of challenge 
doses was determined by Thrombelastography (TEG) to enable an in vivo 
comparison to be drawn against pig blood contaminated with GD in vitro (Section 
3.3.2.). For a GD challenge of 0.3 mg.kg-1 the clotting time was decreased as 
indicated by the decreased “R-time” and increased “angle parameter” compared to 
pre-exposure measurements, an observation consistent with the in vitro studies. 
However, at a higher GD challenge (1 mg.kg-1) there was no difference between the 
end of study values and the pre-exposure measurements (Table 5.5).   
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GD challenge 
(mg.kg-1) 0.3 
 1  3 
  
Pre 
exposure End 
 Pre 
exposure End 
 Pre 
exposure End   
  
  
R(min) 8.8 ± 1.7 4.7 ± 0.4  7.1 ± 3.6 8.3 ± 2.6  4.2 7.3 
  
K(min) 1.9 ± 1.3 1.1 ± 0.2  1.5 ± 5.3 2.6 ± 1.3  1.0 1.3 
  
Angle(deg) 65.0 ± 1.4 73.7 ± 0.3  70.6 ± 3.4 62.7 ± 1.3  77.0 72.3 
  
MA(mm) 72.7 ± 6.0 76.4 ± 2.8  74.8 ± 23.7 72.1 ± 6.5  79.3 77.2 
  
 
Table 5.5: Thrombelastography (TEG) parameters, R Time, K Time, Angle 
Parameter and Maximum Amplitude (defined in Section 3.1.3) measured in pigs 
during steady state anaesthesia both pre GD exposure and at the end of the study 
(immediately preceding apnoea or euthanisation) at a range of challenge doses. Data 
from a total of 9 animals as follows; n=1 for GD challenge of 3 mg.kg-1, n=2 for GD 
challenge of 0.3 mg.kg-1 and n=4 for GD challenge of 1.0 mg.kg-1. 
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5.3.2. In Vivo damaged skin absorption and distribution of GD in the domestic white 
pig. 
The data was split two discrete sets, absorption profiles (Figure 5.2), determined from 
regular blood sampling during each study (Section 5.3.2.1) and distribution profiles 
(Figures 5.3 to 5.5), determined from analysis of radioactivity after post mortem 
(Section 5.3.2.2). The data is presented as both individual animal data and as the 
average ± standard error mean of n=6 animals. 
 
5.3.2.1. Absorption 
Absorption of radiolabelled GD varied markedly between animals and the measured 
blood concentrations were directly related to the animals survival time (Figure 5.2). 
Early deaths had a direct impact on the dose distribution determined post mortem. In 
all the animals, 14C-GD was detectable within the systemic circulation consistently by 
10 minutes post challenge (Figure 5.2). As there was negligible activity detected 
within the dosing template and in the periphery of skin (Figure 5.4), the 14C-GD did 
not spread beyond the central dosing area. This indicated a maximum absorptive 
area of 3.14 cm2. The apparent (measured) absorption rate for 14C-GD into the 
systemic circulation was 37 ± 12 µg.h-1. As the measured appearance of 14C-GD in 
the systemic circulation did not allow for distribution to internal organs, a further 
determination of absorption rate was calculated taking internal dose distribution data 
into account. The apparent absorption rate taking all sampled organs into account 
was 287 ± 120 µg. h-1. It should be noted that as 36% of the radioactivity could not be 
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accounted for (Section 5.3.2.2.) it is not known how much of the applied dose was in 
the body of the animal and how much evaporated, hence the use of the term 
apparent.   
 
 
5.3.2.2. Distribution 
The total measured systemic recovery was 1.95 ± 0.24 % of the original applied 
dose, with the majority of radioactivity located within the blood, liver or kidney (Table 
5.6, Figure 5.3). Local recovery at the skin dosing site accounted for 43.0 ± 9.3 % of 
the 14C-GD application (Table 5.6, Figure 5.4). Unabsorbed radioactivity accounted 
for a further 18.67 ± 8.89 % of the applied dose (Table 5.6, Figure 5.4). This gave a 
total recovered radioactivity of 63.62 ± 8.33 %. The unaccounted for radioactivity 
represented 36.38 ± 8.33 % of the applied dose (Table 5.6, Figure 5.5) and can be 
assumed to have either volatilised or been present in unsampled tissues. The 
proportion of radioactivity recovered locally, unabsorbed or unaccounted for seemed 
primarily to be dependent on the time to death of the animal (Figure 5.5). 
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Figure 5.2: 14C-GD penetration into the system circulation of the large white pig
after application onto damaged ear skin. Each data set represents penetration
determinations from an individual animal. Where,     = animal 1,     = animal 2,
     = animal 3,     = animal 4,     = animal 5 and     = animal 6. Animal 6 survived
for the maximum study duration of 6 hours. Those animals with larger amounts
of 14C-GD penetrated earlier in the time course (animals 1 -4) succumbed to the
toxic effects of GD within 45 minutes of challenge (death indicated by "d"). Each
animal received a GD dose at t=0 of 0.3 mg.kg-1.
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Compartment Location % Recovery 14C GD (ng) /g 
tissue 
Unabsorbed Dosing chamber 1.99 ± 1.60  
 On skin surface 16.7 ± 8.5  
Local recovery Skin dosing site 42.7 ± 9.3  
 Periphery of dosing 
site 
0.33 ± 0.08  
Systemic recovery Brain 0.04 ± 0.004 39.3 ± 4.8 
 Heart 0.09 ± 0.005 44.7 ± 2.8 
 Lung 0.16 ± 0.019 42.8 ± 3.8 
 Spleen 0.03 ± 0.002 33.0 ± 1.7 
 Pancreas 0.02 ± 0.003 41.5 ± 3.5 
 Liver 0.74 ± 0.123 70.6 ± 10.8 
 Kidney 0.11 ± 0.014 104.5 ± 10.3 
 Blood 0.76 ± 0.093 33.9 ± 4.3 
Total Recovery Unabsorbed / Local 
/ Systemic 
63.6 ± 8.3  
Unaccounted Volatilised or in 
unsampled organs 
36.4 ± 8.3  
 
Table 5.6: 14C GD recovery expressed as percentage recovery of the initial applied 
dose. Recovery is assigned to one of four major compartments, namely unabsorbed, 
local recovered, systemic recovered and unaccounted for. Unabsorbed material was 
assigned as the percentage of material residing on the dosing chamber or on the skin 
surface at the end of the study. Local recovery was designated as the percentage of 
14C GD located either within the skin under the dosing site or at the periphery of the 
dosing site. Systemic recovery was the percentage recoveries of radioactivity located 
in the named internal organs and within the blood. Summation of the radioactivity 
within all these compartments gave the total radioactivity recovery. Unaccounted for 
radioactivity was ascribed as either having volatilised from the dosing site or being 
located in unsampled organs. For the tissue recoveries, the amount of GD ng g-1 
tissue was also calculated. All values are average ± standard error mean of n=6 
animals. Each animal received a GD dose of 0.3 mg.kg-1. 
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Figure 5.3: 14C-GD distribution in sampled internal organs in individual
animals after a 0.3 mg.kg-1 damaged ear skin exposure, expressed as
percentage of the applied dose. Organs sampled were:     heart,      spleen,
     lung,      pancreas,     liver,     kidney,     blood and     brain. Organs
were harvested after either the animal had succumbed to GD toxicity or
upon completion of the 6 hour study duration. Recovery from within the
systemic circulation was determined from the final blood sample taken prior
to the end of each study.
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Figure 5.4: 14C-GD distribution for individual animals after a 0.3 mg.kg-1
damaged ear skin exposure, expressed as percentage of the applied dose.
Sampled compartments were:     GD remaining on damaged skin surface,
     GD present with the skin directly under the dosing site,      GD present
within the skin adjacent to the dosing site,      GD absorbed into the dosing
assembly and     GD recovered from sampled organs (detailed in Figure
5.3). Compartments were sampled after either the animal had succumbed
to GD toxicity or upon completion of the 6 hour study duration.
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Figure 5.5: 14C-GD distribution for individual animals after a 0.3 mg.kg-1 damaged ear
skin exposure, expressed as percentage of the applied dose. Sampled compartments
were:     unabsorbed GD,     locally recovered GD and     systemically recovered GD.
The compartment,     "unaccounted" was taken as being 100 - the total measured
recovery. A full description of the sampled locations contributing to each compartment
is given in Table 5.6. Study duration (    ) is displayed on the secondary y axis to relate
the time taken for each animal to succumb to GD toxicity to compartment recoveries.
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5.3.3. Efficacy of a haemostatic decontaminant candidate in vivo 
Data collecting included observed signs, monitored physiological signs, total blood 
cholinesterase and radiological analysis. Together these gave a broad assessment of 
the efficacy of the haemostatic decontaminant against percutaneous GD poisoning 
through damaged skin in the large white pig. Animal usage for the study comprised a 
total of 18 animals; 6 negative controls (no GD challenge, no treatment), 6 positive 
controls (GD challenge, no haemostat treatment) and 6 treatment animals (GD 
challenge, haemostat treatment). All animals were weighed prior to study 
commencement to enable determination of the GD challenge (Figure 5.6). The 6 
negative control animals were the same animals used for comparison in the dose 
ranging study. 
 
5.3.3.1. Distribution of GD in treated and untreated pigs  
The direct quantification of localisation of radioactivity was quantified externally, 
locally and internally (Figure 5.7) with internal localisation broken down by organ type 
(Figure 5.8). For the untreated group, the majority of recovered radioactivity was 
located either on the skin surface or within the skin at the dosing site with a smaller 
portion of radioactivity recovered from the periphery of the dosing site. Internal 
recovery was approximately 1.75% of the initially applied dose. For the WoundstatTM 
treatment group, the majority of the radioactivity (approximately 70%) was 
sequestered by WoundstatTM. Smaller portions of radioactivity were recovered from 
the skin surface or within the skin at the dosing site. As with the untreated group, a 
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small portion of radioactivity was recovered from the periphery of the dosing site. 
Internal recovery was approximately 1% of the initially applied dose for the treated 
animals. 
 
5.3.3.2. Absorption kinetics of GD in treated and untreated pigs 
The amount of 14C-GD in pig blood was quantified at regular time points for the study 
duration of each animal (Figure 5.9). For both study groups the maximum amount of 
GD in the blood was measured within 10 minutes of GD challenge. By 20 minutes the 
amount of GD in the blood had halved and remained constant at this level for the 
study duration for the treatment group. In contrast, for the untreated group, the 
amount of GD in the blood steadily increased as the study progressed. The irregular, 
highly variable initial phases for each group can be primarily attributed to the study 
duration for each animal. Animals that succumbed to GD toxicity early in the time 
course had higher GD blood recoveries than for animals that either succumbed later 
or survived. 
  
5.3.3.3. Whole blood cholinesterase in treated and untreated pigs 
Whole blood cholinesterase did not significantly vary from the original cholinesterase 
value decrease in whole of 100% for the six hour study duration for the control group 
(Figure 5.10). In contrast, there was a rapid blood cholinesterase depletion for all GD 
poisoned animals. For the untreated animals, whole blood cholinesterase decreased 
to less than 5% of the original value by 15 minutes post contamination and remained 
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at this level until the onset of apnoea or until euthanisation. For the treatment group, 
whole blood cholinesterase levels decreased to less than 10% of the original value 
by 15 minutes post contamination and gradually decreased until the onset of apnoea 
or until euthanisation. Whole blood cholinesterase measurements and the amount of 
14C-GD in the blood determined at the same time point were plotted to show the 
effect of nerve agent blood concentration on whole blood cholinesterase (Figure 
5.11). A non linear regression least squares fit analysis was used to curve fit the 
data. 
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Figure 5.6: Animal weights taken immediately prior to study commencement.
All groups comprised 6 animals with the untreated and treated animals
receiving a 0.3 mg.kg-1 GD challenge onto damaged ear skin. The treated
animal group received WoundstatTM treatment at 30 seconds post GD
contamination. All values are mean ± standard deviation of n=6 animals.
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Figure 5.7: 14C-GD distribution for WoundstatTM treated and untreated animals
after a 0.3 mg.kg-1 damaged ear skin exposure, expressed as percentage of the
applied dose. Sampled compartments were:     WoundstatTM sequestered
(treated animals only),     GD remaining on damaged skin surface,     GD
present with the skin directly under the dosing site,      GD present within the
skin adjacent to the dosing site,      GD absorbed into the dosing assembly and
     GD recovered from sampled organs (detailed in Figure 5.8). All values are
mean ± standard deviation of n=6 animals. Compartments were sampled after
either the animal had succumbed to GD toxicity or upon completion of the 6
hour study duration. Statistical significance between same labelled paramaters
is indicated.
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Figure 5.8: 14C-GD internal organ distribution for WoundstatTM treated and
untreated animals after a 0.3 mg.kg-1 damaged ear skin exposure, expressed
as percentage of the applied dose. Sampled internal organs were:     heart,
     spleen,     lung,     pancreas,     liver,     kidney,     blood and     brain.
Organs were harvested after either the animal had succumbed to GD toxicity or
upon completion of the 6 hour study duration. Recovery from within the
systemic circulation was determined from the final blood sample taken prior to
the end of each study. All values are mean ± standard deviation of n=6
animals.Statistical significance between same labelled paramaters is indicated.
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Figure 5.9: 14C-GD penetration into the system circulation of the large white pig
after application onto damaged ear skin for untreated (   ) and WoundstatTM treated
(   ) animals. One animal in the untreated group and two animals in the treated
group survived for the maximum study duration of 6 hours. Those animals with
larger amounts of 14C-GD penetrated earlier in the time course succumbed to the
toxic effects of GD within 45 minutes of challenge. Each animal received a GD dose
at t=0 of 0.3 mg.kg-1. All pre GD challenge values are mean ± standard deviation of
n=6 animals which decreased as animals succumbed to GD toxicity over the study
duration.
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Figure 5.10: Total whole blood cholinesterase (ChE), shown as percentage of
original (pre GD challenge) activity in anaeathetised pigs following damaged ear
exposure to liquid GD. All values are mean ± standard deviation of up to 6
animals. All groups comprised 6 animals with the untreated (     ) and treated
animals (     ) receiving a 0.3 mg.kg-1 GD challenge onto damaged ear skin.
The treated animal group received WoundstatTM treatment at 30 seconds post
GD contamination. The control group (     ) were not exposed to GD and did not
receive treatment.
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Figure 5.11: Comparison of whole blood cholinesterase (% of original) and the 
amount of 14C-GD (or breakdown products) in the blood (determined from 
quantification of radiolabel) for untreated and WoundstatTM treated animals. Each 
animal received a GD dose 0.3 mg.kg-1onto damaged ear skin. A least squares fit 
non linear regression analysis was used to curve fit the data for each group. 
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5.3.3.4. Haematocrit 
Haematocrit measurements taken from whole blood samples throughout each 
experimental time course (Figure 5.12) remained stable at 34 ± 2 % for control 
animals. For GD challenged animals, whether untreated or treated with WoundstatTM, 
haematocrit values were elevated after exposure compared to pre exposure values 
and remained elevated for the study duration (Figure 5.13).  
 
5.3.5.5. Physiological signs of GD poisoning 
Observable clinical signs (miosis, mastication, fasiculations, tremor, convulsion, 
hypersalivation and apnoea) in each experimental group are shown in Table 5.7. One 
animal from the negative control group showed signs (mastication, fasciculation, 
hypersalivation), which could have been mistaken for mild GD poisoning. All animals 
from both the untreated and treated groups showed a number of observable signs 
(with similar times to onset), of GD poisoning. The differences between the untreated 
and treated groups were a lack of observable tremor / convulsions (Frequency 
treated group = 0; frequency untreated group =4) in the treated group. The frequency 
of mastication (treated 3; untreated 4), head / face / neck fasciculation (treated 5; 
untreated 6), limbs / rest of body fasciculation (treated 1; untreated 3), 
hypersalivation (treated 4; untreated 5) and apnoea (treated 6; untreated 4) was less 
in the treated group. Monitored physiological signs for each experimental group were 
pulse rate (Figure 5.14), blood pressure (Figure 5.15), exhaled CO2 (Figure 5.16), 
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breathing rate (Figure 5.17), blood oxygenation (Figure 5.18) and core temperature 
(Figure 5.19). With the exception of core temperature (which declined over the study 
duration for GD poisoned animals), alterations of physiological parameters were 
linked to the onset of apnoea for each animal (Table 5.8). The combination of all 
observed and measured signs for each animal were categorised into an overall 
severity level of no effect, mild, severe or fatal (Figure 5.20). For all animals exposed 
to GD the assigned severity level was either severe or fatal. Where effects resulted in 
fatality, time to death is shown (Figure 5.20). For each of the experimental groups, 
the average survival time and final whole blood cholinesterase values were plotted 
for comparison (Figure 5.21). 
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Figure 5.12: Total whole blood haematocrit (%) in anaesthetised pigs following
damaged ear exposure to liquid GD. All values are mean ± standard deviation of
up to 6 animals. All groups comprised 6 animals with the untreated (     ) and
treated animals (     ) receiving a 0.3 mg.kg-1 GD challenge onto damaged ear
skin with measurements recorded until either the study duration (6 hours) or
until an individual animal had succumbed to GD toxicity. The treated animal
group received WoundstatTM treatment at 30 seconds post GD contamination.
The control group (     ) were not exposed to GD and did not receive treatment.
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Figure 5.13: Total whole blood haematocrit (%) in anaesthetised pigs pre (     )
and post (     ) exposure to liquid GD onto damaged ear skin. Pre exposure values
were taken immediately prior to GD exposure whilst the post exposure values were
taken immediatley prior to either the animal succumbing to GD toxicity or upon
completion of the 6 hour study duration.  The treated animal group received
WoundstatTM treatment at 30 seconds post GD contamination. The control group
were not exposed to GD and did not receive treatment.All values are mean ±
standard deviation of 6 animals.
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  Control Untreated Treated 
  
     
Miosis Frequency 0 2 4 Time to onset (min) N/A 25 ± 18 71 ± 126 
     
Mastication Frequency 1 4 3 Time to onset (min) 42 6 ± 1 7 ± 3 
     
Fasiculation 
(head/face/neck) 
Frequency 0 6 5 
Time to onset (min) N/A 7 ± 9 11 ± 12 
     
Fasiculation 
(limbs and rest 
of body) 
Frequency 1 3 1 
Time to onset (min) 21 6 ± 1 13 
     
Tremor / 
Convulsion 
Frequency 0 3 0 
Time to onset (min) N/A 33 ± 38 N/A 
     
Hypersalivation Frequency 1 5 4 Amount (g) 3.84 19.4 ± 19.9 22.6 ± 18.4 
     
Apnoea Frequency 0 6 4 Time to onset (min) N/A 80 ± 101 127 ± 153 
     
 
Table 5.7: Observed signs of GD poisoning in the anaesthetised large white pig for 
the three experimental groups (Control (no GD, no treatment), Untreated (GD, no 
treatment), Treated (GD with WoundstatTM treatment 30 seconds post GD 
application). Each group contained 6 animals, where, frequency is the number of 
animals in the group that displayed the observable sign with the either the time to 
onset of the sign or the amount of saliva produced. Values are mean ± standard 
deviation of the frequency of the occurrence.   
227 
 
 
 
 
 
 
 
 
 
 
-30 0 30 60 90 120 150 180 210 240 270 300 330 360
100
120
140
160
180
200
220
Figure 5.14: Pulse Rate (beats per minute, bpm), in anaesthetised pigs
following damaged ear exposure to liquid GD. All values are mean ± standard
deviation of up to 6 animals. All groups comprised 6 animals with the untreated
(     ) and treated animals (     ) receiving a 0.3 mg.kg-1 GD challenge onto
damaged ear skin with measurements recorded until either the study duration
(6 hours) or until an individual animal had succumbed to GD toxicity. The
treated animal group received WoundstatTM treatment at 30 seconds post GD
contamination. The control group (     ) were not exposed to GD and did not
receive treatment.
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Figure 5.15: Mean arterial pressure (mmHg), in anaesthetised pigs following
damaged ear exposure to liquid GD. All values are mean ± standard deviation of
up to 6 animals. All groups comprised 6 animals with the untreated  (     ) and
treated animals (     ) receiving a 0.3 mg.kg-1 GD challenge onto damaged ear
skin with measurements recorded until either the study duration (6 hours) or
until an individual animal had succumbed to GD toxicity. The treated animal
group received WoundstatTM treatment at 30 seconds post GD contamination.
The control group (     ) were not exposed to GD and did not receive treatment.
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Figure 5.16: Carbon dioxide (kPa) in anaesthetised pigs following damaged
ear exposure to liquid GD. All values are mean ± standard deviation of up to 6
animals. All groups comprised 6 animals with the untreated  (     ) and treated
animals (     ) receiving a 0.3 mg.kg-1 GD challenge onto damaged ear skin with
measurements recorded until either the study duration (6 hours) or until an
individual animal had succumbed to GD toxicity. The treated animal group
received WoundstatTM treatment at 30 seconds post GD contamination. The
control group (     ) were not exposed to GD and did not receive treatment.
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Figure 5.17: Breathing rate (breaths min-1) in anaesthetised pigs following
damaged ear exposure to liquid GD. All values are mean ± standard deviation
of up to 6 animals. All groups comprised 6 animals with the untreated  (     )
and treated animals (     ) receiving a 0.3 mg.kg-1 GD challenge onto damaged
ear skin with measurements recorded until either the study duration (6 hours)
or until an individual animal had succumbed to GD toxicity. The treated animal
group received WoundstatTM treatment at 30 seconds post GD contamination.
The control group (     ) were not exposed to GD and did not receive treatment.
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Figure 5.18: Percent oxygen saturation (SpO2) in anaesthetised pigs following
damaged ear exposure to liquid GD. All values are mean ± standard deviation
of up to 6 animals. All groups comprised 6 animals with the untreated  (     )
and treated animals (     ) receiving a 0.3 mg.kg-1 GD challenge onto damaged
ear skin with measurements recorded until either the study duration (6 hours)
or until an individual animal had succumbed to GD toxicity. The treated animal
group received WoundstatTM treatment at 30 seconds post GD contamination.
The control group (     ) were not exposed to GD and did not receive treatment.
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Figure 5.19: Core body temperature (°C) in anaesthetised pigs following
damaged ear exposure to liquid GD. All values are mean ± standard deviation
of up to 6 animals. All groups comprised 6 animals with the untreated  (     )
and treated animals (     ) receiving a 0.3 mg.kg-1 GD challenge onto damaged
ear skin with measurements recorded until either the study duration (6 hours)
or until an individual animal had succumbed to GD toxicity. The treated animal
group received WoundstatTM treatment at 30 seconds post GD contamination.
The control group (     ) were not exposed to GD and did not receive treatment.
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  Control Untreated Treated 
  
     
Pulse Rate Pre exposure 163 ± 19 163 ± 30 146 ± 34 End 156 ± 31 115 ± 71 130 ± 24 
     
Systolic 
Pressure 
(mmHg) 
Pre exposure 120 ± 9 113 ± 7 122 ± 18 
End 106 ± 10 88 ± 36 108 ± 40 
     
Diastolic 
Pressure 
(mmHg) 
Pre exposure 93 ± 7 84 ± 7 93 ± 15 
End 79 ± 9 51 ± 36 70 ± 38 
     
Mean Pressure 
(mmHg) 
Pre exposure 107 ± 6* 99 ± 6 109 ± 18 
End 93 ± 8* 65 ± 38 87 ± 39 
     
CO2 (kPa) Pre exposure 6.2 ± 0.1 6.7 ± 0.6 7.2 ± 1.0 End 5.9 ± 0.7 4.6 ± 3.7 7.5 ± 3.7 
     
Breathing Rate 
(min-1) 
Pre exposure 36 ± 13 29 ± 9* 33 ± 13* 
End 33 ± 9 6 ± 5* 17 ± 12* 
     
SpO2 (%) Pre exposure 93 ± 3 91 ± 7* 88 ± 5 End 92 ± 7 46 ± 40* 61 ± 36 
 
Body 
Temperature 
(°C) 
 
 
Pre exposure 
End 
 
38.2± 0.6 
38.1± 0.5 
 
36.5 ± 2.2 
36.6 ± 1.5 
 
36.7 ± 0.8* 
34.4 ± 2.2* 
 
 
Table 5.8: Monitored physiological signs in pigs during steady state anaesthesia both 
pre GD exposure and at the end of the study (immediately preceding apnoea or 
euthanisation) for the three experimental groups (Control (no GD, no treatment), 
Untreated (GD, no treatment), Treated (GD with WoundstatTM treatment 30 seconds 
post GD application). Values are mean ± standard deviation of n=6 animals. 
Statistical significance between values is indicated (*) between pre exposure and end 
of study results. 
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Figure 5.20: Survival time for individual animals in each study group All groups
comprised 6 animals with the untreated and treated animals receiving a 0.3
mg.kg-1GD challenge onto damaged ear skin. The treated animal group received
WoundstatTM treatment at 30 seconds post GD contamination. The control group
were not exposed to GD and did not receive treatment. Physiological effects
were ranked according to severity and assigned as no effect (     ), mild (     ),
severe (     ) and fatal (     ).
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Figure 5.21: Comparison of survival time (min) and final ChE activity for
each study group. Values are mean ± standared deviation of n=6 animals.All
groups comprised 6 animals with the untreated and treated animals receiving
a 0.3 mg.kg-1GD challenge onto damaged ear skin. The treated animal group
received WoundstatTM treatment at 30 seconds post GD contamination. The
control group were not exposed to GD and did not receive treatment.
Statistical significance between same labelled paramaters is indicated.
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5.4. Discussion 
All in vivo work was conducted used a terminally anaesthetised large white pig 
model, with the GD challenge, were appropriate, applied to the ear of the animal. 
This model and dosing site has been previously used for the assessment of 
countermeasures against nerve agents (Chilcott, et al., 2005c;Duncan, et al., 2002). 
In contrast to previous studies, the skin was damaged to allow a more rapid ingress 
of chemical warfare agent, as the likely mode of use of a haemostatic decontaminant 
would be application to damaged skin. Although the skin was damaged, this series of 
studies did not evaluate efficacy of the haemostat in a contaminated haemorrhaging 
model of injury. The haemorrhaging model was evaluated in subsequent studies at 
the United States Army Medical Research Institute of Chemical Defense 
(USAMRICD). The model described in this chapter may be described as a 
contaminated injury model. For the initial in vivo studies with the selected haemostat 
this methodology was used to enable a rigorous test of the haemostats 
decontaminating ability as opposed to its haemostatic ability.  
 
5.4.1. Clinical manifestations of GD poisoning 
The use of animals to acquire clinical information that may be relevant to human 
exposures necessitates that the chosen animal species is relevant. In the case of 
exposure to nerve agents, the guinea pig has been used previously as it gives a 
comparable physiological response to humans. There are a number of drawbacks 
associated with the guinea pig for dermal exposure assessment after nerve agent 
237 
 
 
poisoning including differences in skin absorption rates (Dalton, et al., 2006a) and 
difficulties associated with dosing small volumes of nerve agent (due to the guinea 
pigs size) which often requires the dilution of the nerve agent in a solvent vehicle 
(Murnford and Troyer, 2011). Vehicle effects have been shown to influence skin 
penetration rates (Baynes, et al., 1997;Mills, 2007) meaning that the researcher must 
bear this in mind when considering solvent choice. The pig has neither of these 
potential drawbacks and is generally accepted to be the most suitable model for 
human skin absorption (Simon and Maibach, 2000). The pigs’ larger size means that 
nerve agents can be easily applied without the need for dilution in solvent. 
 
The current study considered an application of GD onto damaged pig ear skin in a 
terminally anaesthetised animal. Differences in permeability have been previously 
shown between application sites for nerve agent percutaneous absorption studies 
(Duncan, et al., 2002), however, as GD deposition was onto damaged skin for the 
current study, it is likely that these differences would be less marked than for an 
undamaged skin percutaneous exposure.    
 
A total of four challenge doses (3 µl.kg-1, 1 µl.kg-1, 0.75 µl.kg-1 and 0.3µl.kg-1) were 
used. The upper dose was based on previous percutaneous LD50 determinations on 
undamaged skin (Knezevic, et al., 1993), whilst the lowest challenge was evaluated 
for the observed 10 fold difference between damaged and undamaged skin 
penetration in vitro (Dalton, et al., 2010). However, the data indicated that of the 
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doses of GD applied to damaged pig ear skin there was no easily definable dose 
response relationship between the challenge levels and it can be inferred that a 
challenge dose of 0.3µl.kg-1 or above of GD applied onto damaged pig ear skin will 
give severe clinical manifestations of GD poisoning within a six hour time frame. 
Instead, “time to death” was used as a marker to normalise the chronology of events 
in the clinical manifestations of GD poisoning. Early signs of GD poisoning included 
mastication, fasiculations and tremor. Intermediate signs included miosis, salivation 
and nasal secretions. Late onset effects (just prior to apnoea) included lacrimation 
and body spasm. All of these gross clinical signs occurred concurrently with a 
measured rapid depletion of whole blood cholinesterase levels. Recent work 
determining inhibition of cholinesterase in blood following intra muscular injection in 
guinea pigs (Bajgar, et al., 2011) showed a remarkably similar cholinesterase 
depletion profile for an LD50 dose of GD and indicates that application of GD onto 
damaged skin is more akin to an intramuscular challenge rather than a percutaneous 
challenge. 
 
In clinical practice, suspected exposure to organophosphate cholinesterase inhibitors 
may be confirmed and the extent of exposure quantified through the measurement of 
plasma and / or erythrocyte cholinesterase activities. Whole blood cholinesterase 
assessment as measured in the current study allowed the contribution of 
cholinesterase depletion in both fractions to be rapidly measured and required a 
minimum of sample preparation. Although cholinesterase determinations are 
routinely made for patients presenting with signs and symptoms of nerve agent 
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poisoning (Evison, et al., 2002), the current study has shown that although rapid 
depletion of whole blood cholinesterase (to less than 5% of pre soman application 
values) did indicate nerve agent poisoning, final clinical outcome for each animal 
could not be correlated with the decrease in whole blood cholinesterase. This finding 
is in agreement with previous work that has shown that in the case of nerve agent 
exposures, cholinesterase activity should only be deemed an indicator of poisoning, 
not a prognostic aid (Chilcott, et al., 2003). Whole blood cholinesterase measurement 
is used as a surrogate for AChE measurement within the nervous system. As the 
action of GD on AChE in the central nervous system defines final clinical outcome it 
must be reiterated that whole blood ChE gives only an indication of what inhibition 
may occur for central nervous system AChE.  
 
The current study indicated that a number of haematological and blood biochemistry 
parameters were elevated after GD exposure including carbon dioxide, potassium, 
glucose, lactate and haematocrit and haemoglobin. Conversely, a number of 
parameters were lower than controls including pO2 and O2Hb. Previous work using 
swine has shown that percutaneous exposure to high doses of GD (15.8 mg kg-1 
(Hanford miniature swine) and 25 mg kg-1 (Chester White / Yorkshire cross swine)) 
caused hyperglycemia in swine that survived for more than 2 hours (James, et al., 
1987). Work evaluating biochemical changes in rats following soman intoxication has 
also shown elevation of glucose concentrations (Jovic, 1974). The current study was 
in agreement with these findings with elevated levels of glucose shown for those 
animals surviving for more than 2 hours. It has been previously postulated that 
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hyperglycaemia may be attributed to a failure of the peripheral tissues to respond to 
insulin (James, et al., 1987). In reported human cases of acetylcholinesterase 
poisoning, hyperglycaemia has been observed (Meller, et al., 1981). However, 
previous work assessing the percutaneous absorption of the nerve agent VX showed 
that VX did not significantly affect glucose utilisation in the pig (Chilcott, et al., 2003). 
Although rare, cases of accidental human poisoning with nerve agents have been 
reported (Sidell, 1974). In contrast to the current study, blood parameters such as 
haematocrit, haemoglobin, calcium, potassium and carbon dioxide were all within 
normal limits for the accidental human poisoning case study, although, it should be 
noted that the patient made a full recovery. The elevated haematocrit and 
haemoglobin levels observed in the current study may be due to dehydration caused 
by excessive salivation whilst the increased carbon dioxide, potassium and lactate 
levels may be ascribed to major organ dysfunction caused by soman intoxication. 
Studies (Chapter 3) using pig blood contaminated with GD in vitro indicated that GD 
had a pro haemostatic effect. Samples analysed using the same methodology but 
from samples withdrawn after GD application in vivo did not replicate the in vitro 
result. Obviously the concentration of GD in the blood samples between the two 
methods varied enormously and it may be concluded that a pro haemostatic effect is 
only produced in blood contaminated with large concentrations of GD. 
 
In the case of nerve agent intoxication, given that cholinesterase monitoring can only 
be used to give a broad indication of the severity and not as a prognostic indicator, it 
has previously been stated that the principle should be to treat the patient not the 
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depression of the cholinesterase (Evison, et al., 2002). Detailed accounts on the 
medical management of nerve agent casualties are available in Chapter 1 of this 
thesis. 
 
In summary, after application of GD onto damaged pig ear skin, the onset of clinical 
manifestations was rapid leading to a number of fatalities within 15 minutes of 
exposure. Whole blood cholinesterase inhibition was similarly rapid with 95% 
inhibition of pre GD exposure values within 5 minutes of exposure. Measurable 
changes in blood parameters, notably haematocrit and blood glucose, were 
observed.     
 
5.4.2. In vivo damaged skin absorption and distribution of GD in the domestic white 
pig 
 
This study has shown that 14C-GD (0.3 mg.kg-1) penetrated though damaged pig ear 
skin in vivo and entered the systemic circulation at an apparent rate of 37 ± 12 µg.h-1. 
This value is not dissimilar to a value obtained for in vivo undamaged cat skin 
penetration of 16.2 µg.cm-2.h-1 (Fredriksson, 1969b). Fredriksson noted, for his study, 
that the value obtained denoted only the absorption of active soman into the blood 
stream from the topical deposit and did not take into account any detoxification 
processes (such as hydrolysis (Fredriksson, 1969a)) that may have occurred in the 
skin. It was postulated that the real value might be considerably higher. Similarly, the 
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current study, using 14C radiolabel, does not discriminate against soman and any 
breakdown products (as it is radiolabel that has been quantified and not soman 
itself). 
 
The value of 37 ± 12 µg.h-1 potentially underestimates the skin penetration rate of 
14C-GD as it is an equilibrium value between the amount penetrating into the blood 
and the amount being removed from the blood into internal organs. Another method 
to determine the penetration rate from in vivo radiometric data is to consider the 
amount of radiolabel within the internal organs and blood at the culmination of a 
study as described by Chilcott and Dalton (Chilcott, et al., 2005c). Using this 
methodology, a derived penetration rate of 287 ± 120 µg.h-1 was obtained. However, 
this is also likely to be an underestimate as lag time (assumed to be negligible for 
damaged skin) along with radioactivity present in unsampled organs (such as the 
digestive system, fat and muscle) are not taken into account. Due to the premature 
deaths in the majority of animals, apparent penetration rates were determined 
between different time points for each animal, generally between 15 and 60 minutes, 
(unless death occurred earlier).  
 
In vitro static diffusion cell systems (Franz, 1975;Friend, 1992), have been used 
extensively for the determination of skin penetration rates of numerous chemicals, 
including chemical warfare agents (Chilcott, et al., 2000;Chilcott, et al., 2001;Dalton, 
et al., 2006a). A previous study, using damaged pig skin gave a direct measure of 
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penetration rate for 14C GD of 337 ± 107 µg cm-2 h-1 (Dalton, et al., 2010). This in vitro 
value is free from potential artefacts such as metabolism and distribution to 
unsampled organs. Given that the derived in vivo value does not take unsampled 
organs into account, it is not surprising that this value is slightly lower than the in vitro 
value. Comparison of the in vitro and in vivo studies shows that the derived 
penetration rate of GD into the blood was 287 ± 120 µg.h-1 whilst the in vitro 
penetration rate was 337 ± 107 µg cm-2 h-1. The maximum absorptive area in vivo 
was assessed as having been up to 3.14 cm2, although the rapid ingress of GD, 
applied as a single droplet, through the damaged skin site likely indicates that the 
area of penetration was much less than this. Difference between the in vitro and in 
vivo value can be ascribed to unsampled organs and / or lack of knowledge 
regarding the exact skin surface spread area of GD in vivo. 
 
The concentration of 14C-GD in blood increased over the time course of each study 
(with the exception of animal 1 which appeared to have received a bolus dose. 
Explanation for this may be due to more rapid blood organ partitioning or due to a 
reduction in partitioning from the skin into the peripheral circulation). In the case of 
those animals succumbing to the toxic effects of GD more rapidly, the concentrations 
of 14C-GD where generally higher earlier than for those animals that survived for 
longer. This observation means that initial concentrations of GD in the systemic 
circulation could be used as an indicator of likely final clinical outcome. That 14C-GD 
concentrations increased throughout each study indicates that there was not a 
complete depletion of surface 14C-GD (or that the agent was rapidly absorbed into 
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the surface layers and continued to be delivered to the circulation from there) during 
the study and that the systemic circulation had not become saturated with 14C-GD.  
 
Previous studies (Chilcott, et al., 2005c) using an in vivo pig ear skin model (albeit 
not damaged) have shown the penetration rate of VX (a nerve agent of lower 
volatility) to be approximately 512 µg cm2 h-1 (taking into account distribution into 
sampled organs). It is interesting to note that the rate of penetration of VX though 
undamaged skin was higher than GD through damaged skin using a similar animal 
model. The volatilities of these nerve agents differ substantially (GD has a volatility of 
3900 mg m-3 whilst VX has a volatility of 10.5 mg m-3 (Munro, et al., 1999)) and offers 
likely explanation for this observation). Between the two nerve agents there is a 300 
fold difference in volatility, and, it has been shown that evaporation from the skin 
surface for percutaneously applied chemicals can significantly impact the dose 
absorbed (Reifenrath and Robinson, 1982). 
 
The high volatility of GD means that the location of the unrecovered fraction of the 
applied dose is not easily identified from the data presented here. For low volatility 
agents, such as VX, it can be reasonably assumed that any unrecovered radioactivity 
would have been present in unsampled tissues. For GD, the unrecovered 
radioactivity was either in the unsampled tissues or had volatilised from the skin 
surface. Obviously, any volatilised material would not be available for skin 
penetration. From the current studies, a large proportion of 14C-GD was unaccounted 
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for (36.4 ± 8.3 % of the applied dose). The standard error can be directly related to 
the survival times of the animals. Typically, animals that succumbed quickly had a 
lower unrecovered fraction than those that survived longer. Logically, this should be 
the case as there would be less time for the GD to volatilise away from the skin 
surface for short duration studies. Interestingly, internal organ recoveries were similar 
for each animal regardless of study duration, with the majority of radioactivity located 
within the blood, liver, lung or kidney, with a lower amount of radioactivity located in 
the brain. It can be inferred that radiolabel located within the liver and kidney are 
likely to be detoxification products which do not contribute to systemic toxicity. Whole 
body auto radiographic studies using 3H soman in a mouse model (Kadar, et al., 
1985) showed similar results, with high concentrations of radioactivity being seen in 
the blood, heart, kidney, lung and skin of mice. Kadar (Kadar, et al., 1985) quantified 
the distribution of soman across the entire animal and observed that radioactivity was 
located in the nasal cavities, lachrymal and sweat glands, striated muscle, bladder, 
intestinal lumen and gallbladder at two hours post challenge. As these sites were not 
sampled during the current study, a portion of the unaccounted for radioactivity may 
have resided in these tissues. The current study also confirmed the findings of Kadar 
that low concentrations of radioactivity were located in the brain. As soman is known 
to severely affect the central nervous system, it shows how small a percentage of the 
applied dose is actually required to reach the target organ to realise its lethal toxic 
effects. 
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Recovery of 14C GD from within the skin exposure site was 43.0 ± 9.3 % of the 
applied dose. This recovery was substantially larger than that found internally within 
the animal. Should the animal have survived the initial intoxication, the dose still 
present within the skin would have continued to be absorbed into the systemic 
circulation or been metabolised in the skin (assuming that the remaining 14C GD was 
free and not bound to tissue components or hydrolysed to a hydrolysis product). The 
existence of a “reservoir” has been previously reported for GD (Kadar, et al., 
1985;Benschop, et al., 1981;Clement, 1982;Nordgren, et al., 1985;Wolthuis, et al., 
1981) and ascribed to potential locations such as skin, lung, muscles, liver and 
plasma. The current study supports the theory of the dermal reservoir in the case of 
dermal exposures. Dermal reservoirs tend to be formed by highly lipophilic chemicals 
(GD has a log P value of approximately 1.824 (Czerwinski, et al., 1998)) which have 
passed through the lipophilic stratum corneum and encountered the more aqueous 
lower skin layers (lower epidermis and dermis), the penetration of the lipophilic 
chemical then slows leading to a reservoir build up.  As the current study examined 
penetration through damaged skin, reservoir effects were limited to either the dermis 
or subcutaneous fat. Dermal reservoirs have been shown for other chemical warfare 
agents (Hattersley, et al., 2008) and offer a target for medical countermeasures 
aimed at limiting systemic absorption after confirmed contamination. 
 
In conclusion, the current study has shown that 14C-GD can rapidly penetrate through 
damaged skin in vivo into the systemic circulation and from there preferentially 
distribute into the liver and kidney. The percentage of 14C-GD measured in brain 
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tissue was 0.04 ± 0.004 of the applied dose which equated to 39.30 ± 4.79 ng 14C-
GD per gram of tissue. Animal survival time was directly related to the measured 
blood concentrations of 14C-GD. 
 
5.4.3. Efficacy of a haemostatic decontaminant candidate in vivo 
The purpose of the study was to determine whether WoundstatTM could be used to 
decontaminate damaged skin that had been contaminated with GD 30 seconds prior 
to WoundstatTM application. Assessment of decontamination efficacy was made 
using a range of techniques including radioactivity, whole blood cholinesterase and 
haematocrit quantification alongside examination of observed and measured 
physiological signs. The combination of these techniques allowed for quantification of 
the internally absorbed dose responsible for the observed and measured 
physiological signs, whole blood cholinesterase and haematocrit levels.   
 
WoundstatTM treatment 30 seconds post GD challenge sequestered 68 ± 26 % of the 
applied 14C-GD. Of the remaining 32% it is likely that a proportion was absorbed prior 
to treatment application and was therefore not available for absorption by 
WoundstatTM. Similar levels of WoundstatTM 14C-GD sequestration were measured in 
the initial in vitro studies for both damaged and undamaged skin (Chapter 4) 
indicating that decontamination must be carried out as rapidly as possible to limit 
percutaneous absorption of GD. A greater proportion of 14C-GD was recovered for 
the treated animals (83 ± 24%) compared to the untreated animals (63 ± 20%) This 
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result was not unexpected as the WoundstatTM treatment would occlude the GD on 
the skin surface and would sequester 14C-GD volatilising from the skin surface. In the 
case of the untreated animals, 14C-GD was free to volatilise from the skin surface. 
Treatment with WoundstatTM substantially reduced the amount of 14C-GD remaining 
on the skin surface (1.8 ± 1.9 %, treated and 16.7 ± 20.8 %, untreated) and 
remaining localised within the skin under the dosing site (7.5 ± 3.8 %, treated and 
42.7 ± 22.7 %, untreated). Although it can be assumed that the GD recovered from 
these compartments would not impact upon systemic toxicity, it would have a bearing 
on contamination spread prevention to first responders and others in the medical 
chain. Any observable or measurable parameters of systemic toxicity including 
cholinesterase inhibition should be directly related to the internally recovered dose of 
GD. WoundstatTM treatment resulted in a reduction of internally measured GD by 
approximately 0.5 % (1.2 ± 0.3 %, treated and 1.7 ± 0.6 %, untreated). This equates 
to a 30% reduction in systemically recovered material. 
 
The absorption of 14C-GD through damaged ear skin and into the systemic blood 
supply had a similar absorption profile whether or not treatment had been given. Both 
groups had animals that had high initial levels of 14C-GD in the blood. These animals 
did not survive for more than 45 minutes into the exposure period. For the animals 
that had a lower initial 14C-GD blood concentration, survival times were lengthened, 
in a number of cases out to the full study duration. In treated animals that survived 
the initial period, 14C-GD absorption rates stabilised by 30 minutes and remained 
constant for the study duration. Conversely, for those animals in the untreated group 
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which survived the initial period, 14C-GD penetration rates steadily increased until 
death or study termination. 
 
WoundstatTM treatment was not able to reduce the rapid decline in whole blood 
cholinesterase, although there was a slight reduction in the amount of the depletion 
compared to the control animals. However, the slight increase in cholinesterase 
activity was not sufficient to reduce the assigned severity level from “severe” or “fatal” 
to a lower category. The increased cholinesterase in the WoundstatTM treatment 
group as measured at 15 minutes gradually decreased, and by 6 hours was at the 
same level as the untreated group. The small difference in cholinesterase activity 
between the two groups allowed the WoundstatTM treated animals to survive for a 
longer time period than the control animals and demonstrates the benefit of 
performing decontamination. The increased survival time period would allow a longer 
therapeutic window for further, nerve agent specific, medical countermeasures to be 
employed. For both the untreated and the WoundstatTM treated groups, haematocrit 
levels increased steadily over the exposure duration, whereas for the negative 
control group haematocrit levels were consistently lower and remained constant. 
There were no observable differences between the two groups in terms of 
physiological signs, indicating that sufficient GD had penetrated systemically to 
cause nerve agent poisoning.  
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The current study has shown that use of WoundstatTM as a decontaminant on 
damaged (non haemorrhaging) pig ear skin was able to increase animal survival 
time, however, it was unable to fully protect against GD toxicity. Most importantly, use 
of WoundstatTM did not enhance the toxicity of GD. 
 
Further note: A complimentary study using the same experimental protocol with 
challenge by VX was however able to offer 100% survival (Lydon, 2012). The 
difference between these observations may lie with the increased penetration 
observed between GD and VX though damaged and undamaged skin. It is likely that 
sufficient GD was able to penetrate through the damaged skin in the initial 30 
seconds prior to WoundstatTM application to have considerable impact on the final 
experimental result. Importantly, the fact that WoundstatTM did not increase the 
toxicity of the evaluated nerve agents allowed it to progress to final evaluation stage 
outlined in Chapter 6.  
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CHAPTER 6: GENERAL DISCUSSION 
 
The work undertaken in support of this PhD thesis comprised a series of studies that 
enabled a range of COTS haemostats to be evaluated for potential use as a 
decontaminant for GD, with associated programmes evaluating the haemostats 
against VX and HD (Lydon, 2012;Hall, 2012). It was hypothesised that it would be 
possible to identify structures with combined haemostatic and decontaminant 
features. Use of in vitro methodologies allowed for selection of candidates with the 
required parameters (maintenance of haemostatic properties, effective CW agent 
decontamination ability on both undamaged and damaged skin and the ability to 
irreversibly sequester CW agent) whilst minimising animal use in accordance with the 
3R’s. Validation of the in vitro static diffusion cell methodology used was required to 
evaluate haemostatic efficacy against GD (skin surface spreading to allow correct 
penetration rate determination and choice of receptor media to ensure that GD was 
adequately soluble). The existence of GD skin reservoirs was shown in vitro, and 
offers potential scope for the development of future medical countermeasures. 
 
The final in vivo studies, evaluating the one, most favourable, candidate from the in 
vitro studies showed that whilst use of WoundstatTM as a single medical 
countermeasure did not give 100% survival, it did potentially offer an increased 
therapeutic window where specific nerve agent therapy adjuncts could be employed. 
Recent work by Joosen (Joosen, et al., 2013) supports the rationale of 
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decontamination prior to medical treatment in the case of percutaneous poisoning by 
nerve agent. Importantly, use of WoundstatTM on damaged skin contaminated with 
GD did not increase GD toxicity. One of the major reasons for the initiation of the 
programme was the concern that use of a haemostatic product in a wound 
contaminated with CW agent would increase the toxicity of the CW agent. Due to the 
potential life threatening nature of haemorrhaging injury it would not be acceptable to 
not give preventative aid, however, it would be nugatory to give aid that would stop 
the haemorrhage but would then increase the toxicity of the CW agent. The output of 
this programme has shown that use of WoundstatTM did not increase the absorption 
of a range of CW agents on either undamaged or injured skin.        
 
This programme has shown that WoundstatTM can be used as a decontaminant, 
without loss of haemostatic ability. The final evaluation was an assessment of 
WoundstatTM efficacy in a CW agent contaminated haemorrhaging injury model. This 
work was carried out by the United States Army Medical Research Institute of 
Chemical Defense (USAMRICD) (Smith, et al., 2011). The study protocol involved 
the creation of an axial pocket (approximately 5 cm in length and 100 ml volume) in a 
terminally anaesthetised large white pig. Chemical warfare agent (VX only, 5 LD50 
challenge) was applied onto the exposed rib cage approximately half way up the 
height of the pocket. The axialary vein was immediately transected and WoundstatTM 
was applied 45 seconds later in sufficient quantity to arrest the haemorrhage. Those 
animals that survived until the maximum study duration (360 minutes) were culled by 
anaesthetic overdose. A total of 9 animals were challenged with VX of which 4 were 
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treated with WoundstatTM. All the animals that did not receive WoundstatTM treatment 
succumbed to VX toxicity (time to death 58 ± 43 minutes). Out of the treatment group 
one animal survived for the study duration. The average time to death for the 
WoundstatTM treatment group was 263 ± 85 minutes. As with the GD studies on 
damaged non haemorrhaging skin none of the animals received any specific nerve 
agent adjunct therapy. In conclusion, the USAMRICD studies indicated that although 
use of WoundstatTM as a standalone treatment did not offer 100% survival, it did offer 
an increased therapeutic window where specific nerve agent therapies could be 
employed. Importantly, the haemorrhaging studies showed that WoundstatTM 
remained an effective haemostat in the presence of VX and, also, did not increase 
the toxicity of VX. 
 
Future investigations into haemostatic decontaminants, should, ideally concentrate 
on the increased therapeutic window and adjunct, chemical warfare agent specific 
therapies that could be given. In the case of nerve agents, the combopen (Section 
1.5.6.2) is available for rapid deployment on the battlefield. However, it is of 
importance to note that the combopen contains atropine, a muscarinic receptor 
antagonist which can cause an increase in heart rate. An increased heart rate could 
potentially cause issues with blood clots formation at the site of traumatic injury. 
 
WoundstatTM was developed for use as a haemostatic agent for complex traumatic 
wounds to fill the perceived shortcomings of tourniquet placement. Approved for use 
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by the FDA in 2007 and fielded for use by the U.S. Army in 2008.  The Committee on 
Tactical Combat Casualty Care (CoTCC) voted to recommend that WoundstatTM 
should be third in the line of treatment for haemorrhage control after the traditional 
tourniquet and Combat Gauze (a gauze type haemostatic agent rather than a powder 
or granule). It was perceived that WoundstatTM could be of use where the 
characteristics of the wound would make a granular agent preferable. In 2009 an All 
Army Activity Message stated that “The risk inherent in WS (WoundstatTM) use 
outweighs its benefits as a back-up agent hemostatic agent to Combat Gauze” 
(Abramson, 2009). Although by this point WoundstatTM was a lead candidate in the 
haemostatic decontaminant programme, the customer requested (as the programme 
was well underway) that work on its use a potential haemostatic decontaminant 
continue. The work reported within this thesis can, therefore, be viewed as proof of 
principle that the development of haemostatic decontaminants is feasible. It is 
interesting to note that research evaluating WoundstatTM against other haemostatic 
agents has also continued (Littlejohn, et al., 2011) despite the U.S. Army withdrawing 
the product from use. 
 
Tourniquet use is typically restricted to limb haemorrhage and is not suitable for use 
on junctional haemorrhage (axillary and inguinal). Management of junctional 
haemorrhage led to the requirement for deployable haemostatic agents in a combat 
setting. Front line deployable haemostats are found as impregnated gauzes or as 
granules based on the mechanism of action of either absorption (zeolites and 
smectites) or tissue sealant characteristics (chitosan). In situations where tourniquet 
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use is impractical, Combat Gauze and WoundstatTM have been shown to the most 
effective topical products for the cessation of junctional haemorrhage. Given that 
WoundstatTM has currently been withdrawn due to safety concerns over its potential 
to cause intravascular clotting and embolism, this leaves Combat Gauze alone as the 
fielded second line treatment. 
 
Although Combat Gauze was not evaluated during the studies reported here as to its 
efficacy as a haemostatic decontaminant, the previous generation of this product, 
Quikclot ACS+ was. The results showed that Quikclot ACS+ significantly reduced 
both the rate and extent of 14C-GD skin absorption (although not as effectively as 
WoundstatTM). However, the active constituents between the two generations of 
product are different. Quikclot ACS+ uses a zeolite, whereas, Combat Gauze uses a 
smectite (Kaolin). It cannot therefore be inferred that Combat Gauze has the potential 
to be as effective a CW agent decontaminant as Quikclot ACS+. Interestingly, the 
most effective haemostatic decontaminant shown by this research (WoundstatTM), 
was also smectite based. It is feasible that Combat Gauze could have similar 
decontaminating properties to WoundstatTM. As a priority, future work in this area 
should evaluate the CW agent decontaminating abilities of Combat Gauze. 
 
WoundstatTM is a solid material composed of mineral smectite (Figure 6.1). The 
general formula for smectites is 2Al2O3.8SiO2.2H2O.nH2O (however, the aluminium 
may be substituted for either iron or magnesium). These clay minerals comprise two 
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silica tetrahedral sheets with a central alumina octahedral sheet which possess a net 
negative charge. The interlayer H2O and exchangeable cations (Calcium, Sodium, 
Potassium) balance the negative charge (Vallenzuela Diaz and de Souza Santos, 
2001). It is recognized that clay minerals have hydrophilic surfaces and that such 
surfaces are not ideal for the absorption of organic molecules, leading to the 
development of organo-clays for this purpose (Boyd, et al., 1988). However, it has 
been shown that potassium and calcium saturated smectite clays can adsorb a range 
of pesticides (Sheng, et al., 2001) including parathion, a nerve agent simulant. Work 
by Li (Li, et al., 2004) indicated that the pesticide adsorption ability of soil clays was 
influenced by the exchangeable cation present with potassium demonstrating the 
strongest affinity for pesticides. Smectite interlayer hydration status has also been 
shown to influence Atrazine sorption, with air dried smectite adsorbing more Atrazine 
than native smectite (Chappell, et al., 2005). More recent work has shown that 
smectites are effective adsorbents for the hydrophobic dibenzo-p-dioxins (Liu, et al., 
2009). Given that smectites are primarily hydrophilic, the ability of GD and other 
chemical warfare agents to adsorb into WoundstatTM is determined by the direct 
interaction of the agent with exchangeable cation and the level of interlayer swelling. 
The fine particulate nature of WoundstatTM gives a large surface area making the 
exchangeable cations readily available.   
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Figure 6.1: WoundstatTM. A solid granular powder composed of mineral smectite. 
Work in this thesis has shown the ability of WoundstatTM to effectively adsorb GD and 
other chemical warfare agents. Images property of TraumaCure. 
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Recent developments in haemostatic materials have seen a number of new products 
receiving FDA approval in addition to Combat Gauze. Celox-A (the original Celox 
reformatted into an applicator for delivery deep into a penetrating wound), Chitoflex 
(based on the original HemCon, but with a less rigid structure) have most recently 
been evaluated (Littlejohn, et al., 2011). Emerging products include hydrophobically 
modified chitosan (Dowling, et al., 2011) and Hemostatic multilayer coatings (Shukla, 
et al., 2012), indicating that interest in haemostatic materials remains undiminished. 
 
In summary, the work reported here had two main themes, firstly, the in vitro skin 
penentration of 14C-GD was characterised in terms of appropriate receptor fluid use, 
rapidity of skin surface spread and reservoir development, which allowed postulation 
of a mechanism of interaction of GD with the skin. Such characterisation has wider 
implications on the relevance of the extrapolation of in vitro to in vivo data. Rapid skin 
surface spread of GD may have implications when extrapolating in vitro to in vivo 
penetration rates (where the area available for skin penetration is not artificially 
limited). Rapid reservoir formation within the skin surface layers has implications not 
only in decontamination regimens, but, also for emergency responders who may 
suffer secondary exposure. Secondly, a number of haemostats were evaluated for 
potential use as decontaminants in GD contaminated environments. A logical 
progression from in vitro to in vivo experimentation enabled efficient selection of 
promising materials whilst minimising animal use. The rapid development of 
improved and novel haemostatic materials means that further assessments of these 
products should be made before they are used in CW agent contaminated wounds. 
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The methodology explored and developed in this thesis will serve as a basis for this 
work to continue. The smectite based WoundstatTM was shown to effectively adsorb 
GD both in vitro and in vivo and retained haemostatic ability even after gross GD 
contamination. It is recommended that the use of specific nerve agent medical 
countermeasures (such as the Combopen) be evaluated in conjunction with 
haemostatic decontaminant application, as work evaluating the combined use of skin 
decontaminants and nerve agent medical countermeasures are currently showing 
positive results (Joosen, et al., 2013).  
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